{
  "meta": {
    "id": "test8",
    "title": "Endocrine System",
    "category": "Subject Wise / Mixed"
  },
  "questions": [
    {
      "text": "Which of the following sites is least commonly preferred for insulin injection?",
      "options": [
        {
          "label": "A",
          "text": "Anterior thigh",
          "correct": false
        },
        {
          "label": "B",
          "text": "Lateral thigh",
          "correct": false
        },
        {
          "label": "C",
          "text": "Upper arm",
          "correct": false
        },
        {
          "label": "D",
          "text": "Around umbilicus",
          "correct": true
        }
      ],
      "correct_answer": "D. Around umbilicus",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture5.jpg"
      ],
      "explanation": "<p><strong>Ans. D. Around umbilicus</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Anterior thigh and B. Lateral thigh C. Upper arm: These areas are common for insulin injections and provide consistent absorption , although generally slower compared to the abdominal wall.</li><li>\u2022 Option A. Anterior thigh</li><li>\u2022 B. Lateral thigh C. Upper arm:</li><li>\u2022 common for insulin injections</li><li>\u2022 consistent</li><li>\u2022 absorption</li><li>\u2022 slower</li><li>\u2022 abdominal wall.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 SITES OF INSULIN INJECTION</li><li>\u27a4 SITES OF INSULIN INJECTION</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "9f2ae976",
      "audio": ""
    },
    {
      "text": "A 60-year-old patient with Type 2 diabetes mellitus is being evaluated for potential adjustments to their diabetes management plan. The patient's current regimen includes metformin and lifestyle modifications. However, recent glycemic control has been suboptimal, and the healthcare provider is considering adding an additional medication to enhance insulin secretion, aiming to achieve better glucose control. Which of the following antidiabetic drugs act by increasing the secretion of insulin, making it a suitable addition to this patient's diabetes management plan?",
      "options": [
        {
          "label": "A",
          "text": "Pramlintide",
          "correct": false
        },
        {
          "label": "B",
          "text": "Metformin",
          "correct": false
        },
        {
          "label": "C",
          "text": "Exenatide",
          "correct": true
        },
        {
          "label": "D",
          "text": "Rosiglitazone",
          "correct": false
        }
      ],
      "correct_answer": "C. Exenatide",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture4.jpg"
      ],
      "explanation": "<p><strong>Ans. C. Exenatide</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Pramlintide : It is an amylin analogu e that mimics the natural hormone amylin . Pramlintide slows gastric emptying, reduces postprandial glucagon secretion, and promotes satiety , leading to decreased caloric intake . However, it does not directly increase insulin secretion.</li><li>\u2022 Option A. Pramlintide</li><li>\u2022 amylin analogu</li><li>\u2022 mimics the natural hormone amylin</li><li>\u2022 slows gastric emptying,</li><li>\u2022 reduces postprandial glucagon secretion,</li><li>\u2022 promotes satiety</li><li>\u2022 decreased caloric intake</li><li>\u2022 does not</li><li>\u2022 increase insulin secretion.</li><li>\u2022 Option B. Metformin : This is a biguanide, which is already part of the patient's regimen. Metformin works mainly by decreasing hepatic glucose production and improving insulin sensitivity but does not increase insulin secretion.</li><li>\u2022 Option B. Metformin</li><li>\u2022 biguanide,</li><li>\u2022 decreasing</li><li>\u2022 hepatic glucose production</li><li>\u2022 insulin sensitivity</li><li>\u2022 does not</li><li>\u2022 increase insulin secretion.</li><li>\u2022 Option D. Rosiglitazone : It belongs to the thiazolidinedione class of drugs, which work by increasing insulin sensitivity rather than directly stimulating insulin secretion.</li><li>\u2022 Option D. Rosiglitazone</li><li>\u2022 thiazolidinedione</li><li>\u2022 increasing insulin sensitivity</li><li>\u2022 stimulating insulin secretion.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 ANTI-DIABETIC DRUGS THAT ACT BY INCREASING THE SECRETION OF INSULIN:</li><li>\u27a4 ANTI-DIABETIC DRUGS THAT ACT BY INCREASING THE SECRETION OF INSULIN:</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "06a65bd8",
      "audio": ""
    },
    {
      "text": "The given figure shows the mechanism of action of Drug Y in treatment of osteoporosis. Which of the following best represents drug Y?",
      "options": [
        {
          "label": "A",
          "text": "Raloxifene",
          "correct": false
        },
        {
          "label": "B",
          "text": "Bisphosphonates",
          "correct": false
        },
        {
          "label": "C",
          "text": "Teriparatide",
          "correct": false
        },
        {
          "label": "D",
          "text": "Denosumab",
          "correct": true
        }
      ],
      "correct_answer": "D. Denosumab",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture16.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D. Denosumab</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Raloxifene: Incorrect for this mechanism. Raloxifene is a selective estrogen receptor modulator (SERM) that mimics estrogen's bone-protective effect s by reducing osteoclast activity, but it does not work by targeting the RANKL-RANK interaction.</li><li>\u2022 Option A. Raloxifene:</li><li>\u2022 Incorrect</li><li>\u2022 Raloxifene is a selective estrogen receptor modulator (SERM)</li><li>\u2022 estrogen's bone-protective effect</li><li>\u2022 reducing osteoclast activity,</li><li>\u2022 does not</li><li>\u2022 RANKL-RANK interaction.</li><li>\u2022 Option B. Bisphosphonates: Also incorrect. Bisphosphonates inhibit osteoclast-mediated bone resorption by inducing osteoclast apoptosis and interfering with the mevalonate pathway , not by RANKL inhibition.</li><li>\u2022 Option B. Bisphosphonates:</li><li>\u2022 incorrect.</li><li>\u2022 inhibit</li><li>\u2022 osteoclast-mediated bone resorption</li><li>\u2022 osteoclast</li><li>\u2022 apoptosis</li><li>\u2022 mevalonate pathway</li><li>\u2022 Option C. Teriparatide: Incorrect for this illustration. Teriparatide, a recombinant form of parathyroid hormone , primarily works by stimulating osteoblasts to promote bone formation rather than inhibiting osteoclasts.</li><li>\u2022 Option C. Teriparatide:</li><li>\u2022 Incorrect</li><li>\u2022 Teriparatide,</li><li>\u2022 parathyroid hormone</li><li>\u2022 stimulating osteoblasts</li><li>\u2022 bone formation rather than inhibiting osteoclasts.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Denosumab is used in the treatment of osteoporosis by targeting the RANKL-RANK interaction , effectively inhibiting osteoclast formation and activity, thus decreasing bone resorption.</li><li>\u27a4 Denosumab</li><li>\u27a4 osteoporosis by targeting the RANKL-RANK interaction</li><li>\u27a4 inhibiting osteoclast</li><li>\u27a4 decreasing bone resorption.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "9ce43baf",
      "audio": ""
    },
    {
      "text": "A 22-year-old female, Neeta, presented to you with complaints of headache and vomiting for 2 months. She has amenorrhea, but the urine pregnancy test is negative. She also complained of secretion of milk from the breasts. A provisional diagnosis of hyperprolactinemia was made, and MRI was suggested. MRI confirmed the presence of a large pituitary adenoma. Neeta was advised surgery; however, she is not willing to undergo surgery. Which of the following medications is most likely to be prescribed to control her symptoms?",
      "options": [
        {
          "label": "A",
          "text": "Sumatriptan",
          "correct": false
        },
        {
          "label": "B",
          "text": "Bromocriptine",
          "correct": true
        },
        {
          "label": "C",
          "text": "Ergotamine",
          "correct": false
        },
        {
          "label": "D",
          "text": "Allopurinol",
          "correct": false
        }
      ],
      "correct_answer": "B. Bromocriptine",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B. Bromocriptine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Sumatriptan : Sumatriptan is a medication used to treat acute migraine headaches . It is a serotonin receptor agonist that causes vasoconstriction of cranial blood vessels. It is not used in the treatment of hyperprolactinemia or pituitary adenomas.</li><li>\u2022 Option A. Sumatriptan</li><li>\u2022 used to treat acute migraine headaches</li><li>\u2022 serotonin receptor agonist</li><li>\u2022 vasoconstriction of cranial blood vessels.</li><li>\u2022 not</li><li>\u2022 hyperprolactinemia or pituitary adenomas.</li><li>\u2022 Option C. Ergotamine : Ergotamine is used for the treatment of migraine headaches . It is an ergot alkaloid that causes vasoconstriction. It does not reduce prolactin levels or treat pituitary adenomas.</li><li>\u2022 Option C. Ergotamine</li><li>\u2022 used for</li><li>\u2022 migraine headaches</li><li>\u2022 ergot alkaloid</li><li>\u2022 vasoconstriction.</li><li>\u2022 does not</li><li>\u2022 prolactin levels or treat pituitary adenomas.</li><li>\u2022 Option D. Allopurinol : Allopurinol is used to decrease high blood uric acid levels , as seen in gout and certain types of kidney stones. It is not relevant to the treatment of hyperprolactinemia or pituitary adenomas.</li><li>\u2022 Option D. Allopurinol</li><li>\u2022 decrease high blood uric acid levels</li><li>\u2022 gout</li><li>\u2022 kidney stones.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Bromocriptine is the appropriate pharmacological treatment for hyperprolactinemia caused by a pituitary adenoma , especially when surgery is not an option.</li><li>\u27a4 Bromocriptine</li><li>\u27a4 hyperprolactinemia</li><li>\u27a4 pituitary adenoma</li><li>\u27a4 Bromocriptine is the preferred choice due to its dual role in reducing prolactin levels and potentially decreasing the size of the adenoma , thus addressing both the hormonal imbalance and its physical cause.</li><li>\u27a4 Bromocriptine</li><li>\u27a4 choice</li><li>\u27a4 reducing prolactin levels and potentially decreasing the size of the</li><li>\u27a4 adenoma</li><li>\u27a4 both</li><li>\u27a4 hormonal imbalance and its physical cause.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d67646f7",
      "audio": ""
    },
    {
      "text": "An obese diabetic patient was on metformin monotherapy, but his sugar levels were not well controlled. He is allergic to sulfa drugs and does not comply with injectable drugs. He has a history of pancreatitis, and family history of bladder carcinoma. In view of the raised glucose levels, you wish to add another anti-diabetic drug. Which one would you prefer?",
      "options": [
        {
          "label": "A",
          "text": "Liraglutide",
          "correct": false
        },
        {
          "label": "B",
          "text": "Sitagliptin",
          "correct": false
        },
        {
          "label": "C",
          "text": "Canagliflozin",
          "correct": true
        },
        {
          "label": "D",
          "text": "Pioglitazone",
          "correct": false
        }
      ],
      "correct_answer": "C. Canagliflozin",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture10.jpg",
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture11.jpg"
      ],
      "explanation": "<p><strong>Ans. C. Canagliflozin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Liraglutide: Not suitable as it is an injectable GLP-1 receptor agonist, and the patient has a non-compliance issue with injectable medications.</li><li>\u2022 Option A. Liraglutide:</li><li>\u2022 Not</li><li>\u2022 injectable GLP-1 receptor agonist,</li><li>\u2022 non-compliance issue</li><li>\u2022 Option B. Sitagliptin: A DPP-4 inhibitor, which has been associated with cases of pancreatitis , making it a less suitable option for a patient with a history of this condition.</li><li>\u2022 Option B. Sitagliptin:</li><li>\u2022 DPP-4 inhibitor,</li><li>\u2022 cases of pancreatitis</li><li>\u2022 less suitable</li><li>\u2022 Option D. Pioglitazone: A thiazolidinedione that has been associated with an i ncreased risk of bladder cancer , especially in individuals with a family history of the disease , thus contraindicating its use in this patient.</li><li>\u2022 Option D. Pioglitazone:</li><li>\u2022 thiazolidinedione</li><li>\u2022 ncreased risk of bladder cancer</li><li>\u2022 family history of the disease</li><li>\u2022 contraindicating its use in this patient.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "48684a4a",
      "audio": ""
    },
    {
      "text": "All the following are contraindications for the use of metformin except?",
      "options": [
        {
          "label": "A",
          "text": "Hypotensive state",
          "correct": false
        },
        {
          "label": "B",
          "text": "Alcoholics",
          "correct": false
        },
        {
          "label": "C",
          "text": "Renal failure",
          "correct": false
        },
        {
          "label": "D",
          "text": "Hypokalemia",
          "correct": true
        }
      ],
      "correct_answer": "D. Hypokalemia",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture1.jpg"
      ],
      "explanation": "<p><strong>Ans. D. Hypokalemia</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Hypotensive state : While not a direct contraindication, caution is advised in conditions that may predispose patients to hypotension , as low perfusion may increase the risk of metformin induced lactic acidosis.</li><li>\u2022 Option A. Hypotensive state</li><li>\u2022 not a direct contraindication,</li><li>\u2022 predispose patients to hypotension</li><li>\u2022 low perfusion</li><li>\u2022 increase the risk of metformin</li><li>\u2022 lactic acidosis.</li><li>\u2022 Option B. Alcoholics : Chronic and excessive alcohol consumption is a contraindication for metformin use due to the increased risk of lactic acidosis , especially in cases of hepatic impairment and acute alcohol intoxication.</li><li>\u2022 Option B. Alcoholics</li><li>\u2022 Chronic and excessive alcohol</li><li>\u2022 contraindication for metformin</li><li>\u2022 increased risk of lactic acidosis</li><li>\u2022 hepatic impairment and acute alcohol intoxication.</li><li>\u2022 Option C. Renal failure : Renal failure or significant renal impairment is a contraindication for the use of metformin due to the increased risk of accumulating metformin and subsequent lactic acidosis . Latest guidelines regarding use of metformin in renal dysfunction include:</li><li>\u2022 Option C. Renal failure</li><li>\u2022 renal impairment is a contraindication</li><li>\u2022 metformin</li><li>\u2022 increased risk of accumulating metformin</li><li>\u2022 lactic acidosis</li><li>\u2022 metformin in renal dysfunction</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Risk factors for metformin induced lactic acidosis :</li><li>\u27a4 Risk factors for metformin induced lactic acidosis</li><li>\u27a4 :</li><li>\u27a4 Hepatic failure Renal failure Alcoholics Metabolic acidosis Elderly Conditions predisposing to hypoxia (Shock, CHF, Severe anemia, Major surgery etc.)</li><li>\u27a4 Hepatic failure</li><li>\u27a4 Renal failure</li><li>\u27a4 Alcoholics</li><li>\u27a4 Metabolic acidosis</li><li>\u27a4 Elderly</li><li>\u27a4 Conditions predisposing to hypoxia (Shock, CHF, Severe anemia, Major surgery etc.)</li><li>\u27a4 Mnemonic:</li><li>\u27a4 Mnemonic:</li><li>\u27a4 MET: MET abolic acidosis</li><li>\u27a4 MET: MET</li><li>\u27a4 F: F ailure (Liver and Renal failure)</li><li>\u27a4 F: F</li><li>\u27a4 O R MIN: O xygen R eaching the tissues is MIN imum (means hypoxia causing conditions)</li><li>\u27a4 O R MIN: O</li><li>\u27a4 R</li><li>\u27a4 MIN</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "1152b628",
      "audio": ""
    },
    {
      "text": "A 70-year-old hypertensive patient with stage 5 chronic kidney disease was diagnosed recently with Type 2 diabetes mellitus. He does not want to take injectable drugs. Which of the following oral hypoglycemic agents will be preferred in this patient that does not require any dose modification in renal failure?",
      "options": [
        {
          "label": "A",
          "text": "Linagliptin",
          "correct": true
        },
        {
          "label": "B",
          "text": "Vildagliptin",
          "correct": false
        },
        {
          "label": "C",
          "text": "Exenatidie",
          "correct": false
        },
        {
          "label": "D",
          "text": "Metformin",
          "correct": false
        }
      ],
      "correct_answer": "A. Linagliptin",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A. Linagliptin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Vildagliptin : While vildagliptin is another DPP-4 inhibitor, it requires dose adjustments in patients with renal impairment , making it less ideal than linagliptin for patients with stage 5 CKD .</li><li>\u2022 Option B. Vildagliptin</li><li>\u2022 vildagliptin</li><li>\u2022 DPP-4 inhibitor,</li><li>\u2022 requires dose adjustments</li><li>\u2022 renal impairment</li><li>\u2022 less ideal than linagliptin</li><li>\u2022 stage 5 CKD</li><li>\u2022 Option C. Exenatide : Exenatide is not an oral hypoglycemic agent but an injectable glucagon-like peptide-1 (GLP-1) receptor agonist. It also requires dose adjustments in patients with renal impairment and would not be suitable for a patient who prefers to avoid injectable drugs.</li><li>\u2022 Option C. Exenatide</li><li>\u2022 Exenatide</li><li>\u2022 not</li><li>\u2022 oral hypoglycemic agent</li><li>\u2022 injectable glucagon-like peptide-1 (GLP-1) receptor agonist.</li><li>\u2022 requires dose adjustments</li><li>\u2022 renal impairment</li><li>\u2022 not</li><li>\u2022 Option D. Metformin : Traditionally, metformin has been contraindicated in patients with significant renal impairment due to the risk of lactic acidosis . Although recent guidelines have provided more lenient criteria for its use in patients with moderate renal impairment , it is generally avoided in stage 5 CKD .</li><li>\u2022 Option D. Metformin</li><li>\u2022 metformin</li><li>\u2022 contraindicated in patients</li><li>\u2022 renal impairment due to the risk of lactic acidosis</li><li>\u2022 more lenient criteria</li><li>\u2022 moderate renal impairment</li><li>\u2022 avoided in stage 5 CKD</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Linagliptin, a DPP-4 inhibitor, is a preferred oral hypoglycemic agent for patients with Type 2 diabetes and severe renal impairment , as it does not require dose adjustments in renal failure , simplifying diabetes management in this population.</li><li>\u27a4 Linagliptin, a DPP-4 inhibitor,</li><li>\u27a4 oral hypoglycemic agent</li><li>\u27a4 Type 2 diabetes and severe renal impairment</li><li>\u27a4 does not</li><li>\u27a4 renal failure</li><li>\u27a4 diabetes management</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "35214d72",
      "audio": ""
    },
    {
      "text": "A lady who was treated for breast cancer is on long-term tamoxifen therapy as she is ER-positive. Drug tamoxifen can increase the risk for which of the following cancers?",
      "options": [
        {
          "label": "A",
          "text": "Carcinoma of ovary",
          "correct": false
        },
        {
          "label": "B",
          "text": "Endometrial carcinoma",
          "correct": true
        },
        {
          "label": "C",
          "text": "Breast carcinoma",
          "correct": false
        },
        {
          "label": "D",
          "text": "Chronic myeloid leukemia",
          "correct": false
        }
      ],
      "correct_answer": "B. Endometrial carcinoma",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B. Endometrial carcinoma</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Carcinoma of the ovary: There is no established link between tamoxifen use and an increased risk of ovarian cancer.</li><li>\u2022 Option</li><li>\u2022 A.</li><li>\u2022 Carcinoma of the ovary:</li><li>\u2022 no</li><li>\u2022 tamoxifen use</li><li>\u2022 Option C. Breast carcinoma: Tamoxifen is actually used to reduce the risk of breast cancer recurrence.</li><li>\u2022 Option</li><li>\u2022 C.</li><li>\u2022 Breast carcinoma:</li><li>\u2022 Tamoxifen</li><li>\u2022 reduce the risk of breast cancer</li><li>\u2022 Option D. Chronic myeloid leukemia: There is no evidence to suggest that tamoxifen increases the risk of developing leukemia.</li><li>\u2022 Option</li><li>\u2022 D.</li><li>\u2022 Chronic myeloid leukemia:</li><li>\u2022 no</li><li>\u2022 tamoxifen increases the risk of developing leukemia.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 While tamoxifen is effective in treating and preventing breast cancer recurrence in ER-positive patients by acting as an estrogen antagonist on breast tissue, its agonistic effects on the uterus can increase the risk of endometrial carcinoma, necessitating careful monitoring and evaluation during therapy.</li><li>\u27a4 tamoxifen</li><li>\u27a4 treating and preventing breast cancer</li><li>\u27a4 ER-positive patients</li><li>\u27a4 acting as an estrogen</li><li>\u27a4 antagonist on breast tissue,</li><li>\u27a4 agonistic effects on the uterus</li><li>\u27a4 increase</li><li>\u27a4 endometrial carcinoma,</li><li>\u27a4 careful</li><li>\u27a4 monitoring and evaluation during therapy.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d01133f8",
      "audio": ""
    },
    {
      "text": "A 65-year-old postmenopausal woman presents to the clinic for a routine health check-up. She is concerned about osteoporosis, as her mother had a hip fracture at the age of 70. She has been on prednisone for the past year for rheumatoid arthritis and is also taking levothyroxine for hypothyroidism. She recently read about the risks of long-term medication use and osteoporosis. She inquiries about her medications and whether any of them could contribute to bone density loss. Which of her current medications is not associated with an increased risk of osteoporosis?",
      "options": [
        {
          "label": "A",
          "text": "Steroids",
          "correct": false
        },
        {
          "label": "B",
          "text": "Alendronate",
          "correct": true
        },
        {
          "label": "C",
          "text": "Thyroxine",
          "correct": false
        },
        {
          "label": "D",
          "text": "Heparin",
          "correct": false
        }
      ],
      "correct_answer": "B. Alendronate",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B. Alendronate</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Steroids: Long-term use of steroids, such as prednisone, is known to cause bone density loss and increase the risk of osteoporosis due to their impact on bone turnover and calcium absorption.</li><li>\u2022 Option A. Steroids:</li><li>\u2022 Long-term use of steroids,</li><li>\u2022 prednisone,</li><li>\u2022 cause bone density loss and increase the risk of</li><li>\u2022 osteoporosis</li><li>\u2022 impact on bone turnover and calcium absorption.</li><li>\u2022 Option C. Thyroxine: Excessive levels of thyroid hormone , whether from hyperthyroidism or over-replacement with levothyroxine, can lead to increased bone resorption and a higher risk of osteoporosis.</li><li>\u2022 Option C. Thyroxine:</li><li>\u2022 Excessive levels of thyroid hormone</li><li>\u2022 hyperthyroidism or over-replacement</li><li>\u2022 levothyroxine,</li><li>\u2022 increased bone resorption and a higher risk of osteoporosis.</li><li>\u2022 Option D. Heparin: Long-term use of heparin can interfere with bone formation and increase the risk of osteoporosis.</li><li>\u2022 Option D. Heparin:</li><li>\u2022 Long-term use of heparin</li><li>\u2022 bone formation and increase the risk of osteoporosis.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Alendronate is used to treat and prevent osteoporosis, whereas steroids, excess thyroxine, and heparin can contribute to the development of osteoporosis.</li><li>\u27a4 Alendronate</li><li>\u27a4 treat and prevent osteoporosis,</li><li>\u27a4 steroids, excess thyroxine, and heparin</li><li>\u27a4 development of osteoporosis.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "2133f1a5",
      "audio": ""
    },
    {
      "text": "Drug of choice for central diabetes Insipidus is. \u200b\u200b\u200b\u200b",
      "options": [
        {
          "label": "A",
          "text": "Desmopressin",
          "correct": true
        },
        {
          "label": "B",
          "text": "Leuprolide",
          "correct": false
        },
        {
          "label": "C",
          "text": "Thiazide diuretics",
          "correct": false
        },
        {
          "label": "D",
          "text": "Insulin",
          "correct": false
        }
      ],
      "correct_answer": "A. Desmopressin",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/01/picture1_dSWDtRK.jpg"
      ],
      "explanation": "<p><strong>Ans. A. Desmopressin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B . Leuprolide : Leuprolide is a gonadotropin-releasing hormone (GnRH) agonist used in the treatment of hormone-sensitive conditions like prostate cancer, endometriosis, and uterine fibroids. It is not used in the treatment of diabetes insipidus as it does not influence ADH secretion or action.</li><li>\u2022 Option B</li><li>\u2022 Leuprolide</li><li>\u2022 gonadotropin-releasing hormone (GnRH) agonist</li><li>\u2022 hormone-sensitive</li><li>\u2022 prostate cancer, endometriosis, and uterine fibroids.</li><li>\u2022 not</li><li>\u2022 diabetes insipidus</li><li>\u2022 not</li><li>\u2022 ADH secretion or action.</li><li>\u2022 Option C . Thiazide Diuretics : Thiazide diuretics are used in the treatment of both nephrogenic diabetes insipidus (a form of the condition caused by the kidneys' inability to respond to ADH) as well as central (neurogenic) diabetes insipidus. They are drug of choice for nephrogenic diabetes insipidus but not central diabetes insipidus. Thiazides reduce urine volume in diabetes insipidus by increasing water absorption in the distal tubules of the kidney, but they do not address the lack of ADH production in central diabetes insipidus.</li><li>\u2022 Option C</li><li>\u2022 Thiazide Diuretics</li><li>\u2022 both nephrogenic diabetes insipidus</li><li>\u2022 kidneys' inability to respond to ADH)</li><li>\u2022 central (neurogenic) diabetes insipidus.</li><li>\u2022 choice for nephrogenic diabetes insipidus</li><li>\u2022 not central diabetes insipidus.</li><li>\u2022 reduce urine volume</li><li>\u2022 increasing water absorption in the distal tubules</li><li>\u2022 do not</li><li>\u2022 lack of ADH production in central</li><li>\u2022 diabetes insipidus.</li><li>\u2022 Option D . Insulin : Insulin is used in the treatment of diabetes mellitus, a completely different condition from diabetes insipidus. Diabetes mellitus involves problems with blood sugar control due to insufficient insulin production (Type 1 diabetes) or insulin resistance (Type 2 diabetes) . It does not directly affect the balance of water in the body, nor is it relevant to the treatment of diabetes insipidus.</li><li>\u2022 Option D</li><li>\u2022 Insulin</li><li>\u2022 treatment of diabetes mellitus,</li><li>\u2022 different</li><li>\u2022 from diabetes insipidus.</li><li>\u2022 Diabetes mellitus</li><li>\u2022 blood sugar control</li><li>\u2022 insufficient insulin production (Type 1 diabetes)</li><li>\u2022 insulin</li><li>\u2022 resistance (Type 2 diabetes)</li><li>\u2022 does not</li><li>\u2022 balance of water in the body, nor</li><li>\u2022 treatment</li><li>\u2022 diabetes insipidus.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "30ddb34b",
      "audio": ""
    },
    {
      "text": "Which of the following drugs can be used for medical adrenalectomy?",
      "options": [
        {
          "label": "A",
          "text": "Metyrapone",
          "correct": false
        },
        {
          "label": "B",
          "text": "Ketoconazole",
          "correct": false
        },
        {
          "label": "C",
          "text": "Aminoglutethimide",
          "correct": false
        },
        {
          "label": "D",
          "text": "All the above",
          "correct": true
        }
      ],
      "correct_answer": "D. All the above",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/01/picture2.jpg"
      ],
      "explanation": "<p><strong>Ans. D. All the above</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Metyrapone: Inhibits 11-\u03b2-hydroxylase, an enzyme critical in the final step of cortisol synthesis in the adrenal cortex . By inhibiting this enzyme , metyrapone effectively reduces cortisol production.</li><li>\u2022 Option A. Metyrapone:</li><li>\u2022 Inhibits 11-\u03b2-hydroxylase,</li><li>\u2022 final step of cortisol synthesis</li><li>\u2022 adrenal cortex</li><li>\u2022 inhibiting this enzyme</li><li>\u2022 metyrapone</li><li>\u2022 reduces cortisol</li><li>\u2022 Option B. Ketoconazole: Is an antifungal medication that also has potent inhibitory effects on adrenal and gonadal steroid synthesis. It works by inhibiting several cytochrome P450 enzymes involved in steroid synthesis, thereby reducing cortisol levels.</li><li>\u2022 Option B. Ketoconazole:</li><li>\u2022 antifungal medication</li><li>\u2022 potent inhibitory effects</li><li>\u2022 adrenal and gonadal steroid synthesis.</li><li>\u2022 inhibiting several cytochrome P450 enzymes</li><li>\u2022 steroid synthesis,</li><li>\u2022 reducing cortisol levels.</li><li>\u2022 Option C. Aminoglutethimide: Inhibits the enzyme P450scc (cholesterol side-chain cleavage enzyme), which is involved in the first step of cortisol synthesis , converting cholesterol to pregnenolone . This results in a decrease in the production of all adrenal steroids , including cortisol.</li><li>\u2022 Option C. Aminoglutethimide:</li><li>\u2022 Inhibits</li><li>\u2022 P450scc (cholesterol side-chain cleavage enzyme),</li><li>\u2022 first</li><li>\u2022 step of cortisol synthesis</li><li>\u2022 cholesterol to pregnenolone</li><li>\u2022 decrease in the production</li><li>\u2022 adrenal</li><li>\u2022 steroids</li><li>\u2022 cortisol.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 DRUGS INHIBITING THE FORMATION OF ADRENAL STEROIDS</li><li>\u27a4 DRUGS INHIBITING THE FORMATION OF ADRENAL STEROIDS</li><li>\u27a4 These drugs can be used for medical adrenalectomy.</li><li>\u27a4 drugs</li><li>\u27a4 medical adrenalectomy.</li><li>\u27a4 Metyrapone Ketoconazole Aminoglutethimide Mitotane</li><li>\u27a4 Metyrapone</li><li>\u27a4 Ketoconazole</li><li>\u27a4 Aminoglutethimide</li><li>\u27a4 Mitotane</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "51dd4857",
      "audio": ""
    },
    {
      "text": "A 28-year-old male presents to the clinic with a history of mild hemophilia A. He reports experiencing prolonged bleeding after minor injuries and is seeking options for management. Which of the following drug can be used in the treatment of mild hemophilia?",
      "options": [
        {
          "label": "A",
          "text": "Corticosteroids",
          "correct": false
        },
        {
          "label": "B",
          "text": "DDAVP",
          "correct": true
        },
        {
          "label": "C",
          "text": "Vitamin K",
          "correct": false
        },
        {
          "label": "D",
          "text": "Tranexamic acid",
          "correct": false
        }
      ],
      "correct_answer": "B. DDAVP",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B. DDAVP</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Corticosteroids are not used in the treatment of hemophilia. They are primarily used to treat inflammation and autoimmune conditions and have no role in increasing clotting factors in hemophilia patients.</li><li>\u2022 Option A. Corticosteroids</li><li>\u2022 not used</li><li>\u2022 hemophilia.</li><li>\u2022 treat inflammation and</li><li>\u2022 autoimmune conditions</li><li>\u2022 no role</li><li>\u2022 increasing clotting factors in hemophilia patients.</li><li>\u2022 Option C. Tranexamic acid is an antifibrinolytic agent that prevents the breakdown of blood clots. While it can be useful in managing bleeding in hemophilia patients , particularly in mucosal bleeding or during dental procedures, it does not address the underlying clotting factor deficiency and is typically used as an adjunct to factor replacement therapy rather than as a primary treatment.</li><li>\u2022 Option C. Tranexamic acid</li><li>\u2022 antifibrinolytic agent</li><li>\u2022 breakdown of blood clots.</li><li>\u2022 bleeding in hemophilia patients</li><li>\u2022 mucosal bleeding or during dental procedures,</li><li>\u2022 does not</li><li>\u2022 clotting factor deficiency</li><li>\u2022 adjunct to factor replacement therapy</li><li>\u2022 primary</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The aim is to understand the treatment modalities available for managing mild hemophilia A, with a focus on the use of DDAVP (Desmopressin) as an effective option for increasing the levels of factor VIII, thereby temporarily correcting the clotting defect . It can result in release of factor VIII and vWF from the endothelium.</li><li>\u27a4 aim</li><li>\u27a4 treatment modalities</li><li>\u27a4 mild hemophilia A,</li><li>\u27a4 DDAVP</li><li>\u27a4 (Desmopressin)</li><li>\u27a4 increasing the levels of factor VIII,</li><li>\u27a4 temporarily</li><li>\u27a4 clotting defect</li><li>\u27a4 release of factor VIII and vWF from the endothelium.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f50e94e5",
      "audio": ""
    },
    {
      "text": "A 30-year-old female presented to the hospital with infertility. After thorough examination and relevant investigations, she was prescribed bromocriptine by the gynecologist. Most likely reason of her infertility is.",
      "options": [
        {
          "label": "A",
          "text": "Hypogonadotropic hypogonadism",
          "correct": false
        },
        {
          "label": "B",
          "text": "Premature ovarian failure",
          "correct": false
        },
        {
          "label": "C",
          "text": "Hyperprolactinemia",
          "correct": true
        },
        {
          "label": "D",
          "text": "Polycystic ovarian disease",
          "correct": false
        }
      ],
      "correct_answer": "C. Hyperprolactinemia",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C. Hyperprolactinemia</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Hypogonadotropic hypogonadism refers to a condition caused by insufficient production of gonadotropin-releasing hormone (GnRH) by the hypothalamus, leading to low levels of LH and FSH and, consequently, impaired gonadal function. Treatment typically involves hormone replacement rather than dopamine agonists.</li><li>\u2022 Option A. Hypogonadotropic hypogonadism</li><li>\u2022 insufficient production of gonadotropin-releasing</li><li>\u2022 hormone (GnRH)</li><li>\u2022 hypothalamus,</li><li>\u2022 low levels of LH and FSH</li><li>\u2022 impaired gonadal function.</li><li>\u2022 hormone replacement</li><li>\u2022 dopamine agonists.</li><li>\u2022 Option B. Premature ovarian failure is characterized by the loss of normal ovarian function before the age of 40 . Women with this condition have low estrogen levels and often elevated gonadotropin levels . Treatment may include hormone replacement therapy, but not specifically bromocriptine.</li><li>\u2022 Option B. Premature ovarian failure</li><li>\u2022 loss of normal ovarian function</li><li>\u2022 40</li><li>\u2022 low estrogen levels</li><li>\u2022 elevated gonadotropin levels</li><li>\u2022 hormone replacement therapy,</li><li>\u2022 not specifically bromocriptine.</li><li>\u2022 Option D. Polycystic ovarian disease (PCOD) , also known as polycystic ovary syndrome (PCOS), is a hormonal disorder causing enlarged ovaries with small cysts on the outer edges . The treatment focuses on managing symptoms and may include lifestyle changes, insulin sensitizers, and fertility treatments , but not typically bromocriptine unless hyperprolactinemia is also present.</li><li>\u2022 Option D. Polycystic ovarian disease (PCOD)</li><li>\u2022 hormonal disorder</li><li>\u2022 enlarged ovaries with small cysts on the outer edges</li><li>\u2022 treatment</li><li>\u2022 lifestyle</li><li>\u2022 changes, insulin sensitizers, and fertility treatments</li><li>\u2022 not</li><li>\u2022 bromocriptine unless hyperprolactinemia</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Hyperprolactinemia, characterized by elevated levels of prolactin, can cause infertility due to its suppression of important reproductive hormones like GnRH, FSH, and LH . Bromocriptine helps restore fertility by lowering prolactin levels.</li><li>\u27a4 Hyperprolactinemia,</li><li>\u27a4 elevated levels of prolactin,</li><li>\u27a4 infertility</li><li>\u27a4 suppression</li><li>\u27a4 GnRH, FSH, and LH</li><li>\u27a4 restore fertility</li><li>\u27a4 lowering prolactin levels.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e760b96e",
      "audio": ""
    },
    {
      "text": "Lente insulin is composed of.",
      "options": [
        {
          "label": "A",
          "text": "30% Amorphous + 70% Crystalline insulin",
          "correct": true
        },
        {
          "label": "B",
          "text": "30% Crystalline + 70% Amorphous insulin",
          "correct": false
        },
        {
          "label": "C",
          "text": "Same as NPH insulin",
          "correct": false
        },
        {
          "label": "D",
          "text": "Only 70% amorphous insulin",
          "correct": false
        }
      ],
      "correct_answer": "A. 30% Amorphous + 70% Crystalline insulin",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A. 30% Amorphous \u00b170% Crystalline insulin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Same as NPH insulin : NPH (Neutral Protamine Hagedorn) insulin is another type of intermediate-acting insulin , but its composition differs from that of Lente insulin . NPH insulin is formulated by combining insulin with protamine to delay its action , not by varying the proportions of amorphous and crystalline insulin.</li><li>\u2022 Option B. Same as NPH insulin</li><li>\u2022 NPH (Neutral Protamine Hagedorn)</li><li>\u2022 intermediate-acting insulin</li><li>\u2022 differs from</li><li>\u2022 Lente insulin</li><li>\u2022 combining insulin with protamine</li><li>\u2022 delay its action</li><li>\u2022 Option D. Only 70% amorphous insulin : This option does not accurately describe any standard insulin formulation. Lente insulin specifically contains both amorphous and crystalline insulin in the proportions of 30% and 70%, respectively.</li><li>\u2022 Option D. Only 70% amorphous insulin</li><li>\u2022 does not</li><li>\u2022 standard insulin formulation.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Lente insulin's unique composition of 30% amorphous and 70% crystalline insulin ensures a delayed absorption , providing an intermediate duration of action that is crucial for maintaining stable blood glucose levels in diabetes management .</li><li>\u27a4 Lente insulin's</li><li>\u27a4 30% amorphous and 70% crystalline insulin</li><li>\u27a4 delayed absorption</li><li>\u27a4 intermediate duration of action</li><li>\u27a4 stable blood glucose levels</li><li>\u27a4 diabetes management</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "225d7b12",
      "audio": ""
    },
    {
      "text": "A 45-year-old patient with a history of chronic uveitis has been on corticosteroid eye drops for an extended period as part of the treatment regimen. During a routine follow-up at the ophthalmology clinic, the ophthalmologist evaluates the patient for potential long-term complications associated with the prolonged use of corticosteroid eye drops. Which of the following is a complication of prolonged use of corticosteroid eye drops?",
      "options": [
        {
          "label": "A",
          "text": "Posterior subcapsular cataract",
          "correct": false
        },
        {
          "label": "B",
          "text": "Iridocyclitis",
          "correct": false
        },
        {
          "label": "C",
          "text": "Open angle glaucoma",
          "correct": true
        },
        {
          "label": "D",
          "text": "Retinoblastoma",
          "correct": false
        }
      ],
      "correct_answer": "C. Open angle glaucoma",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C. Open angle glaucoma</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Posterior subcapsular cataract : Although cataract formation, specifically posterior subcapsular cataracts, can occur with both systemic and prolonged topical corticosteroid use , the direct association is more commonly emphasized with systemic therapy .</li><li>\u2022 Option A. Posterior subcapsular cataract</li><li>\u2022 cataract formation,</li><li>\u2022 systemic and prolonged topical corticosteroid use</li><li>\u2022 more</li><li>\u2022 systemic therapy</li><li>\u2022 Option B. Iridocyclitis : This is an inflammatory condition that corticosteroid eye drops aim to treat , rather than a side effect of their use.</li><li>\u2022 Option B. Iridocyclitis</li><li>\u2022 inflammatory condition</li><li>\u2022 corticosteroid eye drops aim to treat</li><li>\u2022 Option D. Retinoblastoma : Retinoblastoma is a type of eye cancer unrelated to the use of corticosteroid eye drops. It is not a complication of corticosteroid therapy .</li><li>\u2022 Option D. Retinoblastoma</li><li>\u2022 eye cancer</li><li>\u2022 not a complication of corticosteroid therapy</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Adverse effects of corticosteroids ( with prolonged use both as eye drops as well as systemic use )</li><li>\u27a4 Adverse effects of corticosteroids (</li><li>\u27a4 both</li><li>\u27a4 eye drops as well as systemic use</li><li>\u27a4 )</li><li>\u27a4 G \u2013 G laucoma (on topical use)</li><li>\u27a4 G \u2013 G</li><li>\u27a4 L \u2013 L imb muscle atrophy</li><li>\u27a4 L \u2013 L</li><li>\u27a4 U \u2013 U lcer (peptic ulcer)</li><li>\u27a4 U \u2013 U</li><li>\u27a4 C \u2013 C ushing syndrome</li><li>\u27a4 C \u2013 C</li><li>\u27a4 O \u2013 O steoporosis</li><li>\u27a4 O \u2013 O</li><li>\u27a4 C \u2013 C ataract (on systemic use)</li><li>\u27a4 C \u2013 C</li><li>\u27a4 O \u2013 O steonecrosis (avascular necrosis)</li><li>\u27a4 O \u2013 O</li><li>\u27a4 R \u2013 C/I in R enal failure</li><li>\u27a4 R \u2013</li><li>\u27a4 R</li><li>\u27a4 T \u2013 C/I in T uberculosis (particularly ileo-caecal)</li><li>\u27a4 T \u2013</li><li>\u27a4 T</li><li>\u27a4 I \u2013 I mpair healing.</li><li>\u27a4 I \u2013 I</li><li>\u27a4 C \u2013 C/I in C HF</li><li>\u27a4 C \u2013</li><li>\u27a4 C</li><li>\u27a4 O \u2013 O edema</li><li>\u27a4 O \u2013 O</li><li>\u27a4 I \u2013 I nfections (due to immune-suppressant action)</li><li>\u27a4 I \u2013 I</li><li>\u27a4 D \u2013 D iabetes mellitus</li><li>\u27a4 D \u2013 D</li><li>\u27a4 S \u2013 S uppression of HPA-axis</li><li>\u27a4 S \u2013 S</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "8a093df1",
      "audio": ""
    },
    {
      "text": "A 58-year-old patient with Type 2 diabetes mellitus is being evaluated for potential adjustments to their glucose-lowering therapy. The patient's current regimen includes metformin and a once-daily basal insulin. Despite these treatments, the patient's glycemic control remains suboptimal, with particular difficulty managing postprandial blood sugar spikes. The patient has a history of non-alcoholic fatty liver disease but normal liver function tests. The healthcare provider is considering adding repaglinide for treatment of this patient. Which of the following is true about repaglinide?",
      "options": [
        {
          "label": "A",
          "text": "It belongs to sulfonylurea class of drugs.",
          "correct": false
        },
        {
          "label": "B",
          "text": "It is not well absorbed on oral administration.",
          "correct": false
        },
        {
          "label": "C",
          "text": "It is used to control sleep time hyperglycemia.",
          "correct": false
        },
        {
          "label": "D",
          "text": "It should be avoided in patients with liver disease.",
          "correct": true
        }
      ],
      "correct_answer": "D. It should be avoided in patients with liver disease.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D. It should be avoided in patients with liver disease.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. It belongs to the sulfonylurea class of drugs. This statement is incorrect. Repaglinide is a meglitinide , not a sulfonylurea . Both classes of drugs stimulate insulin secretion from the pancreas but through slightly different mechanisms.</li><li>\u2022 Option A. It belongs to the sulfonylurea class of drugs.</li><li>\u2022 incorrect. Repaglinide</li><li>\u2022 meglitinide</li><li>\u2022 not a sulfonylurea</li><li>\u2022 stimulate insulin secretion from the pancreas</li><li>\u2022 Option B. It is not well absorbed on oral administration. This statement is incorrect. Repaglinide is well absorbed when taken orally , which is why it is effective in controlling postprandial (after meal) blood glucose levels .</li><li>\u2022 Option B. It is not well absorbed on oral administration.</li><li>\u2022 incorrect. Repaglinide</li><li>\u2022 well absorbed</li><li>\u2022 orally</li><li>\u2022 controlling postprandial (after meal) blood glucose levels</li><li>\u2022 Option C. It is used to control sleep time hyperglycemia. This statement is incorrect. Repaglinide is primarily used to control postprandial hyperglycemia , not sleep time hyperglycemia. It has a rapid onset and short duration of action , making it suitable for taking before meals to manage blood sugar spikes after eating .</li><li>\u2022 Option C. It is used to control sleep time hyperglycemia.</li><li>\u2022 incorrect. Repaglinide</li><li>\u2022 postprandial hyperglycemia</li><li>\u2022 rapid onset and short duration of action</li><li>\u2022 before meals to manage blood sugar spikes after eating</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Repaglinide is a meglitinide class medication used for the management of postprandial hyperglycemia in patients with Type 2 diabetes . It is important to understand that while repaglinide is effective in controlling blood glucose levels after meals , caution is advised when prescribing it to patients with liver disease due to potential alterations in drug metabolism and clearance.</li><li>\u27a4 Repaglinide</li><li>\u27a4 meglitinide</li><li>\u27a4 postprandial hyperglycemia</li><li>\u27a4 Type 2 diabetes</li><li>\u27a4 repaglinide</li><li>\u27a4 controlling blood glucose levels after meals</li><li>\u27a4 liver disease</li><li>\u27a4 alterations in drug metabolism and clearance.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "43a291e1",
      "audio": ""
    },
    {
      "text": "A 52-year-old patient diagnosed with Graves' disease is under consideration for antithyroid therapy. The patient has a history of atrial fibrillation and is currently on beta-blockers. Given the patient's clinical profile and the need to rapidly achieve euthyroidism while minimizing cardiac complications, the healthcare provider is exploring antithyroid medications that can not only reduce thyroid hormone production but also inhibit the peripheral conversion of thyroxine (T4) to the more active triiodothyronine (T3). Which of the following antithyroid medications can inhibit the peripheral conversion of T4 to T3?",
      "options": [
        {
          "label": "A",
          "text": "Carbimazole",
          "correct": false
        },
        {
          "label": "B",
          "text": "Lugol\u2019s iodine",
          "correct": false
        },
        {
          "label": "C",
          "text": "Propylthiouracil",
          "correct": true
        },
        {
          "label": "D",
          "text": "Methimazole",
          "correct": false
        }
      ],
      "correct_answer": "C. Propylthiouracil",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture3.jpg"
      ],
      "explanation": "<p><strong>Ans. C. Propylthiouracil</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Carbimazole : Carbimazole is a pro-drug that is converted to methimazole in the body . It inhibits thyroid hormone synthesis but does not significantly inhibit the peripheral conversion of T4 to T3.</li><li>\u2022 Option A. Carbimazole</li><li>\u2022 pro-drug</li><li>\u2022 converted to methimazole in the body</li><li>\u2022 inhibits thyroid hormone synthesis</li><li>\u2022 does not</li><li>\u2022 inhibit the peripheral conversion of T4 to T3.</li><li>\u2022 Option B. Lugol\u2019s iodine : Lugol's iodine can quickly reduce the size and vascularity of the thyroid gland and inhibit the release of thyroid hormones , but it does not have a direct inhibitory effect on the peripheral conversion of T4 to T3.</li><li>\u2022 Option B. Lugol\u2019s iodine</li><li>\u2022 reduce the size and vascularity of the thyroid gland</li><li>\u2022 inhibit</li><li>\u2022 thyroid hormones</li><li>\u2022 Option D. Methimazole : Methimazole inhibits thyroid hormone synthesis by blocking the iodination of tyrosine residues in thyroglobulin . Like carbimazole , it does not significantly inhibit the peripheral conversion of T4 to T3.</li><li>\u2022 Option D. Methimazole</li><li>\u2022 inhibits thyroid hormone synthesis</li><li>\u2022 iodination of tyrosine</li><li>\u2022 thyroglobulin</li><li>\u2022 carbimazole</li><li>\u2022 does not</li><li>\u2022 inhibit the peripheral conversion of T4 to T3.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "5a77acd1",
      "audio": ""
    },
    {
      "text": "All of the following are potentially serious side effects of thioamide group of anti-thyroid drugs except?",
      "options": [
        {
          "label": "A",
          "text": "Hepatic dysfunction",
          "correct": false
        },
        {
          "label": "B",
          "text": "Severe rash",
          "correct": false
        },
        {
          "label": "C",
          "text": "Agranulocytosis",
          "correct": false
        },
        {
          "label": "D",
          "text": "Anaphylaxis",
          "correct": true
        }
      ],
      "correct_answer": "D. Anaphylaxis",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D. Anaphylaxis</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Hepatic dysfunction : This is a known serious side effect of thioamides, particularly propylthiouracil. Hepatic dysfunction can range from mild elevation of liver enzymes to severe liver injury and hepatic failure .</li><li>\u2022 Option A.</li><li>\u2022 Hepatic dysfunction</li><li>\u2022 known serious side effect of thioamides,</li><li>\u2022 propylthiouracil.</li><li>\u2022 mild elevation of liver enzymes to severe liver injury and hepatic failure</li><li>\u2022 Option B. Severe rash : Dermatologic reactions, including severe rashes , can occur with thioamide drugs and can sometimes be serious enough to warrant discontinuation of the medication.</li><li>\u2022 Option B. Severe rash</li><li>\u2022 Dermatologic reactions,</li><li>\u2022 rashes</li><li>\u2022 thioamide drugs</li><li>\u2022 warrant discontinuation of the medication.</li><li>\u2022 Option C. Agranulocytosis : A serious and potentially life-threatening decrease in white blood cell count, specifically granulocytes, is a known side effect of thioamides . Agranulocytosis can lead to an increased risk of infections.</li><li>\u2022 Option C. Agranulocytosis</li><li>\u2022 serious and potentially life-threatening</li><li>\u2022 decrease</li><li>\u2022 white blood cell count,</li><li>\u2022 side effect</li><li>\u2022 thioamides</li><li>\u2022 Agranulocytosis</li><li>\u2022 increased risk of infections.</li><li>\u2022 Given the options, the least likely serious side effect of thioamide antithyroid drugs is anaphylaxis .</li><li>\u2022 least likely serious side</li><li>\u2022 anaphylaxis</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Anaphylaxis is not a commonly reported side effect of thioamide antithyroid drugs, making it the least likely serious side effect among the options provided. Common serious side effects include hepatic dysfunction, severe rashes, and agranulocytosis.</li><li>\u27a4 Anaphylaxis</li><li>\u27a4 not</li><li>\u27a4 side effect of thioamide antithyroid drugs,</li><li>\u27a4 least likely serious side effect</li><li>\u27a4 hepatic dysfunction, severe rashes, and agranulocytosis.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a1aa904f",
      "audio": ""
    },
    {
      "text": "Metformin causes a severe, sometimes life-threatening side effect of lactic acidosis. All the following factors increase the risk of lactic acidosis except.",
      "options": [
        {
          "label": "A",
          "text": "Advanced age",
          "correct": false
        },
        {
          "label": "B",
          "text": "Smoking",
          "correct": true
        },
        {
          "label": "C",
          "text": "Liver dysfunction",
          "correct": false
        },
        {
          "label": "D",
          "text": "Renal failure",
          "correct": false
        }
      ],
      "correct_answer": "B. Smoking",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B. Smoking</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Advanced age: Increases the risk because renal function typically declines with age , affecting metformin\u2019s clearance and increasing the likelihood of adverse effects including lactic acidosis.</li><li>\u2022 Option A. Advanced age:</li><li>\u2022 Increases the risk</li><li>\u2022 renal function</li><li>\u2022 declines with age</li><li>\u2022 metformin\u2019s clearance and increasing</li><li>\u2022 adverse effects</li><li>\u2022 lactic acidosis.</li><li>\u2022 Option C. Liver dysfunction: A significant risk factor as liver disease can impair lactate clearance leading to higher lactate levels in the body.</li><li>\u2022 Option C. Liver dysfunction:</li><li>\u2022 risk factor as liver disease</li><li>\u2022 impair lactate clearance</li><li>\u2022 higher lactate levels</li><li>\u2022 Option D. Renal failure: Directly linked to an increased risk due to the role of the kidneys in clearing metformin from the body ; reduced renal function can lead to accumulation of the drug and an increased risk of lactic acidosis .</li><li>\u2022 Option D. Renal failure:</li><li>\u2022 increased risk</li><li>\u2022 kidneys in clearing metformin from the body</li><li>\u2022 reduced renal function</li><li>\u2022 accumulation of the drug</li><li>\u2022 increased risk of lactic acidosis</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Risk factors for metformin induced lactic acidosis :</li><li>\u27a4 Risk factors</li><li>\u27a4 metformin induced lactic acidosis</li><li>\u27a4 Cardiorespiratory insufficiency leading to hypoxia (as in hypotensive state, cardiovascular disease, severe anemia) etc. Hepatic failure Renal failure Alcoholics Elderly</li><li>\u27a4 Cardiorespiratory insufficiency leading to hypoxia (as in hypotensive state, cardiovascular disease, severe anemia) etc.</li><li>\u27a4 Hepatic failure</li><li>\u27a4 Renal failure</li><li>\u27a4 Alcoholics</li><li>\u27a4 Elderly</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "1dde75b3",
      "audio": ""
    },
    {
      "text": "All the following drugs are used in treatment of osteoporosis except.",
      "options": [
        {
          "label": "A",
          "text": "Milnacipran",
          "correct": true
        },
        {
          "label": "B",
          "text": "Teriparatide",
          "correct": false
        },
        {
          "label": "C",
          "text": "Strontium ranelate",
          "correct": false
        },
        {
          "label": "D",
          "text": "Denosumab",
          "correct": false
        }
      ],
      "correct_answer": "A. Milnacipran",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture6.jpg"
      ],
      "explanation": "<p><strong>Ans. A. Milnacipran</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 Option B. Teriparatide : Teriparatide is a recombinant form of parathyroid hormone used in the treatment of osteoporosis. It stimulates new bone formation by acting on osteoblasts , making it effective in reducing the risk of fractures in patients with osteoporosis.</li><li>\u2022 Option B. Teriparatide</li><li>\u2022 recombinant form of parathyroid hormone</li><li>\u2022 osteoporosis.</li><li>\u2022 new bone formation</li><li>\u2022 osteoblasts</li><li>\u2022 reducing the risk of fractures</li><li>\u2022 osteoporosis.</li><li>\u2022 Option C. Strontium ranelate : Strontium ranelate is a medication used to treat severe osteoporosis in postmenopausal women and men at high risk of fractures . It works by simultaneously decreasing bone resorption and increasing bone formation.</li><li>\u2022 Option C. Strontium ranelate</li><li>\u2022 used to treat severe osteoporosis in postmenopausal women</li><li>\u2022 men at high risk of fractures</li><li>\u2022 decreasing bone resorption and increasing bone formation.</li><li>\u2022 Option D. Denosumab : Denosumab is a monoclonal antibody that inhibits RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand) , a protein that acts as the primary signal for bone removal . By inhibiting RANKL, denosumab decreases bone resorption and increases bone mass and strength in patients with osteoporosis.</li><li>\u2022 Option D. Denosumab</li><li>\u2022 monoclonal antibody that inhibits RANKL (Receptor Activator of Nuclear Factor Kappa-B</li><li>\u2022 Ligand)</li><li>\u2022 acts</li><li>\u2022 primary signal for bone removal</li><li>\u2022 By inhibiting RANKL,</li><li>\u2022 decreases bone resorption and</li><li>\u2022 increases bone mass and strength</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Drugs Used for Osteoporosis</li><li>\u27a4 Drugs Used for Osteoporosis</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "5add4a11",
      "audio": ""
    },
    {
      "text": "Drug of choice for treatment of central precocious puberty in girls is.",
      "options": [
        {
          "label": "A",
          "text": "GnRH analogue",
          "correct": true
        },
        {
          "label": "B",
          "text": "Danazol",
          "correct": false
        },
        {
          "label": "C",
          "text": "Cyproterone acetate",
          "correct": false
        },
        {
          "label": "D",
          "text": "Medroxyprogesterone acetate",
          "correct": false
        }
      ],
      "correct_answer": "A. GnRH analogue",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A. GnRH analogue</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Danazol : Danazol is a synthetic steroid with androgenic activity used to treat endometriosis and fibrocystic breast disease. It is not the drug of choice for treating precocious puberty.</li><li>\u2022 Option B. Danazol</li><li>\u2022 synthetic steroid</li><li>\u2022 androgenic activity</li><li>\u2022 endometriosis and fibrocystic breast disease.</li><li>\u2022 not</li><li>\u2022 drug of choice</li><li>\u2022 precocious puberty.</li><li>\u2022 Option C. Cyproterone acetate : Cyproterone acetate is an anti-androgen and progestin medication used for androgen-dependent conditions like s evere acne, excessive hair growth, and androgen-sensitive prostate cancer . While it can reduce androgen effects , it is not the primary treatment for precocious puberty in girls.</li><li>\u2022 Option C. Cyproterone acetate</li><li>\u2022 anti-androgen and progestin</li><li>\u2022 androgen-dependent</li><li>\u2022 evere acne, excessive hair growth, and androgen-sensitive prostate cancer</li><li>\u2022 reduce androgen effects</li><li>\u2022 not</li><li>\u2022 precocious puberty in girls.</li><li>\u2022 Option D. Medroxyprogesterone acetate : Medroxyprogesterone acetate is a progestin used as contraception and in hormone therapy for menopausal symptoms or psychiatric conditions. It is not used as the first-line treatment for precocious puberty.</li><li>\u2022 Option D. Medroxyprogesterone acetate</li><li>\u2022 progestin</li><li>\u2022 contraception and in hormone</li><li>\u2022 therapy</li><li>\u2022 not</li><li>\u2022 first-line treatment for precocious puberty.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 GnRH analogues are the drug of choice for treating central precocious puberty in girls due to their ability to control and regulate the premature release of sex hormones, effectively delaying early puberty. This treatment is not applicable for peripheral precocious puberty, which requires different therapeutic approaches like androgen antagonists or aromatase inhibitors.</li><li>\u27a4 GnRH analogues</li><li>\u27a4 drug of choice</li><li>\u27a4 treating central precocious puberty in girls</li><li>\u27a4 control and regulate the</li><li>\u27a4 premature release of sex hormones,</li><li>\u27a4 delaying early puberty.</li><li>\u27a4 not</li><li>\u27a4 peripheral precocious puberty,</li><li>\u27a4 androgen antagonists or aromatase inhibitors.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "47206141",
      "audio": ""
    },
    {
      "text": "Which of the following is used in the treatment of hyperprolactinemia?",
      "options": [
        {
          "label": "A",
          "text": "Cimetidine",
          "correct": false
        },
        {
          "label": "B",
          "text": "Methysergide",
          "correct": false
        },
        {
          "label": "C",
          "text": "Bromocriptine",
          "correct": true
        },
        {
          "label": "D",
          "text": "Ondansetron",
          "correct": false
        }
      ],
      "correct_answer": "C. Bromocriptine",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture7.jpg"
      ],
      "explanation": "<p><strong>Ans. C. Bromocriptine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Cimetidine : Cimetidine is a histamine H2 receptor antagonist used primarily to treat peptic ulcer disease and g astroesophageal reflux disease (GERD) . It is not used in the treatment of hyperprolactinemia.</li><li>\u2022 Option A. Cimetidine</li><li>\u2022 histamine H2 receptor antagonist</li><li>\u2022 peptic ulcer disease and</li><li>\u2022 astroesophageal reflux disease (GERD)</li><li>\u2022 not</li><li>\u2022 hyperprolactinemia.</li><li>\u2022 Option B. Methysergide : Methysergide is a medication used to prevent migraine headache. It is not used for the treatment of hyperprolactinemia.</li><li>\u2022 Option B. Methysergide</li><li>\u2022 Methysergide</li><li>\u2022 prevent migraine headache.</li><li>\u2022 Option D. Ondansetron : Ondansetron is a serotonin 5-HT3 receptor antagonist used primarily to prevent nausea and vomiting associated with chemotherapy, radiation therapy, and surgery. It is not used in the treatment of hyperprolactinemia.</li><li>\u2022 Option D. Ondansetron</li><li>\u2022 serotonin 5-HT3 receptor antagonist</li><li>\u2022 prevent nausea and vomiting</li><li>\u2022 chemotherapy, radiation therapy, and surgery.</li><li>\u2022 not</li><li>\u2022 hyperprolactinemia.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Uses of Dopamine Agonists</li><li>\u27a4 Uses of Dopamine Agonists</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ef7a51ad",
      "audio": ""
    },
    {
      "text": "Octreotide is used in all except?",
      "options": [
        {
          "label": "A",
          "text": "Glucagonoma",
          "correct": false
        },
        {
          "label": "B",
          "text": "Insulinoma",
          "correct": false
        },
        {
          "label": "C",
          "text": "Carcinoid syndrome",
          "correct": false
        },
        {
          "label": "D",
          "text": "Glioma",
          "correct": true
        }
      ],
      "correct_answer": "D. Glioma",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture8.jpg"
      ],
      "explanation": "<p><strong>Ans. D. Glioma</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Glucagonoma : Octreotide is used in the management of glucagonoma, a rare type of pancreatic neuroendocrine tumor that secretes excessive amounts of glucagon. Octreotide helps in controlling symptoms by inhibiting glucagon secretion.</li><li>\u2022 Option A. Glucagonoma</li><li>\u2022 Octreotide</li><li>\u2022 glucagonoma,</li><li>\u2022 pancreatic neuroendocrine tumor</li><li>\u2022 secretes excessive amounts of glucagon.</li><li>\u2022 inhibiting glucagon secretion.</li><li>\u2022 Option B. Insulinoma : Although insulinomas produce excessive insulin, octreotide can sometimes be used in the management of these tumors to help control hypoglycemia , particularly in patients with metastatic disease or those who are not candidates for surgery.</li><li>\u2022 Option B. Insulinoma</li><li>\u2022 insulinomas produce excessive insulin,</li><li>\u2022 octreotide</li><li>\u2022 help control hypoglycemia</li><li>\u2022 metastatic disease</li><li>\u2022 not candidates for</li><li>\u2022 surgery.</li><li>\u2022 Option C. Carcinoid syndrome : Octreotide is effectively used in the treatment of carcinoid syndrome , which is characterized by flushing, diarrhea, and wheezing due to the secretion of serotonin and other vasoactive substances by carcinoid tumors. Octreotide helps in reducing these symptoms by inhibiting the secretion of these substances.</li><li>\u2022 Option C. Carcinoid syndrome</li><li>\u2022 Octreotide</li><li>\u2022 carcinoid syndrome</li><li>\u2022 flushing, diarrhea, and wheezing</li><li>\u2022 secretion of serotonin</li><li>\u2022 vasoactive substances</li><li>\u2022 carcinoid tumors.</li><li>\u2022 Octreotide</li><li>\u2022 inhibiting the secretion of these substances.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Uses of Octreotide</li><li>\u27a4 Uses of Octreotide</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "9d61014a",
      "audio": ""
    },
    {
      "text": "All the following statements about octreotide are true except.",
      "options": [
        {
          "label": "A",
          "text": "It is effective orally.",
          "correct": true
        },
        {
          "label": "B",
          "text": "It is used for the treatment of acromegaly.",
          "correct": false
        },
        {
          "label": "C",
          "text": "It can be used for the management of secretory Diarrhea.",
          "correct": false
        },
        {
          "label": "D",
          "text": "It can be used in portal hypertension.",
          "correct": false
        }
      ],
      "correct_answer": "A. It is effective orally.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A. It is effective orally.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. It is used for the treatment of acromegaly : This statement is true . Octreotide is used in the treatment of acromegaly, a condition characterized by excessive growth hormone production, leading to enlarged features. Octreotide helps by inhibiting growth hormone secretion.</li><li>\u2022 Option B. It is used for the treatment of acromegaly</li><li>\u2022 true</li><li>\u2022 Octreotide</li><li>\u2022 treatment of acromegaly,</li><li>\u2022 excessive growth hormone production, leading to enlarged</li><li>\u2022 Octreotide</li><li>\u2022 inhibiting</li><li>\u2022 growth hormone secretion.</li><li>\u2022 Option C. It can be used for the management of secretory Diarrhea : This is also true. Octreotide can manage secretory diarrhea, including that caused by certain tumors (like carcinoid tumors or VIPomas), by inhibiting the secretion of various gastrointestinal hormones and substances.</li><li>\u2022 Option C. It can be used for the management of secretory Diarrhea</li><li>\u2022 true.</li><li>\u2022 secretory diarrhea,</li><li>\u2022 caused by certain tumors (like carcinoid tumors or VIPomas),</li><li>\u2022 inhibiting the secretion</li><li>\u2022 hormones and substances.</li><li>\u2022 Option D. It can be used in portal hypertension : True. Octreotide is used in the management of portal hypertension, particularly to control variceal bleeding, by reducing blood flow to the gastrointestinal tract and lowering portal vein pressure.</li><li>\u2022 Option D. It can be used in portal hypertension</li><li>\u2022 True.</li><li>\u2022 portal hypertension,</li><li>\u2022 control variceal bleeding,</li><li>\u2022 reducing blood flow</li><li>\u2022 gastrointestinal tract</li><li>\u2022 lowering portal vein pressure.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 While octreotide is a valuable medication in the management of acromegaly, secretory diarrhea, and portal hypertension, it must be administered through parenteral routes due to its poor oral bioavailability.</li><li>\u27a4 octreotide</li><li>\u27a4 acromegaly, secretory diarrhea, and portal hypertension,</li><li>\u27a4 parenteral routes</li><li>\u27a4 poor oral bioavailability.</li><li>\u27a4 Note - You can remember this fact from the name of the drug. If the name of a drug ends with \u2018tide\u2019, it is a peptide and peptides cannot be given orally because, the presence of peptidases (like pepsin, trypsin etc.) will make these inactive.</li><li>\u27a4 Note</li><li>\u27a4 name of a drug ends with \u2018tide\u2019,</li><li>\u27a4 peptide and peptides</li><li>\u27a4 cannot be given orally</li><li>\u27a4 presence of peptidases (like pepsin, trypsin etc.)</li><li>\u27a4 inactive.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "8658993b",
      "audio": ""
    },
    {
      "text": "Which of the following statements about iodine is false?",
      "options": [
        {
          "label": "A",
          "text": "Contraindicated in hyperthyroidism.",
          "correct": true
        },
        {
          "label": "B",
          "text": "Causes iodism.",
          "correct": false
        },
        {
          "label": "C",
          "text": "Inhibits the release of thyroxine.",
          "correct": false
        },
        {
          "label": "D",
          "text": "Inhibits the synthesis of iodo thyroxine and iodothyronine.",
          "correct": false
        }
      ],
      "correct_answer": "A. Contraindicated in hyperthyroidism.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A. Contraindicated in hyperthyroidism.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Causes iodism : This statement is true. Iodism refers to a set of symptoms including metallic taste, burning mouth and throat, sore teeth and gums, symptoms of a head cold, and sometimes stomach upset and diarrhea. These symptoms can occur with the use of iodine supplements or drugs.</li><li>\u2022 Option B. Causes iodism</li><li>\u2022 Option C. Inhibits the release of thyroxine : True. High doses of iodine can temporarily inhibit the release of thyroxine (T4) and triiodothyronine (T3) from the thyroid gland, a phenomenon known as the Wolff-Chaikoff effect.</li><li>\u2022 Option C. Inhibits the release of thyroxine</li><li>\u2022 Option D. Inhibits the synthesis of iodo thyroxine and iodothyronine : True. Iodine in large doses can inhibit the synthesis of thyroid hormones (thyroxine [T4] and triiodothyronine [T3]) by interfering with the iodination of tyrosyl residues in thyroglobulin and the coupling of iodotyrosyl residues to form iodothyronines.</li><li>\u2022 Option D. Inhibits the synthesis of iodo thyroxine and iodothyronine</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Iodine is not universally contraindicated in hyperthyroidism. It can be used strategically to manage certain aspects of the condition, such as preoperative preparation and acute crisis management, through its temporary inhibitory effects on thyroid hormone synthesis and release.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d4998821",
      "audio": ""
    },
    {
      "text": "All the following antidiabetic drugs act by release of insulin except?",
      "options": [
        {
          "label": "A",
          "text": "SGLT 2 inhibitor",
          "correct": true
        },
        {
          "label": "B",
          "text": "DPP IV inhibitor",
          "correct": false
        },
        {
          "label": "C",
          "text": "Meglitinide analogues",
          "correct": false
        },
        {
          "label": "D",
          "text": "GLP1 agonist",
          "correct": false
        }
      ],
      "correct_answer": "A. SGLT 2 inhibitor",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture9.jpg"
      ],
      "explanation": "<p><strong>Ans. A. SGLT 2 inhibitor</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. DPP-IV inhibitor : DPP-IV inhibitors like sitagliptin work by inhibiting the enzyme dipeptidyl peptidase-4, which is responsible for the degradation of incretin hormones. By inhibiting this enzyme, the levels of incretin hormones (such as GLP-1) are increased, which in turn stimulates the release of insulin in a glucose-dependent manner.</li><li>\u2022 Option B. DPP-IV inhibitor</li><li>\u2022 sitagliptin work by inhibiting the enzyme dipeptidyl peptidase-4,</li><li>\u2022 degradation of incretin hormones.</li><li>\u2022 inhibiting this enzyme,</li><li>\u2022 levels of incretin hormones (such as GLP-1) are</li><li>\u2022 increased,</li><li>\u2022 stimulates the release of insulin in a glucose-dependent manner.</li><li>\u2022 Option C. Meglitinide analogues : Meglitinide analogues like repaglinide stimulate the pancreas to release more insulin . They bind to specific channels on pancreatic beta cells, causing these cells to release insulin, thereby reducing blood glucose levels.</li><li>\u2022 Option C. Meglitinide analogues</li><li>\u2022 repaglinide stimulate the pancreas to release more insulin</li><li>\u2022 bind</li><li>\u2022 specific channels on pancreatic beta cells,</li><li>\u2022 cells to release insulin,</li><li>\u2022 reducing blood glucose levels.</li><li>\u2022 Option D. GLP-1 agonist : GLP-1 agonists like exenatide mimic the action of the incretin hormone GLP-1, which increases insulin secretion from the pancreas in a glucose-dependent manner. Additionally, GLP-1 agonists reduce glucagon secretion and slow gastric emptying.</li><li>\u2022 Option D. GLP-1 agonist</li><li>\u2022 exenatide mimic</li><li>\u2022 incretin hormone GLP-1,</li><li>\u2022 increases insulin</li><li>\u2022 secretion</li><li>\u2022 glucose-dependent manner.</li><li>\u2022 GLP-1 agonists reduce glucagon secretion and slow</li><li>\u2022 gastric emptying.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 CLASSIFICATION OF ANTI-DIABETIC DRUGS</li><li>\u27a4 CLASSIFICATION OF ANTI-DIABETIC DRUGS</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f3b5f2f2",
      "audio": ""
    },
    {
      "text": "Which of the following patients should be treated with either an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker?",
      "options": [
        {
          "label": "A",
          "text": "A 24-year-old woman with type 1 diabetes with two positive spot microalbuminuria tests 1 week apart",
          "correct": false
        },
        {
          "label": "B",
          "text": "A 32-year-old woman with type 1 diabetes with a blood glucose of 328 mg/dL and a positive spot microalbuminuria test",
          "correct": false
        },
        {
          "label": "C",
          "text": "A 48-year-old man with type 2 diabetes with a positive spot microalbuminuria test 1 week after starting a new exercise program",
          "correct": false
        },
        {
          "label": "D",
          "text": "A 56-year-old man with type 2 diabetes with two positive spot microalbuminuria tests 3 months apart",
          "correct": true
        }
      ],
      "correct_answer": "D. A 56-year-old man with type 2 diabetes with two positive spot microalbuminuria tests 3 months apart",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) A 56-year-old man with type 2 diabetes with two positive spot microalbuminuria tests 3 months apart</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. The testing interval of 1 week is too soon for confirmation of persistent microalbuminuria.</li><li>\u2022 Option A.</li><li>\u2022 interval of 1 week</li><li>\u2022 persistent microalbuminuria.</li><li>\u2022 Option B. The presence of severe hyperglycemia can transiently increase albumin excretion , potentially confounding the test result.</li><li>\u2022 Option B.</li><li>\u2022 severe hyperglycemia</li><li>\u2022 transiently increase albumin excretion</li><li>\u2022 test result.</li><li>\u2022 Option C. Vigorous exercise can also transiently increase albumin excretion, making the test result unreliable.</li><li>\u2022 Option C.</li><li>\u2022 Vigorous exercise</li><li>\u2022 increase albumin excretion,</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In the management of diabetic nephropathy, ACE inhibitors or ARBs should be initiated in patients with type 2 diabetes who have confirmed persistent microalbuminuria, indicated by at least two positive microalbuminuria tests spaced 3 to 6 months apart, without the influence of confounding factors.</li><li>\u27a4 diabetic nephropathy, ACE inhibitors or ARBs</li><li>\u27a4 type 2 diabetes</li><li>\u27a4 confirmed persistent microalbuminuria,</li><li>\u27a4 at least two positive microalbuminuria tests</li><li>\u27a4 3 to 6 months</li><li>\u27a4 without</li><li>\u27a4 confounding factors.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e67097a3",
      "audio": ""
    },
    {
      "text": "Ulipristal is a relatively new drug being used by gynecologists. It acts as a?",
      "options": [
        {
          "label": "A",
          "text": "GnRH agonist",
          "correct": false
        },
        {
          "label": "B",
          "text": "Androgen antagonist",
          "correct": false
        },
        {
          "label": "C",
          "text": "Selective estrogen receptor modulator",
          "correct": false
        },
        {
          "label": "D",
          "text": "Selective progesterone receptor modulator",
          "correct": true
        }
      ],
      "correct_answer": "D. Selective progesterone receptor modulator",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D. Selective progesterone receptor modulator</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. GnRH agonist : GnRH agonists work by initially stimulating and then downregulating the production of gonadotropins (LH and FSH) , leading to a decrease in estrogen and testosterone production . Examples include leuprolide and goserelin . Ulipristal does not act through this mechanism.</li><li>\u2022 Option A. GnRH agonist</li><li>\u2022 initially stimulating and then downregulating the production of gonadotropins (LH</li><li>\u2022 and FSH)</li><li>\u2022 decrease in estrogen and testosterone production</li><li>\u2022 leuprolide and goserelin</li><li>\u2022 Ulipristal does</li><li>\u2022 not act</li><li>\u2022 mechanism.</li><li>\u2022 Option B. Androgen antagonist : Androgen antagonists block the effects of androgens (male hormones) at their receptor sites . They are used in conditions like prostate cancer and hirsutism in women. Ulipristal does not function as an androgen antagonist.</li><li>\u2022 Option B. Androgen antagonist</li><li>\u2022 block the effects of androgens (male hormones) at their receptor sites</li><li>\u2022 prostate cancer and hirsutism in women.</li><li>\u2022 Option C. Selective estrogen receptor modulator : SERMs, such as tamoxifen or raloxifene, act on estrogen receptors , having agonistic or antagonistic effects depending on the target tissue . Ulipristal, however, specifically modulates progesterone receptors, not estrogen receptors.</li><li>\u2022 Option C. Selective estrogen receptor modulator</li><li>\u2022 tamoxifen or raloxifene,</li><li>\u2022 estrogen receptors</li><li>\u2022 agonistic or antagonistic effects depending on the target tissue</li><li>\u2022 Ulipristal,</li><li>\u2022 modulates progesterone receptors,</li><li>\u2022 not</li><li>\u2022 estrogen receptors.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Ulipristal is a selective progesterone receptor modulator (SPRM) used in gynecology for emergency contraception and the treatment of uterine fibroids . Its unique action on progesterone receptors allows for versatile therapeutic effects in reproductive health.</li><li>\u27a4 Ulipristal</li><li>\u27a4 selective progesterone receptor modulator (SPRM)</li><li>\u27a4 gynecology for emergency contraception</li><li>\u27a4 uterine fibroids</li><li>\u27a4 action on progesterone receptors</li><li>\u27a4 versatile therapeutic effects</li><li>\u27a4 reproductive</li><li>\u27a4 health.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "de19c9a5",
      "audio": ""
    },
    {
      "text": "What are the appropriate instructions to be given while prescribing bisphosphonates to a patient?",
      "options": [
        {
          "label": "A",
          "text": "To be given an empty stomach with a full glass of water.",
          "correct": true
        },
        {
          "label": "B",
          "text": "Must be taken along with food.",
          "correct": false
        },
        {
          "label": "C",
          "text": "Should be stopped if features of gastritis develop.",
          "correct": false
        },
        {
          "label": "D",
          "text": "Should be stopped if bone pains occur.",
          "correct": false
        }
      ],
      "correct_answer": "A. To be given an empty stomach with a full glass of water.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A. To be given empty stomach with a glass of water</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Must be taken along with food : This instruction is incorrect because food significantly decreases the absorption of bisphosphonates. They should be taken on an empty stomach.</li><li>\u2022 Option B. Must be taken along with food</li><li>\u2022 incorrect</li><li>\u2022 food</li><li>\u2022 decreases the absorption of</li><li>\u2022 bisphosphonates.</li><li>\u2022 should be taken</li><li>\u2022 empty stomach.</li><li>\u2022 Option C. Should be stopped if features of gastritis develop : While patients should report any severe gastrointestinal symptoms to their healthcare provider, the decision to stop the medication should be made by the physician. Management strategies may include evaluating the patient's condition, considering an alternative bisphosphonate formulation (e.g., intravenous), or addressing the gastritis while continuing treatment as necessary.</li><li>\u2022 Option C. Should be stopped if features of gastritis develop</li><li>\u2022 severe gastrointestinal symptoms</li><li>\u2022 healthcare provider,</li><li>\u2022 decision to stop</li><li>\u2022 by the physician.</li><li>\u2022 alternative bisphosphonate formulation (e.g., intravenous),</li><li>\u2022 addressing</li><li>\u2022 gastritis</li><li>\u2022 continuing treatment as necessary.</li><li>\u2022 Option D. Should be stopped if bone pains occur : Bone pain can be a side effect of bisphosphonates, but patients should consult their healthcare provider before stopping the medication . The provider may assess the cause of bone pain and consider alternative treatments or supportive measures rather than immediately discontinuing the bisphosphonate.</li><li>\u2022 Option D. Should be stopped if bone pains occur</li><li>\u2022 side effect of bisphosphonates,</li><li>\u2022 should consult</li><li>\u2022 healthcare provider</li><li>\u2022 stopping the medication</li><li>\u2022 cause of bone pain</li><li>\u2022 alternative</li><li>\u2022 treatments or supportive</li><li>\u2022 immediately discontinuing the bisphosphonate.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 When prescribing bisphosphonates, it is crucial to instruct patients to take the medication on an empty stomach with plenty of water and to remain upright for at least 30 to 60 minutes afterward to prevent gastrointestinal complications and ensure optimal absorption of the drug.</li><li>\u27a4 bisphosphonates,</li><li>\u27a4 crucial to instruct patients</li><li>\u27a4 empty stomach</li><li>\u27a4 plenty of</li><li>\u27a4 water</li><li>\u27a4 upright for</li><li>\u27a4 least 30 to 60 minutes</li><li>\u27a4 prevent gastrointestinal complications</li><li>\u27a4 optimal</li><li>\u27a4 absorption of the drug.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "052d9960",
      "audio": ""
    },
    {
      "text": "Table sugar is not used in treating hypoglycemia secondary to?",
      "options": [
        {
          "label": "A",
          "text": "Acarbose",
          "correct": true
        },
        {
          "label": "B",
          "text": "Metformin",
          "correct": false
        },
        {
          "label": "C",
          "text": "Glipizide",
          "correct": false
        },
        {
          "label": "D",
          "text": "Insulin",
          "correct": false
        }
      ],
      "correct_answer": "A. Acarbose",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A. Acarbose</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Metformin : Metformin primarily works by decreasing hepatic glucose production and improving insulin sensitivity . It does not directly cause hypoglycemia when used alone but can contribute to low blood sugar levels if used in combination with other antidiabetic drugs. Table sugar can be used to treat hypoglycemia secondary to metformin.</li><li>\u2022 Option B. Metformin</li><li>\u2022 decreasing hepatic glucose production</li><li>\u2022 improving insulin sensitivity</li><li>\u2022 does not</li><li>\u2022 hypoglycemia</li><li>\u2022 low blood sugar levels</li><li>\u2022 Table sugar</li><li>\u2022 treat hypoglycemia</li><li>\u2022 secondary to metformin.</li><li>\u2022 Option C. Glipizide : Glipizide is a sulfonylurea that stimulates insulin secretion from the pancreatic beta cells . Hypoglycemia caused by glipizide can be treated with table sugar, as it effectively raises blood glucose levels.</li><li>\u2022 Option C. Glipizide</li><li>\u2022 sulfonylurea</li><li>\u2022 stimulates insulin secretion from the pancreatic beta cells</li><li>\u2022 Hypoglycemia</li><li>\u2022 glipizide</li><li>\u2022 table sugar,</li><li>\u2022 raises blood glucose levels.</li><li>\u2022 Option D. Insulin : Insulin administration can lead to hypoglycemia if the dose is too high relative to the patient's insulin needs. Table sugar is effective in treating hypoglycemia secondary to insulin use because it quickly raises blood glucose levels.</li><li>\u2022 Option D. Insulin</li><li>\u2022 Insulin</li><li>\u2022 lead to hypoglycemia</li><li>\u2022 too high</li><li>\u2022 patient's insulin</li><li>\u2022 Table sugar</li><li>\u2022 hypoglycemia</li><li>\u2022 insulin</li><li>\u2022 raises blood glucose levels.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The treatment of hypoglycemia in patients taking acarbose requires glucose (dextrose) rather than sucrose (table sugar) due to acarbose's mechanism of action on carbohydrate digestion.</li><li>\u27a4 hypoglycemia</li><li>\u27a4 acarbose requires glucose (dextrose)</li><li>\u27a4 sucrose (table sugar)</li><li>\u27a4 acarbose's mechanism of action on carbohydrate digestion.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e71ea009",
      "audio": ""
    },
    {
      "text": "Mechanism of action of finasteride is?",
      "options": [
        {
          "label": "A",
          "text": "Androgen receptor antagonist",
          "correct": false
        },
        {
          "label": "B",
          "text": "5-\u03b1 reductase inhibitor",
          "correct": true
        },
        {
          "label": "C",
          "text": "17-\u03b1 hydroxylase inhibitor",
          "correct": false
        },
        {
          "label": "D",
          "text": "Aromatase inhibitor",
          "correct": false
        }
      ],
      "correct_answer": "B. 5-\u03b1 reductase inhibitor",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B. 5-\u03b1 reductase inhibitor</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Androgen Receptor Antagonist</li><li>\u2022 Option A. Androgen Receptor Antagonist</li><li>\u2022 Mechanism : Blocks androgens like testosterone and DHT from binding to their receptors in the body.</li><li>\u2022 Mechanism</li><li>\u2022 Blocks androgens</li><li>\u2022 testosterone and DHT</li><li>\u2022 binding to their receptors</li><li>\u2022 Example: Flutamide , bicalutamide , and enzalutamide are used primarily in the treatment of prostate cancer by inhibiting the action of androgens at their receptor sites.</li><li>\u2022 Example:</li><li>\u2022 Flutamide</li><li>\u2022 bicalutamide</li><li>\u2022 enzalutamide</li><li>\u2022 treatment of prostate cancer</li><li>\u2022 inhibiting</li><li>\u2022 androgens at their receptor sites.</li><li>\u2022 Option C. 17-\u03b1 Hydroxylase Inhibitor</li><li>\u2022 Option C. 17-\u03b1 Hydroxylase Inhibitor</li><li>\u2022 Mechanism: Inhibits the enzyme 17-\u03b1 hydroxylase, which is crucial in the biosynthesis of cortisol and androgens in the adrenal glands.</li><li>\u2022 Mechanism:</li><li>\u2022 Inhibits</li><li>\u2022 17-\u03b1 hydroxylase,</li><li>\u2022 biosynthesis of cortisol and androgens</li><li>\u2022 adrenal</li><li>\u2022 glands.</li><li>\u2022 Example: Ketoconazole (at high doses) can inhibit adrenal and gonadal steroid synthesis and is used off-label for this purpose, though it is primarily an antifungal medication.</li><li>\u2022 Example:</li><li>\u2022 Ketoconazole</li><li>\u2022 inhibit adrenal and gonadal steroid synthesis</li><li>\u2022 off-label</li><li>\u2022 antifungal medication.</li><li>\u2022 Option D. Aromatase Inhibitor</li><li>\u2022 Option D. Aromatase Inhibitor</li><li>\u2022 Mechanism: Blocks the enzyme aromatase, which converts androgens into estrogens , thereby reducing estrogen levels.</li><li>\u2022 Mechanism:</li><li>\u2022 Blocks</li><li>\u2022 aromatase,</li><li>\u2022 androgens into estrogens</li><li>\u2022 estrogen levels.</li><li>\u2022 Example: Anastrozole , letrozole , and exemestane are aromatase inhibitors used in the treatment of estrogen receptor-positive breast cancer in postmenopausal women.</li><li>\u2022 Example:</li><li>\u2022 Anastrozole</li><li>\u2022 letrozole</li><li>\u2022 exemestane</li><li>\u2022 inhibitors</li><li>\u2022 estrogen receptor-positive</li><li>\u2022 breast cancer in postmenopausal women.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 DRUGS USED FOR BENIGN PROSTATIC HYPERPLASIA</li><li>\u27a4 DRUGS USED FOR BENIGN PROSTATIC HYPERPLASIA</li><li>\u27a4 Tamsulosin: Alpha 1a-antagonist. Decreases smooth muscle tone of prostate and bladder neck which leads to improved urine flow , but it will not lead to reduction in size of prostate. Finasteride: 5-alpha reductase (type II) inhibitor. Prevents conversion of testosterone to dihydrotestosterone (DHT) . DHT causes growth and differentiation in the prostate . Type 2 isoform of this enzyme is expressed by stromal cells in the prostate. Reduction in levels of DHT prevents further growth and sometimes reduces the size of the prostate as well. Flutamide: Oral nonsteroidal antiandrogen which inhibits androgen binding to its receptor. It is used in the treatment of metastatic prostatic cancer. Tadalafil: Treatment with PDE-5 inhibitors can be considered in patients who have erectile dysfunction and mild or moderate symptoms of BPH . Tadalafil is approved by the FDA for use in BPH.</li><li>\u27a4 Tamsulosin: Alpha 1a-antagonist. Decreases smooth muscle tone of prostate and bladder neck which leads to improved urine flow , but it will not lead to reduction in size of prostate.</li><li>\u27a4 Tamsulosin:</li><li>\u27a4 Alpha 1a-antagonist.</li><li>\u27a4 Decreases</li><li>\u27a4 smooth muscle tone of prostate and bladder neck</li><li>\u27a4 improved urine flow</li><li>\u27a4 not lead to reduction in size of prostate.</li><li>\u27a4 Finasteride: 5-alpha reductase (type II) inhibitor. Prevents conversion of testosterone to dihydrotestosterone (DHT) . DHT causes growth and differentiation in the prostate . Type 2 isoform of this enzyme is expressed by stromal cells in the prostate. Reduction in levels of DHT prevents further growth and sometimes reduces the size of the prostate as well.</li><li>\u27a4 Finasteride:</li><li>\u27a4 5-alpha reductase (type II) inhibitor.</li><li>\u27a4 testosterone to dihydrotestosterone (DHT)</li><li>\u27a4 growth and differentiation in the prostate</li><li>\u27a4 Type 2 isoform</li><li>\u27a4 stromal cells in the prostate. Reduction</li><li>\u27a4 DHT prevents further growth</li><li>\u27a4 size of the prostate</li><li>\u27a4 Flutamide: Oral nonsteroidal antiandrogen which inhibits androgen binding to its receptor. It is used in the treatment of metastatic prostatic cancer.</li><li>\u27a4 Flutamide:</li><li>\u27a4 nonsteroidal antiandrogen</li><li>\u27a4 inhibits androgen binding to its receptor.</li><li>\u27a4 metastatic prostatic cancer.</li><li>\u27a4 Tadalafil: Treatment with PDE-5 inhibitors can be considered in patients who have erectile dysfunction and mild or moderate symptoms of BPH . Tadalafil is approved by the FDA for use in BPH.</li><li>\u27a4 Tadalafil:</li><li>\u27a4 PDE-5 inhibitors</li><li>\u27a4 erectile dysfunction</li><li>\u27a4 mild or</li><li>\u27a4 moderate symptoms of BPH</li><li>\u27a4 FDA for use in BPH.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "1a5190c3",
      "audio": ""
    },
    {
      "text": "A patient of diabetes mellitus and hypertension is admitted in the hospital with features of sepsis and there is increase in serum creatinine levels. Which of the following drugs should be stopped?",
      "options": [
        {
          "label": "A",
          "text": "Metformin",
          "correct": true
        },
        {
          "label": "B",
          "text": "Insulin",
          "correct": false
        },
        {
          "label": "C",
          "text": "Metoprolol",
          "correct": false
        },
        {
          "label": "D",
          "text": "Linagliptin",
          "correct": false
        }
      ],
      "correct_answer": "A. Metformin",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A. Metformin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Insulin : Insulin may still be needed to manage the patient' s blood glucose levels, especially in the stress of sepsis , which can cause hyperglycemia.</li><li>\u2022 Option B. Insulin</li><li>\u2022 s blood glucose levels,</li><li>\u2022 stress of sepsis</li><li>\u2022 hyperglycemia.</li><li>\u2022 Option C. Metoprolol : It is a lipid soluble beta-blocker used to manage hypertension and other cardiovascular conditions . It is safe in renal failure . Beta blockers which should be avoided in renal failure are atenolol, nadolol and sotalol (ANS)</li><li>\u2022 Option C. Metoprolol</li><li>\u2022 lipid soluble beta-blocker</li><li>\u2022 hypertension</li><li>\u2022 cardiovascular conditions</li><li>\u2022 safe</li><li>\u2022 renal failure</li><li>\u2022 Beta blockers</li><li>\u2022 avoided in renal failure are atenolol, nadolol and sotalol (ANS)</li><li>\u2022 Option D. Linagliptin : A DPP-4 inhibitor used in the management of type 2 diabetes. It is considered safe in patients with renal impairment unlike other drugs in this group.</li><li>\u2022 Option D. Linagliptin</li><li>\u2022 DPP-4 inhibitor</li><li>\u2022 type 2 diabetes.</li><li>\u2022 renal impairment</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In patients with diabetes and renal impairment, especially in acute settings such as sepsis, metformin should be discontinued to prevent the risk of lactic acidosis. It is important to monitor renal function closely and adjust medication as needed based on the patient\u2019s current health status.</li><li>\u27a4 diabetes and renal impairment,</li><li>\u27a4 acute settings such as sepsis,</li><li>\u27a4 metformin</li><li>\u27a4 risk of lactic acidosis.</li><li>\u27a4 monitor renal function</li><li>\u27a4 current health status.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "6c3ce945",
      "audio": ""
    },
    {
      "text": "Which of the following pairs of antidiabetic drug and its mechanism of action is correct?",
      "options": [
        {
          "label": "A",
          "text": "Glibenclamide\u2014Na K ATPase blocker",
          "correct": false
        },
        {
          "label": "B",
          "text": "Biguanides\u2014AMP kinase activation",
          "correct": true
        },
        {
          "label": "C",
          "text": "Vildagliptin\u2014SGLT2 inhibitor",
          "correct": false
        },
        {
          "label": "D",
          "text": "Voglibose\u2014DPP4 inhibitor",
          "correct": false
        }
      ],
      "correct_answer": "B. Biguanides\u2014AMP kinase activation",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B. Biguanides\u2014AMP kinase activation</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Glibenclamide\u2014Na K ATPase blocker : This statement is incorrect. Glibenclamide (also known as glyburide in some regions) is a sulfonylurea , which acts as a K_ATP channel blocker on pancreatic beta cells, thereby stimulating insulin secretion . It does not block Na K ATPase.</li><li>\u2022 Option A. Glibenclamide\u2014Na K ATPase blocker</li><li>\u2022 incorrect. Glibenclamide</li><li>\u2022 glyburide</li><li>\u2022 sulfonylurea</li><li>\u2022 K_ATP channel blocker</li><li>\u2022 pancreatic beta cells,</li><li>\u2022 stimulating insulin secretion</li><li>\u2022 does not block Na K ATPase.</li><li>\u2022 Option C. Vildagliptin\u2014SGLT2 inhibitor : This statement is incorrect. Vildagliptin is a DPP-4 inhibitor , not an SGLT2 inhibitor. It works by preventing the breakdown of incretin hormones , which increases insulin release and decreases glucagon levels in a glucose-dependent manner.</li><li>\u2022 Option C. Vildagliptin\u2014SGLT2 inhibitor</li><li>\u2022 incorrect.</li><li>\u2022 DPP-4 inhibitor</li><li>\u2022 preventing the breakdown of incretin hormones</li><li>\u2022 increases insulin release and decreases glucagon levels</li><li>\u2022 Option D. Voglibose\u2014DPP4 inhibitor : This statement is incorrect . Voglibose is an alpha-glucosidase inhibitor , not a DPP-4 inhibitor. It works by delaying the digestion of carbohydrates , thereby blunting postprandial blood glucose spikes.</li><li>\u2022 Option D. Voglibose\u2014DPP4 inhibitor</li><li>\u2022 incorrect</li><li>\u2022 alpha-glucosidase inhibitor</li><li>\u2022 delaying the digestion of carbohydrates</li><li>\u2022 blunting postprandial blood glucose spikes.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Biguanides like metformin activate AMPK, l eading to decreased hepatic glucose production and increased insulin sensitivity without directly stimulating insulin secretion . This mechanism is fundamental in the management of type 2 diabetes, making it a cornerstone of therapy.</li><li>\u27a4 Biguanides</li><li>\u27a4 metformin activate AMPK, l</li><li>\u27a4 decreased hepatic glucose production and increased insulin sensitivity without directly stimulating insulin secretion</li><li>\u27a4 mechanism</li><li>\u27a4 type 2 diabetes,</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "19082d24",
      "audio": ""
    },
    {
      "text": "Longest acting insulin among the following is?",
      "options": [
        {
          "label": "A",
          "text": "Neutral protamine Hagedorn",
          "correct": false
        },
        {
          "label": "B",
          "text": "Insulin glulisine",
          "correct": false
        },
        {
          "label": "C",
          "text": "Insulin glargine",
          "correct": true
        },
        {
          "label": "D",
          "text": "Lente insulin",
          "correct": false
        }
      ],
      "correct_answer": "C. Insulin glargine",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture15.jpg"
      ],
      "explanation": "<p><strong>Ans. C. Insulin glargine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Neutral protamine Hagedorn (NPH) : NPH insulin is an intermediate-acting insulin with a duration of action that typically ranges from 16 to 24 hours . While it does provide longer coverage than short-acting insulins, it does not last as long as insulin glargine.</li><li>\u2022 Option A. Neutral protamine Hagedorn (NPH)</li><li>\u2022 intermediate-acting insulin</li><li>\u2022 duration of action</li><li>\u2022 16 to 24 hours</li><li>\u2022 longer coverage than short-acting insulins,</li><li>\u2022 Option B. Insulin glulisine : Insulin glulisine is a rapid-acting insulin analog with a quick onset of action (approximately 15 minutes ) and a shorter duration of action (3 to 5 hours) , making it well-suited for controlling blood sugar levels during meals.</li><li>\u2022 Option B. Insulin glulisine</li><li>\u2022 rapid-acting insulin analog</li><li>\u2022 quick onset of action</li><li>\u2022 15 minutes</li><li>\u2022 shorter duration of action (3 to 5 hours)</li><li>\u2022 well-suited for controlling blood sugar levels during meals.</li><li>\u2022 Option D. Lente insulin : Lente insulin is an intermediate-acting insulin with a duration of action similar to NPH insulin. It is not as long-acting as insulin glargine.</li><li>\u2022 Option D. Lente insulin</li><li>\u2022 intermediate-acting insulin</li><li>\u2022 duration of action</li><li>\u2022 NPH insulin.</li><li>\u2022 not</li><li>\u2022 long-acting as insulin glargine.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 INSULIN PREPARATIONS</li><li>\u27a4 INSULIN PREPARATIONS</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "99b5f5d2",
      "audio": ""
    },
    {
      "text": "Which of the following drugs is used for the treatment of syndrome of inappropriate secretion of ADH (SIADH)?",
      "options": [
        {
          "label": "A",
          "text": "Tolvaptan",
          "correct": true
        },
        {
          "label": "B",
          "text": "Desmopressin",
          "correct": false
        },
        {
          "label": "C",
          "text": "vW factor",
          "correct": false
        },
        {
          "label": "D",
          "text": "Terlipressin",
          "correct": false
        }
      ],
      "correct_answer": "A. Tolvaptan",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A. Tolvaptan</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Desmopressin : Desmopressin is a synthetic analog of antidiuretic hormone (ADH) used to treat conditions like central diabetes insipidus (where ADH is deficient), not SIADH, where ADH secretion is excessive.</li><li>\u2022 Option B. Desmopressin</li><li>\u2022 synthetic analog of antidiuretic hormone (ADH)</li><li>\u2022 central</li><li>\u2022 diabetes insipidus (where ADH is deficient),</li><li>\u2022 ADH secretion is excessive.</li><li>\u2022 Option C. vW factor : Von Willebrand factor (vWF) concentrates are used in the treatment of Von Willebrand disease and certain types of hemophilia, not in the management of SIADH.</li><li>\u2022 Option C. vW factor</li><li>\u2022 Von Willebrand factor (vWF)</li><li>\u2022 Von Willebrand disease and certain</li><li>\u2022 types of hemophilia,</li><li>\u2022 Option D. Terlipressin : Terlipressin is a synthetic analog of vasopressin used primarily in the treatment of esophageal variceal bleeding and hepatorenal syndrome, not SIADH.</li><li>\u2022 Option D. Terlipressin</li><li>\u2022 Terlipressin</li><li>\u2022 synthetic analog of vasopressin</li><li>\u2022 esophageal variceal</li><li>\u2022 bleeding and hepatorenal syndrome,</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 For SIADH , where excessive ADH leads to water retention and hyponatremia, Tolvaptan is a valuable treatment option due to its selective action on V2 receptors , promoting the correction of sodium levels while avoiding the excessive loss of electrolytes.</li><li>\u27a4 SIADH</li><li>\u27a4 excessive ADH</li><li>\u27a4 water retention and hyponatremia,</li><li>\u27a4 Tolvaptan</li><li>\u27a4 selective action on V2 receptors</li><li>\u27a4 promoting the correction of sodium levels</li><li>\u27a4 excessive loss of electrolytes.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "3377fcec",
      "audio": ""
    },
    {
      "text": "A patient presented with swelling in the neck as shown in figure. She also complained of decreased appetite, fatigue, cold intolerance, and menstrual irregularities. She gained 10 kg weight in the last 4-5 months. Thyroid function tests showed normal T4 levels but elevated TSH levels. The patient should be treated with.",
      "options": [
        {
          "label": "A",
          "text": "Liothyronine",
          "correct": false
        },
        {
          "label": "B",
          "text": "L-Thyroxine",
          "correct": true
        },
        {
          "label": "C",
          "text": "Carbimazole",
          "correct": false
        },
        {
          "label": "D",
          "text": "Steroids",
          "correct": false
        }
      ],
      "correct_answer": "B. L-Thyroxine",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture22.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B. L-Thyroxine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Liothyronine : Liothyronine is a synthetic form of triiodothyronine (T3) . While it can be used in certain specific situations, such as in combination therapy with levothyroxine for some patients, L-Thyroxine remains the primary treatment for hypothyroidism due to its stability, longer half-life, and more consistent serum levels.</li><li>\u2022 Option A. Liothyronine</li><li>\u2022 synthetic form of triiodothyronine (T3)</li><li>\u2022 used</li><li>\u2022 specific situations,</li><li>\u2022 combination therapy with levothyroxine</li><li>\u2022 L-Thyroxine</li><li>\u2022 primary treatment</li><li>\u2022 hypothyroidism</li><li>\u2022 stability, longer half-life, and more consistent serum levels.</li><li>\u2022 Option C. Carbimazole : Carbimazole is used to treat hyperthyroidism, not hypothyroidism. It works by inhibiting the synthesis of thyroid hormones, which would be contraindicated in a patient already showing signs of low thyroid hormone activity.</li><li>\u2022 Option C. Carbimazole</li><li>\u2022 treat hyperthyroidism,</li><li>\u2022 inhibiting the synthesis of</li><li>\u2022 thyroid hormones,</li><li>\u2022 contraindicated in a patient</li><li>\u2022 signs of low thyroid hormone activity.</li><li>\u2022 Option D. Steroids : Steroids are not a primary treatment for primary hypothyroidism . They can be used in specific cases of t hyroiditis where inflammation is a significant component, but they would not be the first choice i n typical hypothyroidism treatment.</li><li>\u2022 Option D. Steroids</li><li>\u2022 not a primary treatment for primary hypothyroidism</li><li>\u2022 specific cases of</li><li>\u2022 hyroiditis</li><li>\u2022 inflammation is a significant</li><li>\u2022 not be the first choice i</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In a patient with hypothyroidism indicated by symptoms of thyroid hormone deficiency and elevated TSH levels with normal T4, L-Thyroxine is the appropriate treatment to normalize thyroid function and alleviate symptoms.</li><li>\u27a4 hypothyroidism</li><li>\u27a4 thyroid hormone deficiency</li><li>\u27a4 elevated TSH levels</li><li>\u27a4 normal T4, L-Thyroxine</li><li>\u27a4 treatment</li><li>\u27a4 normalize thyroid function and alleviate symptoms.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "aba1ad01",
      "audio": ""
    },
    {
      "text": "A 58-year-old female with a history of type 2 diabetes mellitus presents to the clinic with complaints of recurrent urinary tract infections (UTIs) over the past few months. She reports symptoms of urgency, frequency, and dysuria. Her diabetes has been managed with an antidiabetic medication added to her regimen about 6 months ago, around the time the UTIs started becoming more frequent. Her medical history is otherwise unremarkable, and she is not on any other new medications. Which of the following drugs in her treatment regimen is most likely implicated in causing this adverse effect?",
      "options": [
        {
          "label": "A",
          "text": "Sitagliptin",
          "correct": false
        },
        {
          "label": "B",
          "text": "Dapagliflozin",
          "correct": true
        },
        {
          "label": "C",
          "text": "Linagliptin",
          "correct": false
        },
        {
          "label": "D",
          "text": "Pramlintide",
          "correct": false
        }
      ],
      "correct_answer": "B. Dapagliflozin",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B. Dapagliflozin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Sitagliptin and C. Linagliptin : Both are Dipeptidyl peptidase-4 (DPP-4) inhibitors. They work by increasing incretin levels, which inhibit glucagon release and increase insulin secretion . DPP-4 inhibitors are not commonly associated with an increased risk of UTIs.</li><li>\u2022 Option A. Sitagliptin</li><li>\u2022 C. Linagliptin</li><li>\u2022 Dipeptidyl peptidase-4 (DPP-4) inhibitors.</li><li>\u2022 increasing incretin levels,</li><li>\u2022 inhibit glucagon release and increase insulin secretion</li><li>\u2022 not</li><li>\u2022 increased risk</li><li>\u2022 of UTIs.</li><li>\u2022 Option D. Pramlintide : An amylin analogue used in addition to insulin therapy in type 1 and type 2 diabetes to improve glycemic control. Pramlintide is not associated with an increased risk of UTIs.</li><li>\u2022 Option D. Pramlintide</li><li>\u2022 amylin analogue</li><li>\u2022 insulin therapy in type 1 and type 2 diabetes</li><li>\u2022 glycemic</li><li>\u2022 Pramlintide</li><li>\u2022 not</li><li>\u2022 increased risk of UTIs.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Dapagliflozin is an SGLT2 inhibitor that can increase the risk of urinary tract infections due to glucosuria, which can encourage bacterial growth in the urinary tract. Important points about SGLT2 Inhibitors are -</li><li>\u27a4 Dapagliflozin is an SGLT2 inhibitor</li><li>\u27a4 increase the risk of urinary tract infections</li><li>\u27a4 glucosuria,</li><li>\u27a4 bacterial growth</li><li>\u27a4 Important points about SGLT2 Inhibitors are -</li><li>\u27a4 These reduce reabsorption of filtered glucose and lowers the renal threshold for glucose , and thereby increases urinary glucose excretion. These are NOT recommended for patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. These should NOT be initiated in patients with an eGFR less than 60 mL/min/1 .73 m 2. Adverse Effects: Increases the risk of genital mycotic infections. Urinary tract infections. Hypotension. I mpairment in Renal Function. Increases in Low-Density Lipoprotein Cholesterol (LDL-C)</li><li>\u27a4 These reduce reabsorption of filtered glucose and lowers the renal threshold for glucose , and thereby increases urinary glucose excretion.</li><li>\u27a4 reduce reabsorption of filtered glucose</li><li>\u27a4 lowers the renal threshold for glucose</li><li>\u27a4 increases urinary</li><li>\u27a4 glucose excretion.</li><li>\u27a4 These are NOT recommended for patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.</li><li>\u27a4 NOT</li><li>\u27a4 type 1 diabetes mellitus</li><li>\u27a4 diabetic ketoacidosis.</li><li>\u27a4 These should NOT be initiated in patients with an eGFR less than 60 mL/min/1 .73 m 2.</li><li>\u27a4 NOT</li><li>\u27a4 eGFR less than 60 mL/min/1 .73 m 2.</li><li>\u27a4 Adverse Effects: Increases the risk of genital mycotic infections. Urinary tract infections. Hypotension. I mpairment in Renal Function. Increases in Low-Density Lipoprotein Cholesterol (LDL-C)</li><li>\u27a4 Increases the risk of genital mycotic infections. Urinary tract infections. Hypotension. I mpairment in Renal Function. Increases in Low-Density Lipoprotein Cholesterol (LDL-C)</li><li>\u27a4 Increases the risk of genital mycotic infections.</li><li>\u27a4 Increases</li><li>\u27a4 genital mycotic infections.</li><li>\u27a4 Urinary tract infections.</li><li>\u27a4 Urinary tract infections.</li><li>\u27a4 Hypotension.</li><li>\u27a4 Hypotension.</li><li>\u27a4 I mpairment in Renal Function.</li><li>\u27a4 mpairment in Renal Function.</li><li>\u27a4 Increases in Low-Density Lipoprotein Cholesterol (LDL-C)</li><li>\u27a4 Increases in Low-Density Lipoprotein Cholesterol (LDL-C)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "33627ac7",
      "audio": ""
    },
    {
      "text": "The effectiveness of oral contraceptives is reduced by? Captopril Furosemide Ampicillin Rifampicin",
      "options": [
        {
          "label": "A",
          "text": "1 and 4 correct.",
          "correct": false
        },
        {
          "label": "B",
          "text": "2 and 3 correct.",
          "correct": false
        },
        {
          "label": "C",
          "text": "1, 2, and 3 correct.",
          "correct": false
        },
        {
          "label": "D",
          "text": "3 and 4 correct.",
          "correct": true
        }
      ],
      "correct_answer": "D. 3 and 4 correct.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D. 3 and 4 correct</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 1. Captopril : An angiotensin-converting enzyme (ACE) inhibitor used to treat hypertension and heart failure . There is no evidence to suggest that captopril significantly affects the effectiveness of oral contraceptives. 2. Furosemide : A loop diureti c used in the treatment of edema and hypertension. Like captopril, frusemide does not have a known interaction that significantly reduces the effectiveness of oral contraceptives.</li><li>\u2022 1. Captopril : An angiotensin-converting enzyme (ACE) inhibitor used to treat hypertension and heart failure . There is no evidence to suggest that captopril significantly affects the effectiveness of oral contraceptives.</li><li>\u2022 1. Captopril</li><li>\u2022 angiotensin-converting enzyme (ACE) inhibitor</li><li>\u2022 treat hypertension and heart failure</li><li>\u2022 no</li><li>\u2022 captopril significantly affects</li><li>\u2022 oral contraceptives.</li><li>\u2022 2. Furosemide : A loop diureti c used in the treatment of edema and hypertension. Like captopril, frusemide does not have a known interaction that significantly reduces the effectiveness of oral contraceptives.</li><li>\u2022 2. Furosemide</li><li>\u2022 loop diureti</li><li>\u2022 edema and hypertension.</li><li>\u2022 captopril, frusemide does not</li><li>\u2022 interaction</li><li>\u2022 reduces the effectiveness of oral contraceptives.</li><li>\u2022 Therefore, the correct pairing is Option C. Ampicillin and D. Rifampicin as both can reduce the effectiveness of oral contraceptives through different mechanisms \u2014 ampicillin through it s effect on gut flora and rifampicin through enzyme induction leading to increased metabolism of contraceptives.</li><li>\u2022 Option C. Ampicillin</li><li>\u2022 D. Rifampicin</li><li>\u2022 both</li><li>\u2022 reduce the effectiveness</li><li>\u2022 oral contraceptives</li><li>\u2022 different mechanisms</li><li>\u2022 ampicillin</li><li>\u2022 s effect on gut flora</li><li>\u2022 rifampicin</li><li>\u2022 leading to</li><li>\u2022 increased metabolism of contraceptives.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Antibiotics like ampicillin and enzyme inducers like rifampicin can decrease the effectiveness of oral contraceptives.</li><li>\u27a4 Antibiotics</li><li>\u27a4 ampicillin</li><li>\u27a4 enzyme inducers</li><li>\u27a4 rifampicin</li><li>\u27a4 decrease the effectiveness of oral contraceptives.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e1f1ace5",
      "audio": ""
    },
    {
      "text": "Non-pulsatile administration of GnRH agonist can be used in all of the following conditions except.",
      "options": [
        {
          "label": "A",
          "text": "Endometriosis",
          "correct": false
        },
        {
          "label": "B",
          "text": "Male infertility",
          "correct": true
        },
        {
          "label": "C",
          "text": "Precocious puberty",
          "correct": false
        },
        {
          "label": "D",
          "text": "Prostatic carcinoma",
          "correct": false
        }
      ],
      "correct_answer": "B. Male infertility",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B. Male infertility</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Endometriosis : Continuous GnRH agonist treatment can suppress ovarian function and is beneficial in conditions like endometriosis.</li><li>\u2022 Option A.</li><li>\u2022 Endometriosis</li><li>\u2022 Continuous GnRH agonist</li><li>\u2022 suppress ovarian function</li><li>\u2022 endometriosis.</li><li>\u2022 Option C. Precocious Puberty : GnRH agonists are used to suppress premature gonadotropin secretion in children with central precocious puberty.</li><li>\u2022 Option C.</li><li>\u2022 Precocious Puberty</li><li>\u2022 GnRH agonists</li><li>\u2022 premature gonadotropin secretion</li><li>\u2022 central</li><li>\u2022 precocious puberty.</li><li>\u2022 Option D. Prostatic Carcinoma : In men with advanced prostate cancer, continuous GnRH agonist treatment is used to suppress androgen production.</li><li>\u2022 Option D.</li><li>\u2022 Prostatic Carcinoma</li><li>\u2022 advanced prostate cancer,</li><li>\u2022 GnRH agonist</li><li>\u2022 suppress</li><li>\u2022 androgen production.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Non-pulsatile administration of GnRH agonists is utilized for conditions requiring suppression of gonadotropin secretion , such as endometriosis, prostatic carcinoma, and precocious puberty, but not for male infertility , which requires pulsatile treatment to stimulate gonadotropin release.</li><li>\u27a4 Non-pulsatile administration of GnRH agonists</li><li>\u27a4 suppression of gonadotropin secretion</li><li>\u27a4 endometriosis, prostatic carcinoma, and precocious puberty,</li><li>\u27a4 not</li><li>\u27a4 male infertility</li><li>\u27a4 pulsatile treatment</li><li>\u27a4 gonadotropin release.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "1d088f05",
      "audio": ""
    },
    {
      "text": "Which of the following drug is approved for treatment of type 1 as well as type 2 diabetes mellitus?",
      "options": [
        {
          "label": "A",
          "text": "Pramlintide",
          "correct": true
        },
        {
          "label": "B",
          "text": "Metformin",
          "correct": false
        },
        {
          "label": "C",
          "text": "Sitagliptin",
          "correct": false
        },
        {
          "label": "D",
          "text": "Glipizide",
          "correct": false
        }
      ],
      "correct_answer": "A. Pramlintide",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A. Pramlintide</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Metformin : Primarily used in the treatment of type 2 diabetes mellitus, metformin is a biguanide that reduces hepatic glucose production and improves insulin sensitivity. It is not used in the treatment of type 1 diabetes because type 1 diabetes involves insulin deficiency, and metformin does not replace insulin.</li><li>\u2022 Option B. Metformin</li><li>\u2022 type 2 diabetes mellitus,</li><li>\u2022 biguanide</li><li>\u2022 reduces hepatic</li><li>\u2022 glucose production and improves insulin sensitivity.</li><li>\u2022 not used</li><li>\u2022 type 1 diabetes</li><li>\u2022 insulin deficiency,</li><li>\u2022 metformin does not replace insulin.</li><li>\u2022 Option C. Sitagliptin : A dipeptidyl peptidase-4 (DPP-4) inhibitor used in the treatment of type 2 diabetes . It works by increasing incretin levels , which inhibit glucagon release and increase insulin secretion in a glucose-dependent manner. Sitagliptin is not approved for use in type 1 diabetes.</li><li>\u2022 Option C. Sitagliptin</li><li>\u2022 dipeptidyl peptidase-4 (DPP-4) inhibitor</li><li>\u2022 type 2 diabetes</li><li>\u2022 increasing</li><li>\u2022 incretin levels</li><li>\u2022 inhibit glucagon release and increase insulin secretion</li><li>\u2022 glucose-dependent</li><li>\u2022 Sitagliptin</li><li>\u2022 not</li><li>\u2022 type 1 diabetes.</li><li>\u2022 Option D. Glipizide : A sulfonylurea used in the treatment of type 2 diabetes . It stimulates the release of insulin from pancreatic \u03b2-cells . Because individuals with type 1 diabetes have little to no insulin production, sulfonylureas like glipizide are not effective for type 1 diabetes.</li><li>\u2022 Option D. Glipizide</li><li>\u2022 sulfonylurea</li><li>\u2022 type 2 diabetes</li><li>\u2022 release of insulin from pancreatic \u03b2-cells</li><li>\u2022 type 1 diabetes</li><li>\u2022 no insulin production, sulfonylureas like glipizide</li><li>\u2022 type 1 diabetes.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Pramlintide is approved for both type 1 and type 2 diabetes as an adjunct to insulin therapy due to its role in modulating gastric emptying and blood glucose levels post meals.</li><li>\u27a4 Pramlintide</li><li>\u27a4 both type 1 and type 2 diabetes</li><li>\u27a4 adjunct to insulin therapy</li><li>\u27a4 modulating gastric</li><li>\u27a4 emptying and blood glucose levels post meals.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "043b0514",
      "audio": ""
    },
    {
      "text": "Insulin having the longest duration of action is?",
      "options": [
        {
          "label": "A",
          "text": "Isophane insulin",
          "correct": false
        },
        {
          "label": "B",
          "text": "Insulin glargine",
          "correct": false
        },
        {
          "label": "C",
          "text": "Insulin-zinc suspension",
          "correct": false
        },
        {
          "label": "D",
          "text": "Insulin degludec",
          "correct": true
        }
      ],
      "correct_answer": "D. Insulin degludec",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture24.jpg"
      ],
      "explanation": "<p><strong>Ans. D. Insulin degludec</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Isophane insulin (NPH) : Intermediate-acting insulin with an effective duration of 10-20 hours , making it shorter in duration compared to insulin degludec.</li><li>\u2022 Option</li><li>\u2022 A.</li><li>\u2022 insulin (NPH)</li><li>\u2022 Intermediate-acting insulin</li><li>\u2022 10-20 hours</li><li>\u2022 shorter in</li><li>\u2022 duration</li><li>\u2022 insulin degludec.</li><li>\u2022 Option B . Insulin glargine : Another long-acting insulin with a duration of approximately 24 hours, but still shorter than insulin degludec.</li><li>\u2022 Option</li><li>\u2022 B</li><li>\u2022 Insulin glargine</li><li>\u2022 long-acting insulin</li><li>\u2022 duration of approximately 24 hours,</li><li>\u2022 still shorter than insulin</li><li>\u2022 degludec.</li><li>\u2022 Option C. Insulin-zinc suspension (Lente) : Consists of 30% amorphous and 70% crystalline insulin , classified as intermediate-acting with a duration similar to NPH.</li><li>\u2022 Option</li><li>\u2022 C.</li><li>\u2022 Insulin-zinc suspension (Lente)</li><li>\u2022 30% amorphous and 70% crystalline insulin</li><li>\u2022 intermediate-acting</li><li>\u2022 duration similar to NPH.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Insulin Preparations</li><li>\u27a4 Insulin Preparations</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c6ee6c0c",
      "audio": ""
    },
    {
      "text": "Which of the following SERM is approved for treatment of dyspareunia in post-menopausal females?",
      "options": [
        {
          "label": "A",
          "text": "Raloxifene",
          "correct": false
        },
        {
          "label": "B",
          "text": "Tamoxifen",
          "correct": false
        },
        {
          "label": "C",
          "text": "Ospemifene",
          "correct": true
        },
        {
          "label": "D",
          "text": "Clomiphene citrate",
          "correct": false
        }
      ],
      "correct_answer": "C. Ospemifene",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/03/picture1.jpg"
      ],
      "explanation": "<p><strong>Ans. C. Ospemifene</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Raloxifene: Raloxifene is a SERM that is used primarily for the prevention and treatment of osteoporosis in postmenopausal women and to reduce the risk of invasive breast cancer in postmenopausal women with osteoporosis or at high risk for breast cancer . It is not used for dyspareunia.</li><li>\u2022 Option A. Raloxifene:</li><li>\u2022 SERM</li><li>\u2022 used primarily</li><li>\u2022 prevention and treatment of osteoporosis</li><li>\u2022 postmenopausal women</li><li>\u2022 reduce the risk of invasive breast cancer</li><li>\u2022 postmenopausal women</li><li>\u2022 osteoporosis</li><li>\u2022 high</li><li>\u2022 breast cancer</li><li>\u2022 not used for dyspareunia.</li><li>\u2022 Option B. Tamoxifen: Tamoxifen is used primarily in the treatment and prevention of breast cancer. While it has estrogen-like effects on certain tissues, it is not approved for the t reatment of dyspareunia.</li><li>\u2022 Option B. Tamoxifen:</li><li>\u2022 treatment and prevention of breast cancer.</li><li>\u2022 estrogen-like effects</li><li>\u2022 not</li><li>\u2022 reatment of dyspareunia.</li><li>\u2022 Option D. Clomiphene citrate: Clomiphene citrate is used as a fertility medication to induce ovulation in women who do not ovulate, including those with polycystic ovary syndrome (PCOS) . It is not used for the treatment of dyspareunia.</li><li>\u2022 Option D. Clomiphene citrate:</li><li>\u2022 fertility medication to induce ovulation in women</li><li>\u2022 polycystic ovary syndrome (PCOS)</li><li>\u2022 not</li><li>\u2022 treatment of dyspareunia.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Ospemifene is the SERM, approved for the treatment of dyspareunia in postmenopausal women.</li><li>\u27a4 Ospemifene</li><li>\u27a4 SERM,</li><li>\u27a4 treatment of dyspareunia in postmenopausal women.</li><li>\u27a4 SELECTIVE ESTROGEN RECEPTOR MODULATORS:</li><li>\u27a4 SELECTIVE ESTROGEN RECEPTOR MODULATORS:</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "927aed47",
      "audio": ""
    },
    {
      "text": "All the following agents are correctly paired with an appropriate clinical use of the drug except.",
      "options": [
        {
          "label": "A",
          "text": "Desmopressin: Treatment of diabetes insipidus.",
          "correct": false
        },
        {
          "label": "B",
          "text": "Octreotide: Treatment of bleeding esophageal varices.",
          "correct": false
        },
        {
          "label": "C",
          "text": "Oxytocin: Induction of labor.",
          "correct": false
        },
        {
          "label": "D",
          "text": "Goserelin: Growth hormone deficiency",
          "correct": true
        }
      ],
      "correct_answer": "D. Goserelin: Growth hormone deficiency",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D. Goserelin: Growth hormone deficiency</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Desmopressin: Desmopressin is a synthetic analogue of vasopressin and is drug of choice for the treatment of central diabetes insipidus and nocturnal enuresis. It is also used for managing bleeding in patients with von Willebrand disease and mild hemophilia A due to its ability to increase the levels of von Willebrand factor and factor VIII .</li><li>\u2022 Option A. Desmopressin:</li><li>\u2022 synthetic analogue of vasopressin</li><li>\u2022 central</li><li>\u2022 diabetes insipidus and nocturnal enuresis.</li><li>\u2022 bleeding</li><li>\u2022 with von Willebrand disease and mild hemophilia A</li><li>\u2022 increase the levels of von Willebrand factor and factor VIII</li><li>\u2022 Option B. Octreotide: Octreotide is a somatostatin analogue that can reduce portal blood flow and is used in the management of bleeding esophageal varices as an adjunct to specific treatments like endoscopic band ligation or sclerotherapy.</li><li>\u2022 Option B. Octreotide:</li><li>\u2022 somatostatin analogue</li><li>\u2022 reduce portal blood flow</li><li>\u2022 used</li><li>\u2022 bleeding esophageal varices</li><li>\u2022 endoscopic band ligation or sclerotherapy.</li><li>\u2022 Option C. Oxytocin: Oxytocin is a peptide hormone and is drug of choice to induce labor in pregnant women who are at or near term when there is a medical reason for inducing labor, or to strengthen labor contractions during childbirth.</li><li>\u2022 Option C. Oxytocin:</li><li>\u2022 peptide hormone</li><li>\u2022 drug of choice</li><li>\u2022 induce labor in pregnant women</li><li>\u2022 at or near</li><li>\u2022 inducing labor, or to strengthen labor contractions during childbirth.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Goserelin is a GnRH agonist used primarily in the treatment of hormone-sensitive cancers and is not indicated for growth hormone deficiency, which would require growth hormone therapy or other specific treatments related to growth hormone biosynthesis or action.</li><li>\u27a4 Goserelin</li><li>\u27a4 GnRH agonist</li><li>\u27a4 hormone-sensitive cancers</li><li>\u27a4 not indicated for growth hormone</li><li>\u27a4 deficiency,</li><li>\u27a4 growth hormone therapy</li><li>\u27a4 specific treatments</li><li>\u27a4 growth hormone biosynthesis or</li><li>\u27a4 action.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "7a531079",
      "audio": ""
    },
    {
      "text": "Which of the following statements is true about metformin?",
      "options": [
        {
          "label": "A",
          "text": "Metformin is inappropriate for initial management of type 2 diabetes.",
          "correct": false
        },
        {
          "label": "B",
          "text": "Metformin decreases hepatic glucose production.",
          "correct": true
        },
        {
          "label": "C",
          "text": "Metformin undergoes significant metabolism via the cytochrome enzymes.",
          "correct": false
        },
        {
          "label": "D",
          "text": "Weight gain is a common adverse effect.",
          "correct": false
        }
      ],
      "correct_answer": "B. Metformin decreases hepatic glucose production.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B. Metformin decreases hepatic glucose production.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Metformin is inappropriate for initial management of type 2 diabetes: This statement is false. Metformin is considered the first-line therapy for the management of type 2 diabetes in the absence of contraindications.</li><li>\u2022 Option A. Metformin is inappropriate for initial management of type 2 diabetes:</li><li>\u2022 false.</li><li>\u2022 first-line therapy</li><li>\u2022 type 2 diabetes</li><li>\u2022 absence of contraindications.</li><li>\u2022 Option C. Metformin undergoes significant metabolism via the cytochrome enzymes: This statement is false. Metformin is not metabolized by the cytochrome P450 enzyme system and is excreted unchanged in the urine.</li><li>\u2022 Option C. Metformin undergoes significant metabolism via the cytochrome enzymes:</li><li>\u2022 false.</li><li>\u2022 not</li><li>\u2022 excreted unchanged in the urine.</li><li>\u2022 Option D. Weight gain is a common adverse effect: This statement is false. Unlike some other diabetes medications, metformin is not associated with weight gain and is often chosen for its weight-neutral or weight-reducing effect.</li><li>\u2022 Option D. Weight gain is a common adverse effect:</li><li>\u2022 false.</li><li>\u2022 diabetes medications,</li><li>\u2022 not associated with weight gain</li><li>\u2022 weight-neutral or weight-reducing effect.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Metformin is an effective first-line treatment for type 2 diabetes due to its ability to decrease hepatic glucose production, increase insulin sensitivity, and support peripheral glucose uptake without causing significant weight gain or undergoing metabolism by the liver's cytochrome P450 system.</li><li>\u27a4 Metformin</li><li>\u27a4 first-line treatment for type 2 diabetes</li><li>\u27a4 ability to decrease hepatic glucose production,</li><li>\u27a4 increase</li><li>\u27a4 insulin sensitivity,</li><li>\u27a4 peripheral glucose uptake</li><li>\u27a4 without</li><li>\u27a4 weight gain or undergoing metabolism</li><li>\u27a4 liver's cytochrome P450 system.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "049e0f9a",
      "audio": ""
    },
    {
      "text": "A 43-year-old man with type 2 diabetes mellitus is interested in alternative methods of insulin administration because he has difficulty with injections due to a significant needle phobia. He has heard about an inhaled form of insulin and asks about its use and any potential limitations. Which of the following statements about inhaled insulin (Afrezza) is incorrect?",
      "options": [
        {
          "label": "A",
          "text": "It is the only approved inhalational insulin.",
          "correct": false
        },
        {
          "label": "B",
          "text": "It is used before meals to control postprandial hyperglycemia.",
          "correct": false
        },
        {
          "label": "C",
          "text": "It is indicated as a replacement for injectable insulin.",
          "correct": true
        },
        {
          "label": "D",
          "text": "It should be avoided in chronic smokers.",
          "correct": false
        }
      ],
      "correct_answer": "C. It is indicated as a replacement for injectable insulin.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C. Indicated as a replacement for injectable insulin.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. It is the only approved inhalational insulin: This statement is correct. Afrezza is currently the only inhalational insulin approved by the FDA.</li><li>\u2022 Option A. It is the only approved inhalational insulin:</li><li>\u2022 correct. Afrezza</li><li>\u2022 inhalational insulin</li><li>\u2022 FDA.</li><li>\u2022 Option B. It is used before meals to control postprandial hyperglycemia: This statement is correct . Afrezza is a rapid-acting insulin taken at the beginning of a meal to control blood sugar spikes after eating.</li><li>\u2022 Option B. It is used before meals to control postprandial hyperglycemia:</li><li>\u2022 correct</li><li>\u2022 Afrezza</li><li>\u2022 rapid-acting insulin</li><li>\u2022 beginning of a meal</li><li>\u2022 control blood sugar spikes after eating.</li><li>\u2022 Option D. It should be avoided in chronic smokers: This statement is correct. Afrezza is contraindicated in patients who smoke or have recently stopped smoking because of the risk of acute bronchospasm.</li><li>\u2022 Option D. It should be avoided in chronic smokers:</li><li>\u2022 correct. Afrezza is contraindicated</li><li>\u2022 smoke or</li><li>\u2022 recently stopped smoking</li><li>\u2022 risk</li><li>\u2022 acute bronchospasm.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Inhaled insulin (Afrezza) is an innovative rapid-acting insulin administered before meals to manage postprandial hyperglycemia, but it is not a full substitute for injectable insulin, especially in terms of providing basal insulin coverage.</li><li>\u27a4 Inhaled insulin (Afrezza)</li><li>\u27a4 rapid-acting insulin</li><li>\u27a4 before meals</li><li>\u27a4 postprandial hyperglycemia,</li><li>\u27a4 not</li><li>\u27a4 full substitute for injectable insulin,</li><li>\u27a4 basal insulin coverage.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "176a0318",
      "audio": ""
    },
    {
      "text": "Which of the following drugs used to treat type II diabetes mellitus does not cause weight gain?",
      "options": [
        {
          "label": "A",
          "text": "Metformin",
          "correct": true
        },
        {
          "label": "B",
          "text": "Glimepiride",
          "correct": false
        },
        {
          "label": "C",
          "text": "Pioglitazone",
          "correct": false
        },
        {
          "label": "D",
          "text": "Gliclazide",
          "correct": false
        }
      ],
      "correct_answer": "A. Metformin",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/03/picture2.jpg"
      ],
      "explanation": "<p><strong>Ans. A. Metformin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Glimepiride: Glimepiride is a sulfonylurea , which works by increasing insulin secretion from the pancreas. Sulfonylureas can cause weight gain as a side effect.</li><li>\u2022 Option B. Glimepiride:</li><li>\u2022 sulfonylurea</li><li>\u2022 increasing insulin secretion</li><li>\u2022 pancreas.</li><li>\u2022 weight gain as a side effect.</li><li>\u2022 Option C. Pioglitazone: Pioglitazone is a thiazolidinedione, which improves insulin sensitivity but is associated with weight gain, often due to fluid retention and fat accumulation.</li><li>\u2022 Option C. Pioglitazone:</li><li>\u2022 thiazolidinedione,</li><li>\u2022 improves insulin sensitivity</li><li>\u2022 weight gain,</li><li>\u2022 fluid retention and fat accumulation.</li><li>\u2022 Option D. Gliclazide: Gliclazide is another sulfonylurea with a mechanism of action similar to glimepiride, and it can also cause weight gain.</li><li>\u2022 Option D. Gliclazide:</li><li>\u2022 sulfonylurea</li><li>\u2022 similar to glimepiride,</li><li>\u2022 weight gain.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Effect of antidiabetic drugs on weight</li><li>\u27a4 Effect of antidiabetic drugs on weight</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ab4f7da9",
      "audio": ""
    },
    {
      "text": "Long term steroid therapy can lead to suppression of hypothalamic pituitary-adrenal axis. It can be overcome by using alternate day therapy with corticosteroids. Which of the following steroids is unsuitable for alternate day therapy for such purpose?",
      "options": [
        {
          "label": "A",
          "text": "Cortisol",
          "correct": false
        },
        {
          "label": "B",
          "text": "Prednisolone",
          "correct": false
        },
        {
          "label": "C",
          "text": "Betamethasone",
          "correct": true
        },
        {
          "label": "D",
          "text": "Hydrocortisone",
          "correct": false
        }
      ],
      "correct_answer": "C. Betamethasone",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C. Betamethasone</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Cortisol: Cortisol, also known as hydrocortisone when used as a medication, has a short duration of action, making it suitable for alternate day therapy.</li><li>\u2022 Option A. Cortisol:</li><li>\u2022 Cortisol,</li><li>\u2022 hydrocortisone</li><li>\u2022 short duration of action,</li><li>\u2022 alternate day therapy.</li><li>\u2022 Option B. Prednisolone: Prednisolone is an intermediate-acting corticosteroid that is commonly used in alternate day therapy to reduce HPA axis suppression.</li><li>\u2022 Option B. Prednisolone:</li><li>\u2022 intermediate-acting corticosteroid</li><li>\u2022 alternate day therapy to</li><li>\u2022 reduce HPA axis suppression.</li><li>\u2022 Option D. Hydrocortisone: Hydrocortisone is essentially synthetic cortisol with a short duration of action , suitable for alternate day therapy to minimize HPA axis suppression.</li><li>\u2022 Option D. Hydrocortisone:</li><li>\u2022 essentially synthetic cortisol</li><li>\u2022 short duration of action</li><li>\u2022 alternate day</li><li>\u2022 minimize HPA axis suppression.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Betamethasone's long duration of action makes it inappropriate for alternate day therapy designed to mitigate HPA axis suppression, unlike shorter-acting steroids like hydrocortisone , which are better suited for such treatment schedules.</li><li>\u27a4 Betamethasone's long duration of action</li><li>\u27a4 alternate day therapy</li><li>\u27a4 mitigate HPA axis</li><li>\u27a4 suppression,</li><li>\u27a4 shorter-acting steroids like hydrocortisone</li><li>\u27a4 better</li><li>\u27a4 treatment schedules.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "73688ff0",
      "audio": ""
    },
    {
      "text": "Which one of the following statements about metformin is NOT true?",
      "options": [
        {
          "label": "A",
          "text": "Does not stimulate insulin release.",
          "correct": false
        },
        {
          "label": "B",
          "text": "Decreases hepatic glucose production.",
          "correct": false
        },
        {
          "label": "C",
          "text": "Can be safely used in patients with renal dysfunction.",
          "correct": true
        },
        {
          "label": "D",
          "text": "Can be combined with sulfonylureas.",
          "correct": false
        }
      ],
      "correct_answer": "C. Can be safely used in patients with renal dysfunction.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C. Can be safely used in patients with renal dysfunction.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Does not stimulate insulin release: This statement is true. Metformin works by improving insulin sensitivity and decreasing glucose production in the liver rather than stimulating insulin release.</li><li>\u2022 Option A.</li><li>\u2022 Does not stimulate insulin release:</li><li>\u2022 true.</li><li>\u2022 improving insulin sensitivity</li><li>\u2022 decreasing glucose production in the liver</li><li>\u2022 Option B. Decreases hepatic glucose production: This statement is true and describes one of the primary mechanisms of metformin's action.</li><li>\u2022 Option B.</li><li>\u2022 Decreases hepatic glucose production:</li><li>\u2022 true</li><li>\u2022 Option D. Can be combined with sulfonylureas: This statement is true . Metformin is often used in combination with sulfonylureas to enhance glucose control in patients with type 2 diabetes.</li><li>\u2022 Option D.</li><li>\u2022 Can be combined with sulfonylureas:</li><li>\u2022 true</li><li>\u2022 Metformin</li><li>\u2022 combination</li><li>\u2022 sulfonylureas</li><li>\u2022 enhance glucose control in patients with type 2 diabetes.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 While metformin is a first-line treatment for type 2 diabetes, its use must be carefully considered in patients with renal dysfunction due to the increased risk of lactic acidosis, a serious and potentially fatal condition</li><li>\u27a4 metformin is a first-line treatment for type 2 diabetes,</li><li>\u27a4 carefully</li><li>\u27a4 renal dysfunction</li><li>\u27a4 increased risk of lactic acidosis,</li><li>\u27a4 potentially fatal condition</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "37cffaca",
      "audio": ""
    },
    {
      "text": "All the following statements are true except.",
      "options": [
        {
          "label": "A",
          "text": "Terlipressin is preferred over desmopressin for treatment of bleeding esophageal varices.",
          "correct": false
        },
        {
          "label": "B",
          "text": "Desmopressin is not useful for treatment of nephrogenic diabetes insipidus.",
          "correct": false
        },
        {
          "label": "C",
          "text": "Amiloride is used for treatment of lithium induced diabetes insipidus.",
          "correct": false
        },
        {
          "label": "D",
          "text": "Desmopressin can be used for treatment of both pituitary and renal diabetes insipidus.",
          "correct": true
        }
      ],
      "correct_answer": "D. Desmopressin can be used for treatment of both pituitary and renal diabetes insipidus.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D. Desmopressin can be used for treatment of both pituitary and renal diabetes insipidus.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Terlipressin is preferred over desmopressin for treatment of bleeding esophageal varices: True. Terlipressin, a synthetic analogue of vasopressin with V1 agonistic action, reduces portal pressure and is preferred in the treatment of esophageal variceal bleeding due to its longer activity and fewer side effects.</li><li>\u2022 Option A. Terlipressin is preferred over desmopressin for treatment of bleeding esophageal varices:</li><li>\u2022 True.</li><li>\u2022 synthetic</li><li>\u2022 analogue of vasopressin</li><li>\u2022 V1 agonistic</li><li>\u2022 reduces portal pressure</li><li>\u2022 treatment of esophageal variceal bleeding</li><li>\u2022 longer activity and fewer side effects.</li><li>\u2022 Option B. Desmopressin is not useful for treatment of nephrogenic diabetes insipidus: True. Desmopressin is ineffective in nephrogenic DI because the kidney does not respond to ADH.</li><li>\u2022 Option B. Desmopressin is not useful for treatment of nephrogenic diabetes insipidus:</li><li>\u2022 True.</li><li>\u2022 ineffective</li><li>\u2022 nephrogenic DI</li><li>\u2022 kidney does not respond to ADH.</li><li>\u2022 Option C. Amiloride is used for treatment of lithium induced diabetes insipidus: True . Amiloride blocks the entry of lithium ions through sodium channels in the collecting duct cells , effectively mitigating the diabetes insip idus induced by lithium.</li><li>\u2022 Option C. Amiloride is used for treatment of lithium induced diabetes insipidus:</li><li>\u2022 True</li><li>\u2022 blocks</li><li>\u2022 entry of lithium ions</li><li>\u2022 sodium channels in the collecting duct cells</li><li>\u2022 mitigating the diabetes insip</li><li>\u2022 lithium.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Desmopressin is effective for treating central diabetes insipidus because it acts on V2 receptors to mitigate the symptoms , but it does not work for nephrogenic diabetes insipidus , where the kidney is unresponsive to ADH .</li><li>\u27a4 Desmopressin</li><li>\u27a4 central diabetes insipidus</li><li>\u27a4 acts on V2 receptors</li><li>\u27a4 mitigate the symptoms</li><li>\u27a4 does not</li><li>\u27a4 nephrogenic diabetes insipidus</li><li>\u27a4 kidney is unresponsive to ADH</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "7750b70b",
      "audio": ""
    },
    {
      "text": "A 55-year-old female has been diagnosed with postmenopausal osteoporosis. She has a past medical history of ethanol abuse, alcoholic liver disease, erosive esophagitis, and hypothyroidism. Which of the following would be the primary reason oral bisphosphonates should be used with caution in this patient?",
      "options": [
        {
          "label": "A",
          "text": "Age.",
          "correct": false
        },
        {
          "label": "B",
          "text": "Erosive esophagitis.",
          "correct": true
        },
        {
          "label": "C",
          "text": "Liver disease.",
          "correct": false
        },
        {
          "label": "D",
          "text": "Thyroid disease.",
          "correct": false
        }
      ],
      "correct_answer": "B. Erosive esophagitis.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B. Erosive esophagitis</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Age: While the incidence of osteoporosis increases with age, age itself is not a reason to use bisphosphonates with caution. These medications are actually often indicated to manage osteoporosis in older adults.</li><li>\u2022 Option A.</li><li>\u2022 Age:</li><li>\u2022 incidence of osteoporosis increases with age,</li><li>\u2022 not</li><li>\u2022 bisphosphonates with</li><li>\u2022 caution.</li><li>\u2022 indicated</li><li>\u2022 osteoporosis in older adults.</li><li>\u2022 Option C. Liver disease: Liver disease is not a direct contraindication for the use of bisphosphonates. These drugs are primarily cleared by the kidneys , so liver impairment does not typically impact their use or dosing.</li><li>\u2022 Option C.</li><li>\u2022 Liver disease:</li><li>\u2022 not a direct contraindication for the use of bisphosphonates.</li><li>\u2022 cleared by the kidneys</li><li>\u2022 liver impairment does not typically impact their use or dosing.</li><li>\u2022 Option D. Thyroid disease: Thyroid disease, specifically hypothyroidism, is not a contraindication for bisphosphonate therapy. However, thyroid hormone levels should be managed appropriately as thyroid dysfunction can influence bone metabolism.</li><li>\u2022 Option D.</li><li>\u2022 Thyroid disease:</li><li>\u2022 specifically hypothyroidism,</li><li>\u2022 not a contraindication for bisphosphonate</li><li>\u2022 thyroid hormone levels</li><li>\u2022 thyroid dysfunction can influence bone metabolism.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Oral bisphosphonates should be used with caution in patients with a history of erosive esophagitis due to the risk of esophageal irritation and potential exacerbation of the esophageal condition.</li><li>\u27a4 Oral bisphosphonates</li><li>\u27a4 used with caution in patients with a history of erosive esophagitis</li><li>\u27a4 risk of esophageal</li><li>\u27a4 irritation and potential exacerbation of the esophageal condition.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f0670de9",
      "audio": ""
    },
    {
      "text": "Which of the following drug is a selective progesterone receptor modulator that can be used as an emergency contraceptive even after 3 days of unprotected intercourse?",
      "options": [
        {
          "label": "A",
          "text": "Onapristone",
          "correct": false
        },
        {
          "label": "B",
          "text": "Gestrinone",
          "correct": false
        },
        {
          "label": "C",
          "text": "Mifepristone",
          "correct": false
        },
        {
          "label": "D",
          "text": "Ulipristal",
          "correct": true
        }
      ],
      "correct_answer": "D. Ulipristal",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D. Ulipristal</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Onapristone: Although a selective progesterone receptor modulator , it is not indicated for emergency contraception.</li><li>\u2022 Option A. Onapristone:</li><li>\u2022 selective progesterone receptor modulator</li><li>\u2022 not</li><li>\u2022 emergency contraception.</li><li>\u2022 Option B. Gestrinone: This SPRM is not commonly used for emergency contraception.</li><li>\u2022 Option B. Gestrinone:</li><li>\u2022 SPRM is not</li><li>\u2022 emergency contraception.</li><li>\u2022 Option C. Mifepristone: Also an SPRM used for emergency contraception but is effective if used within 72 hours of unprotected intercourse , which is a shorter window compared to ulipristal.</li><li>\u2022 Option C. Mifepristone:</li><li>\u2022 SPRM</li><li>\u2022 emergency contraception</li><li>\u2022 effective</li><li>\u2022 within 72 hours of unprotected intercourse</li><li>\u2022 shorter window compared to ulipristal.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Ulipristal (30 mg) is effective as an emergency contraceptive up to 5 days after unprotected intercourse , making it a superior option for extending the window of opportunity for emergency contraception compared to other options like mifepristone and levonorgestrel.</li><li>\u27a4 Ulipristal (30 mg)</li><li>\u27a4 emergency contraceptive up to 5 days</li><li>\u27a4 unprotected intercourse</li><li>\u27a4 extending</li><li>\u27a4 window of opportunity for emergency contraception</li><li>\u27a4 mifepristone and levonorgestrel.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "9bfc77f7",
      "audio": ""
    },
    {
      "text": "Which of the following are adverse effects of SGLT2 inhibitors? Ketoacidosis Urosepsis Fournier's gangrene Angioedema",
      "options": [
        {
          "label": "A",
          "text": "1, 2 and 4 are correct.",
          "correct": false
        },
        {
          "label": "B",
          "text": "1, 2 and 3 are correct.",
          "correct": true
        },
        {
          "label": "C",
          "text": "Only 4 is correct.",
          "correct": false
        },
        {
          "label": "D",
          "text": "All are correct.",
          "correct": false
        }
      ],
      "correct_answer": "B. 1, 2 and 3 are correct.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B. 1, 2 and 3 are correct.</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 While SGLT2 inhibitors are effective for lowering glucose levels in patients with type 2 diabetes, they can lead to serious side effects such as ketoacidosis, urosepsis, and Fournier's gangrene. It is important for healthcare providers to monitor for signs of these conditions and for patients to be aware of their symptoms.</li><li>\u27a4 SGLT2 inhibitors</li><li>\u27a4 lowering glucose levels</li><li>\u27a4 type 2 diabetes,</li><li>\u27a4 ketoacidosis, urosepsis, and Fournier's gangrene.</li><li>\u27a4 healthcare</li><li>\u27a4 monitor for signs</li><li>\u27a4 aware of their symptoms.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "dba1d3c0",
      "audio": ""
    },
    {
      "text": "Teriparatide is a drug used in osteoporosis that acts by stimulation of osteoblasts. It is?",
      "options": [
        {
          "label": "A",
          "text": "Recombinant PTH [rPTH]",
          "correct": true
        },
        {
          "label": "B",
          "text": "Recombinant calcitonin",
          "correct": false
        },
        {
          "label": "C",
          "text": "Recombinant insulin",
          "correct": false
        },
        {
          "label": "D",
          "text": "Recombinant prolactin",
          "correct": false
        }
      ],
      "correct_answer": "A. Recombinant PTH [rPTH]",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A. Recombinant PTH [rPTH]</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Recombinant calcitonin: This is incorrect as calcitonin is a hormone that primarily helps regulate calcium levels by inhibiting osteoclast activity , thereby reducing bone resorption.</li><li>\u2022 Option B. Recombinant calcitonin:</li><li>\u2022 incorrect</li><li>\u2022 helps regulate calcium levels</li><li>\u2022 inhibiting osteoclast activity</li><li>\u2022 reducing bone resorption.</li><li>\u2022 Option C. Recombinant insulin: Incorrect. Insulin is a hormone related to glucose metabolism , not directly involved in bone metabolism.</li><li>\u2022 Option C. Recombinant insulin:</li><li>\u2022 Incorrect.</li><li>\u2022 glucose metabolism</li><li>\u2022 not</li><li>\u2022 bone</li><li>\u2022 metabolism.</li><li>\u2022 Option D. Recombinant prolactin: Incorrect . Prolactin is a hormone primarily involved in lactation and has no direct therapeutic application in osteoporosis treatment.</li><li>\u2022 Option D. Recombinant prolactin:</li><li>\u2022 Incorrect</li><li>\u2022 Prolactin</li><li>\u2022 lactation</li><li>\u2022 no direct therapeutic</li><li>\u2022 osteoporosis treatment.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Teriparatide , a recombinant form of PTH, is a unique treatment for osteoporosis that stimulates osteoblasts to increase bone formation . Due to its mode of action and associated risks , it is used selectively and typically followed by treatment with bisphosphonates to consolidate the gains in bone density.</li><li>\u27a4 Teriparatide</li><li>\u27a4 recombinant form of PTH,</li><li>\u27a4 unique treatment for osteoporosis</li><li>\u27a4 stimulates osteoblasts to increase bone</li><li>\u27a4 formation</li><li>\u27a4 mode of action and associated risks</li><li>\u27a4 selectively and typically followed</li><li>\u27a4 bisphosphonates</li><li>\u27a4 consolidate the gains</li><li>\u27a4 bone density.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e7c1a26e",
      "audio": ""
    },
    {
      "text": "Mechanism action of sulfonylureas is?",
      "options": [
        {
          "label": "A",
          "text": "ATP dependent Na channel blocker",
          "correct": false
        },
        {
          "label": "B",
          "text": "ATP dependent K channel blocker",
          "correct": true
        },
        {
          "label": "C",
          "text": "ATP dependent Cl channel blocker",
          "correct": false
        },
        {
          "label": "D",
          "text": "ATP dependent Ca channel blocker",
          "correct": false
        }
      ],
      "correct_answer": "B. ATP dependent K channel blocker",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture13.jpg",
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture14.jpg"
      ],
      "explanation": "<p><strong>Ans. B. ATP dependent K channel blocker</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. ATP dependent Na channel blocker: Incorrect. Sulfonylureas do not interact with sodium channels in their primary mechanism of action.</li><li>\u2022 Option A. ATP dependent Na channel blocker:</li><li>\u2022 Incorrect. Sulfonylureas do not interact</li><li>\u2022 sodium channels</li><li>\u2022 Option C. ATP dependent Cl channel blocker: Incorrect. Chloride channels are not involved in the mechanism of action of sulfonylureas.</li><li>\u2022 Option C. ATP dependent Cl channel blocker:</li><li>\u2022 Incorrect. Chloride channels</li><li>\u2022 not</li><li>\u2022 sulfonylureas.</li><li>\u2022 Option D. ATP dependent Ca channel blocker: Incorrect . While calcium channels play a role in the mechanism, sulfonylureas do not block them; instead, they cause them to open by depolarizing the cell membrane through the inhibition of potassium efflux.</li><li>\u2022 Option D. ATP dependent Ca channel blocker:</li><li>\u2022 Incorrect</li><li>\u2022 calcium channels</li><li>\u2022 sulfonylureas do not</li><li>\u2022 block</li><li>\u2022 open by depolarizing the cell membrane</li><li>\u2022 inhibition of potassium efflux.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "690d3adb",
      "audio": ""
    },
    {
      "text": "Drug Z shown in figure is likely to be?",
      "options": [
        {
          "label": "A",
          "text": "\u200b\u200b\u200b\u200b\u200b\u200b Pramlintide",
          "correct": false
        },
        {
          "label": "B",
          "text": "Canagliflozin",
          "correct": true
        },
        {
          "label": "C",
          "text": "Exenatide",
          "correct": false
        },
        {
          "label": "D",
          "text": "Vildagliptin",
          "correct": false
        }
      ],
      "correct_answer": "B. Canagliflozin",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture17.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B. Canagliflozin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Pramlintide is incorrect because it is an amylin analogue , not an SGLT2 inhibitor. It is used in the treatment of type 1 and type 2 diabetes mellitus to complement insulin therapy.</li><li>\u2022 Option A.</li><li>\u2022 Pramlintide</li><li>\u2022 incorrect</li><li>\u2022 amylin analogue</li><li>\u2022 not an SGLT2 inhibitor.</li><li>\u2022 type 1 and</li><li>\u2022 type 2 diabetes mellitus</li><li>\u2022 Option C. Exenatide is incorrect because it is a GLP-1 (glucagon-like peptide-1) analogue , which stimulates insulin release and is not involved in the renal reabsorption of glucose.</li><li>\u2022 Option C.</li><li>\u2022 Exenatide</li><li>\u2022 incorrect</li><li>\u2022 GLP-1 (glucagon-like peptide-1) analogue</li><li>\u2022 insulin release</li><li>\u2022 Option D. Vildagliptin is incorrect because it is a DPP-4 (Dipeptidyl peptidase-4) inhibitor that prolongs the action of endogenous GLP-1, thereby increasing insulin secretion, but does not directly cause glucosuria as SGLT2 inhibitors do.</li><li>\u2022 Option D.</li><li>\u2022 Vildagliptin</li><li>\u2022 incorrect</li><li>\u2022 DPP-4 (Dipeptidyl peptidase-4) inhibitor</li><li>\u2022 endogenous</li><li>\u2022 GLP-1,</li><li>\u2022 increasing insulin secretion,</li><li>\u2022 does not</li><li>\u2022 glucosuria as SGLT2 inhibitors do.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Sodium glucose co-transporter-2 inhibitors (SGLT-2 inhibitors):</li><li>\u27a4 Sodium glucose co-transporter-2 inhibitors (SGLT-2 inhibitors):</li><li>\u27a4 Glucose is freely filtered by the renal glomeruli and is reabsorbed in the proximal tubules by the action of sodium-glucose transporters (SGLTs). Sodium-glucose transporter 2 (SGLT2) accounts for 90% of glucose reabsorption , and its inhibition causes glycosuria and lowers glucose levels in patients with type 2 diabetes. SGLT2 inhibitors lower glucose levels by changing the renal threshold and not by insulin action. The SGLT2 inhibitors canagliflozin, dapagliflozin, and empagliflozin , all oral medications, are approved for clinical use. Side effects of SGLT2 inhibitors include ketoacidosis, urosepsis, Fournier's gangrene, increased incidence of UTI and genital infections.</li><li>\u27a4 Glucose is freely filtered by the renal glomeruli and is reabsorbed in the proximal tubules by the action of sodium-glucose transporters (SGLTs).</li><li>\u27a4 Glucose</li><li>\u27a4 freely filtered</li><li>\u27a4 renal glomeruli</li><li>\u27a4 reabsorbed in the proximal tubules</li><li>\u27a4 sodium-glucose transporters (SGLTs).</li><li>\u27a4 Sodium-glucose transporter 2 (SGLT2) accounts for 90% of glucose reabsorption , and its inhibition causes glycosuria and lowers glucose levels in patients with type 2 diabetes.</li><li>\u27a4 90% of glucose reabsorption</li><li>\u27a4 inhibition causes glycosuria and</li><li>\u27a4 lowers glucose levels in patients with type 2 diabetes.</li><li>\u27a4 SGLT2 inhibitors lower glucose levels by changing the renal threshold and not by insulin action.</li><li>\u27a4 lower glucose levels</li><li>\u27a4 renal threshold</li><li>\u27a4 The SGLT2 inhibitors canagliflozin, dapagliflozin, and empagliflozin , all oral medications, are approved for clinical use.</li><li>\u27a4 SGLT2 inhibitors canagliflozin, dapagliflozin, and empagliflozin</li><li>\u27a4 Side effects of SGLT2 inhibitors include ketoacidosis, urosepsis, Fournier's gangrene, increased incidence of UTI and genital infections.</li><li>\u27a4 Side effects</li><li>\u27a4 inhibitors include ketoacidosis, urosepsis, Fournier's gangrene, increased incidence of UTI and genital infections.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "11bc24be",
      "audio": ""
    },
    {
      "text": "The oral contraceptives shown in the figure are.",
      "options": [
        {
          "label": "A",
          "text": "Monophasic combined OCPs",
          "correct": true
        },
        {
          "label": "B",
          "text": "Biphasic combined OCPs",
          "correct": false
        },
        {
          "label": "C",
          "text": "Triphasic combined OCPs",
          "correct": false
        },
        {
          "label": "D",
          "text": "Emergency pills",
          "correct": false
        }
      ],
      "correct_answer": "A. Monophasic combined OCPs",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture19.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A. Monophasic combined OCPs</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Biphasic pills will have three colors. The first 10 tablets with less content of E+P, the next 11 tablets of different color containing higher amounts of hormones and last 7 tablets of different color that contain only iron.</li><li>\u2022 Option</li><li>\u2022 B. Biphasic pills will have three colors.</li><li>\u2022 first 10 tablets</li><li>\u2022 less content of E+P,</li><li>\u2022 11 tablets of different color</li><li>\u2022 higher amounts of hormones</li><li>\u2022 7 tablets of different color</li><li>\u2022 iron.</li><li>\u2022 Option C. Triphasic pills will have four colors. First 6 tablets, 6-10 tablets, 11-21 tablets and last 7 tablets of different color.</li><li>\u2022 Option</li><li>\u2022 C. Triphasic pills will have four colors.</li><li>\u2022 First 6 tablets, 6-10 tablets, 11-21 tablets and last 7 tablets</li><li>\u2022 different color.</li><li>\u2022 Option D. Emergency pills are incorrect because emergency contraception is not presented in a 28-day format but rather as a one-time dose or a short series of pills intended for immediate use after unprotected sex.</li><li>\u2022 Option</li><li>\u2022 D.</li><li>\u2022 Emergency pills</li><li>\u2022 incorrect</li><li>\u2022 emergency contraception</li><li>\u2022 not</li><li>\u2022 28-day</li><li>\u2022 one-time dose</li><li>\u2022 short series of pills</li><li>\u2022 immediate use after unprotected sex.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Monophasic combined OCPs consist of 21 active pills with a consistent dose of estrogen and progesterone , followed by 7 non-hormonal (iron) pills, and are represented in a pack with two colors\u201421 of one color and 7 of another, not to be confused with biphasic or triphasic pills which have varying hormone dosages and more color variation.</li><li>\u27a4 Monophasic combined OCPs</li><li>\u27a4 21 active pills</li><li>\u27a4 estrogen and progesterone</li><li>\u27a4 7 non-hormonal (iron) pills,</li><li>\u27a4 two colors\u201421 of one color</li><li>\u27a4 7 of another,</li><li>\u27a4 biphasic or triphasic pills</li><li>\u27a4 varying hormone dosages and more color variation.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "5910f57a",
      "audio": ""
    },
    {
      "text": "Only oral drug effective for treatment of condition shown in figure is?",
      "options": [
        {
          "label": "A",
          "text": "Octreotide",
          "correct": false
        },
        {
          "label": "B",
          "text": "Levo-thyroxine",
          "correct": false
        },
        {
          "label": "C",
          "text": "Cabergoline",
          "correct": true
        },
        {
          "label": "D",
          "text": "Pegvisomant",
          "correct": false
        }
      ],
      "correct_answer": "C. Cabergoline",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture20.jpg"
      ],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture21.jpg"
      ],
      "explanation": "<p><strong>Ans. C. Cabergoline</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Octreotide is incorrect because it is an injectable somatostatin analog used in the treatment of Acromegaly.</li><li>\u2022 Option A.</li><li>\u2022 Octreotide</li><li>\u2022 incorrect</li><li>\u2022 injectable somatostatin analog</li><li>\u2022 Acromegaly.</li><li>\u2022 Option B . Levo-thyroxine is incorrect because it is used to treat hypothyroidism and has no therapeutic role in the treatment of Acromegaly.</li><li>\u2022 Option B</li><li>\u2022 Levo-thyroxine</li><li>\u2022 incorrect</li><li>\u2022 treat hypothyroidism</li><li>\u2022 Option D. Pegvisomant is incorrect because it is an injectable growth hormone receptor antagonist used for Acromegaly but is not an oral medication.</li><li>\u2022 Option D.</li><li>\u2022 Pegvisomant</li><li>\u2022 incorrect</li><li>\u2022 injectable growth hormone receptor antagonist</li><li>\u2022 Acromegaly</li><li>\u2022 not</li><li>\u2022 oral medication.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 DRUGS FOR ACROMEGALY</li><li>\u27a4 DRUGS FOR ACROMEGALY</li><li>\u27a4 DRUGS FOR ACROMEGALY</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "4ce4aa73",
      "audio": ""
    },
    {
      "text": "All the following drug\u2019s act by increasing the secretion of insulin except?",
      "options": [
        {
          "label": "A",
          "text": "Rosiglitazone",
          "correct": true
        },
        {
          "label": "B",
          "text": "Repaglinide",
          "correct": false
        },
        {
          "label": "C",
          "text": "Exenatide",
          "correct": false
        },
        {
          "label": "D",
          "text": "Sitagliptin",
          "correct": false
        }
      ],
      "correct_answer": "A. Rosiglitazone",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture23.jpg"
      ],
      "explanation": "<p><strong>Ans. A. Rosiglitazone</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Repaglinide is a meglitinide which acts as a potassium ATP (K_ATP) channel blocker on pancreatic beta cells, directly stimulating the secretion of insulin.</li><li>\u2022 Option B.</li><li>\u2022 Repaglinide</li><li>\u2022 meglitinide</li><li>\u2022 acts as a potassium ATP (K_ATP)</li><li>\u2022 stimulating</li><li>\u2022 secretion of insulin.</li><li>\u2022 Option C. Exenatide is an incretin mimetic, which mimics the action of incretins like GLP-1 to increase insulin secretion in response to high blood glucose levels.</li><li>\u2022 Option C.</li><li>\u2022 Exenatide</li><li>\u2022 incretin mimetic,</li><li>\u2022 incretins like GLP-1 to increase insulin secretion</li><li>\u2022 high blood glucose levels.</li><li>\u2022 Option D. Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that prevents the breakdown of incretins, thereby prolonging their action and leading to increased insulin secretion.</li><li>\u2022 Option D.</li><li>\u2022 Sitagliptin</li><li>\u2022 dipeptidyl peptidase-4 (DPP-4) inhibitor</li><li>\u2022 breakdown of incretins,</li><li>\u2022 increased insulin secretion.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "878492ad",
      "audio": ""
    },
    {
      "text": "All the following statements about insulin preparations are correct except?",
      "options": [
        {
          "label": "A",
          "text": "Afrezza can be used as a replacement for injectable insulin.",
          "correct": true
        },
        {
          "label": "B",
          "text": "Glargine is never mixed with other insulins because of its acidic pH.",
          "correct": false
        },
        {
          "label": "C",
          "text": "Degludec is a long-acting subcutaneous depot insulin.",
          "correct": false
        },
        {
          "label": "D",
          "text": "Lente is a mixture of 70% crystalline and 30% amorphous insulin.",
          "correct": false
        }
      ],
      "correct_answer": "A. Afrezza can be used as a replacement for injectable insulin.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A. Afrezza can be used as a replacement for injectable insulin.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Glargine is never mixed with other insulins because of its acidic pH: This statement is correct. Insulin glargine has an acidic pH of about 4, which can cause precipitation when mixed with other insulins, hence it should not be mixed with them.</li><li>\u2022 Option</li><li>\u2022 B.</li><li>\u2022 Glargine is never mixed with other insulins because of its acidic pH:</li><li>\u2022 correct.</li><li>\u2022 acidic pH of about 4,</li><li>\u2022 precipitation</li><li>\u2022 mixed with other insulins,</li><li>\u2022 not be mixed</li><li>\u2022 Option C. Degludec is a long-acting subcutaneous depot insulin: This statement is correct. Insulin degludec provides a long-acting basal insulin effect due to its unique formulation t hat allows it to form a depot after subcutaneous injection, releasing insulin steadily over 24 hours or longer.</li><li>\u2022 Option</li><li>\u2022 C.</li><li>\u2022 Degludec is a long-acting subcutaneous depot insulin:</li><li>\u2022 correct. Insulin degludec</li><li>\u2022 long-acting</li><li>\u2022 basal insulin effect</li><li>\u2022 unique formulation t</li><li>\u2022 subcutaneous injection, releasing insulin</li><li>\u2022 steadily over 24 hours or longer.</li><li>\u2022 Option D. Lente is a mixture of 70% crystalline and 30% amorphous insulin: This statement is correct . Lente insulin is composed of 70% crystalline insulin, which provides a longer-acting effect , and 30% amorphous insulin, which acts more quickly, making it a mixed intermediate-acting insulin.</li><li>\u2022 Option</li><li>\u2022 D.</li><li>\u2022 Lente is a mixture of 70% crystalline and 30% amorphous insulin:</li><li>\u2022 correct</li><li>\u2022 Lente insulin</li><li>\u2022 70% crystalline insulin,</li><li>\u2022 longer-acting effect</li><li>\u2022 30% amorphous insulin,</li><li>\u2022 acts more quickly,</li><li>\u2022 mixed intermediate-acting insulin.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Afrezza is not a full replacement for injectable insulin; it is used to supplement long-acting insulin therapies by managing acute meal time blood sugar increases in patients with diabetes.</li><li>\u27a4 Afrezza</li><li>\u27a4 not</li><li>\u27a4 injectable insulin;</li><li>\u27a4 long-acting insulin</li><li>\u27a4 acute</li><li>\u27a4 meal time blood sugar increases</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "85613f1e",
      "audio": ""
    },
    {
      "text": "A second-year medical student is studying the pharmacological properties of estrogens and Selective Estrogen Receptor Modulators (SERMs) to understand their therapeutic applications and mechanisms of action. The student is particularly interested in how SERMs compare to natural estrogens, such as 17-\u03b2-estradiol, in their mode of action and effects on various tissues. Compared to 17-\u03b2-estradiol, a natural estrogen, which of the following properties is characteristic of Selective Estrogen Receptor Modulators (SERMs)?",
      "options": [
        {
          "label": "A",
          "text": "They are active orally.",
          "correct": false
        },
        {
          "label": "B",
          "text": "They are estrogen antagonists in all tissues.",
          "correct": false
        },
        {
          "label": "C",
          "text": "They have tissue-specific effects.",
          "correct": true
        },
        {
          "label": "D",
          "text": "They are more potent than 17-\u03b2-estradiol.",
          "correct": false
        }
      ],
      "correct_answer": "C. They have tissue-specific effects.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C. They have tissue-specific effects.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. They are active orally: While many SERMs are indeed orally active, this is not a distinctive feature compared to17-\u03b2- estradiol, which can also be administered orally in its synthetic forms.</li><li>\u2022 Option A. They are active orally:</li><li>\u2022 SERMs</li><li>\u2022 orally active,</li><li>\u2022 not</li><li>\u2022 estradiol,</li><li>\u2022 administered orally</li><li>\u2022 Option B. They are estrogen antagonists in all tissues: This is not accurate. SERMs do not uniformly act as estrogen antagonists in all tissues . Instead, their action is selective like raloxifene is agonistic in some tissues (like bones and cardiovascular system ) and antagonistic in others (like breast and uterine tissues ).</li><li>\u2022 Option B. They are estrogen antagonists in all tissues:</li><li>\u2022 not accurate. SERMs do not</li><li>\u2022 estrogen antagonists in all tissues</li><li>\u2022 selective like raloxifene is agonistic in some tissues</li><li>\u2022 bones and cardiovascular system</li><li>\u2022 antagonistic</li><li>\u2022 breast and uterine tissues</li><li>\u2022 Option D. They are more potent than 17-\u03b2-estradiol: This is not necessarily true . The potency of SERMs compared to 17-\u03b2-estradiol varies and is not the primary distinguishing facto r. Their significance lies in their selective action rather than their overall potency.</li><li>\u2022 Option D. They are more potent than 17-\u03b2-estradiol:</li><li>\u2022 not</li><li>\u2022 true</li><li>\u2022 SERMs compared to 17-\u03b2-estradiol</li><li>\u2022 not</li><li>\u2022 distinguishing facto</li><li>\u2022 selective action</li><li>\u2022 rather than</li><li>\u2022 overall potency.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The defining characteristic of Selective Estrogen Receptor Modulators (SERMs) is their tissue-specific effects , enabling them to selectively modulate estrogen receptors in different tissues , which contrasts with the uniform agonist activity of n atural estrogens like 17-\u03b2-estradiol across all estrogen-responsive tissues.</li><li>\u27a4 Selective Estrogen Receptor Modulators (SERMs)</li><li>\u27a4 tissue-specific effects</li><li>\u27a4 selectively modulate estrogen receptors</li><li>\u27a4 different tissues</li><li>\u27a4 contrasts</li><li>\u27a4 uniform agonist activity</li><li>\u27a4 atural estrogens</li><li>\u27a4 17-\u03b2-estradiol</li><li>\u27a4 estrogen-responsive tissues.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "70d7fa79",
      "audio": ""
    },
    {
      "text": "52-year-old postmenopausal patient has evidence of low bone mineral density. She and her physician are considering therapy with raloxifene or a combination of conjugated estrogens and medroxyprogesterone acetate. Which of the following patient characteristics is most likely to lead them to select raloxifene?",
      "options": [
        {
          "label": "A",
          "text": "Previous hysterectomy",
          "correct": false
        },
        {
          "label": "B",
          "text": "Recurrent vaginitis",
          "correct": false
        },
        {
          "label": "C",
          "text": "Strong family history of breast cancer",
          "correct": true
        },
        {
          "label": "D",
          "text": "Troublesome hot flushes",
          "correct": false
        }
      ],
      "correct_answer": "C. Strong family history of breast cancer",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C. Strong family history of breast cancer</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Previous hysterectomy: Previous hysterectomy is a better option fo r those drugs which increase risk of endometrial carcinoma, as there is no endometrium, so no risk. As raloxifene does not increase the risk (rather it decreases the risk ) of endometrial carcinoma, this characteristic would not influence the choice towards raloxifene.</li><li>\u2022 Option</li><li>\u2022 A.</li><li>\u2022 Previous hysterectomy:</li><li>\u2022 better option</li><li>\u2022 r those drugs</li><li>\u2022 increase risk of endometrial</li><li>\u2022 carcinoma,</li><li>\u2022 no endometrium,</li><li>\u2022 no risk.</li><li>\u2022 raloxifene does not increase the risk</li><li>\u2022 decreases the risk</li><li>\u2022 endometrial carcinoma,</li><li>\u2022 would not</li><li>\u2022 choice towards raloxifene.</li><li>\u2022 Option B. Recurrent vaginitis: Patients suffering from recurrent vaginitis might benefit more from estrogen therapy, which can help maintain vaginal health and pH balance , rather than raloxifene.</li><li>\u2022 Option</li><li>\u2022 B.</li><li>\u2022 Recurrent vaginitis:</li><li>\u2022 Patients suffering</li><li>\u2022 recurrent vaginitis</li><li>\u2022 benefit more from estrogen therapy,</li><li>\u2022 vaginal health and pH balance</li><li>\u2022 Option D. Troublesome hot flushes: Raloxifene is not effective for the treatment of hot flushes and might actually exacerbate them. In this case, HRT would be more appropriate to alleviate menopausal symptoms such as hot flushes.</li><li>\u2022 Option</li><li>\u2022 D.</li><li>\u2022 Troublesome hot flushes:</li><li>\u2022 not effective for the treatment of hot flushes</li><li>\u2022 exacerbate them.</li><li>\u2022 HRT would be more appropriate</li><li>\u2022 alleviate menopausal symptoms</li><li>\u2022 hot flushes.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Hormone replacement therapy (Combination of estrogen and progesterone) increases the risk of breast cancer whereas raloxifene has protective effective on breast cancer.</li><li>\u27a4 Hormone replacement therapy (Combination of estrogen and progesterone)</li><li>\u27a4 breast cancer</li><li>\u27a4 raloxifene</li><li>\u27a4 protective effective on breast cancer.</li><li>\u27a4 Actions of Raloxifene:</li><li>\u27a4 Actions of Raloxifene:</li><li>\u27a4 It is a selective estrogen receptor modulator. It acts like an estrogen agonist in bone and decreases bone resorption . Thus, it is used for treatment of osteoporosis. It increases HDL/LDL cholesterol ratio and thus has a favorable effect on lipid profile. It acts as ER antagonist on breast and endometrial tissue and thus can decrease the risk of breast cancer as well as endometrial cancer. It increases the formation of clotting factors and thus the risk of thromboembolism is increased with the use of raloxifene .</li><li>\u27a4 It is a selective estrogen receptor modulator.</li><li>\u27a4 selective estrogen receptor modulator.</li><li>\u27a4 It acts like an estrogen agonist in bone and decreases bone resorption . Thus, it is used for treatment of osteoporosis.</li><li>\u27a4 estrogen agonist in bone</li><li>\u27a4 decreases bone resorption</li><li>\u27a4 osteoporosis.</li><li>\u27a4 It increases HDL/LDL cholesterol ratio and thus has a favorable effect on lipid profile.</li><li>\u27a4 increases HDL/LDL cholesterol ratio</li><li>\u27a4 lipid profile.</li><li>\u27a4 It acts as ER antagonist on breast and endometrial tissue and thus can decrease the risk of breast cancer as well as endometrial cancer.</li><li>\u27a4 acts as ER antagonist</li><li>\u27a4 breast and endometrial tissue</li><li>\u27a4 decrease the risk of breast cancer</li><li>\u27a4 endometrial cancer.</li><li>\u27a4 It increases the formation of clotting factors and thus the risk of thromboembolism is increased with the use of raloxifene .</li><li>\u27a4 increases</li><li>\u27a4 clotting factors</li><li>\u27a4 thromboembolism is increased</li><li>\u27a4 use of</li><li>\u27a4 raloxifene</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "bfc2b5e6",
      "audio": ""
    },
    {
      "text": "All the following steroids have selective action on glucocorticoid receptors except?",
      "options": [
        {
          "label": "A",
          "text": "Dexamethasone",
          "correct": false
        },
        {
          "label": "B",
          "text": "Betamethasone",
          "correct": false
        },
        {
          "label": "C",
          "text": "Triamcinolone",
          "correct": false
        },
        {
          "label": "D",
          "text": "Prednisolone",
          "correct": true
        }
      ],
      "correct_answer": "D. Prednisolone",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/03/picture3.jpg"
      ],
      "explanation": "<p><strong>Ans. D. Prednisolone</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Dexamethasone , B. Betamethasone , and C. Triamcinolone are noted for their high glucocorticoid activity with minimal to no mineralocorticoid effects. These steroids are particularly useful when strong anti-inflammatory action is needed without the accompanying salt and water retention that can accompany mineralocorticoid activity.</li><li>\u2022 Option</li><li>\u2022 A.</li><li>\u2022 Dexamethasone</li><li>\u2022 B.</li><li>\u2022 Betamethasone</li><li>\u2022 and C.</li><li>\u2022 Triamcinolone</li><li>\u2022 high glucocorticoid activity</li><li>\u2022 minimal to</li><li>\u2022 no mineralocorticoid effects.</li><li>\u2022 steroids</li><li>\u2022 strong anti-inflammatory action</li><li>\u2022 salt and water retention</li><li>\u2022 mineralocorticoid activity.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "bd43f717",
      "audio": ""
    },
    {
      "text": "Exenatide is a new drug approved for treatment of type 2 diabetes mellitus. What is the mechanism of action of this drug?",
      "options": [
        {
          "label": "A",
          "text": "Bile acid sequestrant",
          "correct": false
        },
        {
          "label": "B",
          "text": "LPL activator",
          "correct": false
        },
        {
          "label": "C",
          "text": "CETP inhibitor",
          "correct": false
        },
        {
          "label": "D",
          "text": "GLP-1 analogue",
          "correct": true
        }
      ],
      "correct_answer": "D. GLP-1 analogue",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture2.jpg"
      ],
      "explanation": "<p><strong>Ans. D. GLP-1 analogue</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Bile acid sequestrant: Incorrect for Exenatide. Bile acid sequestrants, such as cholestyramine and colestipol, are primarily used to manage dyslipidemia by binding bile acids in the intestine.</li><li>\u2022 Option A. Bile acid sequestrant:</li><li>\u2022 Incorrect for Exenatide.</li><li>\u2022 cholestyramine and colestipol,</li><li>\u2022 dyslipidemia by binding bile acids</li><li>\u2022 Option B. LPL activator: Incorrect for Exenatide. Drugs that activate lipoprotein lipase (LPL), such as fibrates, are used to treat hypertriglyceridemia by enhancing the breakdown of triglyceride-rich lipoproteins .</li><li>\u2022 Option B. LPL activator:</li><li>\u2022 Incorrect</li><li>\u2022 activate lipoprotein lipase (LPL),</li><li>\u2022 fibrates,</li><li>\u2022 hypertriglyceridemia</li><li>\u2022 triglyceride-rich lipoproteins</li><li>\u2022 Option C. CETP inhibitor: Incorrect for Exenatide. CETP inhibitors, like anacetrapib, are used to increase high-density lipoprotein (HDL) cholesterol levels by inhibiting the cholesteryl ester transfer protein .</li><li>\u2022 Option C. CETP inhibitor:</li><li>\u2022 Incorrect</li><li>\u2022 anacetrapib,</li><li>\u2022 increase high-density lipoprotein (HDL) cholesterol levels</li><li>\u2022 inhibiting</li><li>\u2022 cholesteryl ester transfer protein</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Exenatide , as a GLP-1 analogue , is effective in treating type 2 diabetes by enhancing insulin secretion in response to high blood glucose levels , slowing gastric emptying, and reducing appetite , thus improving glycemic control .</li><li>\u27a4 Exenatide</li><li>\u27a4 GLP-1 analogue</li><li>\u27a4 type 2 diabetes</li><li>\u27a4 insulin secretion</li><li>\u27a4 high blood glucose levels</li><li>\u27a4 slowing gastric emptying, and reducing appetite</li><li>\u27a4 improving glycemic control</li><li>\u27a4 Parenteral Anti-diabetic drugs:</li><li>\u27a4 Parenteral Anti-diabetic drugs:</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "9b7d6641",
      "audio": ""
    },
    {
      "text": "Which of the following pairs of drugs and its indications is matched incorrectly?",
      "options": [
        {
          "label": "A",
          "text": "Bromocriptine- Treatment of precocious puberty",
          "correct": true
        },
        {
          "label": "B",
          "text": "Octreotide- treatment of diarrhea associated with vasoactive intestinal peptide tumors.",
          "correct": false
        },
        {
          "label": "C",
          "text": "Desmopressin- treatment of diabetes insipidus",
          "correct": false
        },
        {
          "label": "D",
          "text": "Leuprolide- treatment of infertility",
          "correct": false
        }
      ],
      "correct_answer": "A. Bromocriptine- Treatment of precocious puberty",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A. Bromocriptine- Treatment of precocious puberty</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Octreotide: Correctly matched. Octreotide, an octapeptide analog of somatostatin, is effective in reducing the severe secretory diarrhea associated with conditions like carcinoid syndrome and vasoactive intestinal peptide tumors (VIPomas).</li><li>\u2022 Option B. Octreotide:</li><li>\u2022 Correctly</li><li>\u2022 octapeptide analog of somatostatin,</li><li>\u2022 severe</li><li>\u2022 secretory diarrhea</li><li>\u2022 carcinoid syndrome and vasoactive intestinal peptide tumors (VIPomas).</li><li>\u2022 Option C. Desmopressin: Correctly matched. Desmopressin is used in the management of central diabetes insipidus, nocturnal enuresis, and von Willebrand\u2019s disease. It acts by mimicking vasopressin , thus helping control urine production and improving blood clotting factors.</li><li>\u2022 Option C. Desmopressin:</li><li>\u2022 Correctly</li><li>\u2022 central diabetes insipidus, nocturnal</li><li>\u2022 enuresis, and von Willebrand\u2019s disease.</li><li>\u2022 mimicking vasopressin</li><li>\u2022 urine production</li><li>\u2022 improving</li><li>\u2022 blood clotting factors.</li><li>\u2022 Option D. Leuprolide: Correctly matched when considering its use in reproductive health. Leuprolide, a GnRH analog , can be administered in a pulsatile fashion to treat conditions like anovulatory infertility , which relies on stimulating follicular development and ovulation.</li><li>\u2022 Option D. Leuprolide:</li><li>\u2022 Correctly matched</li><li>\u2022 reproductive health.</li><li>\u2022 GnRH analog</li><li>\u2022 pulsatile</li><li>\u2022 anovulatory infertility</li><li>\u2022 stimulating follicular development and ovulation.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Bromocriptine: Used for treatment of hyperprolactinemia, acromegaly, and type 2 diabetes mellitus.</li><li>\u27a4 Bromocriptine:</li><li>\u27a4 hyperprolactinemia, acromegaly, and type 2 diabetes mellitus.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "985c427c",
      "audio": ""
    },
    {
      "text": "Based on the mechanism shown in figure. Drug X is likely to be?",
      "options": [
        {
          "label": "A",
          "text": "Canagliflozin",
          "correct": false
        },
        {
          "label": "B",
          "text": "Exenatide",
          "correct": false
        },
        {
          "label": "C",
          "text": "Pramlintide",
          "correct": false
        },
        {
          "label": "D",
          "text": "Vildagliptin",
          "correct": true
        }
      ],
      "correct_answer": "D. Vildagliptin",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture18.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D. Vildagliptin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Canagliflozin is incorrect because it is an SGLT-2 inhibitor, which promotes glucosuria by preventing glucose reabsorption in the renal tubules, which is unrelated to the DPP-4 inhibition pathway.</li><li>\u2022 Option A.</li><li>\u2022 Canagliflozin</li><li>\u2022 incorrect</li><li>\u2022 SGLT-2 inhibitor,</li><li>\u2022 glucosuria</li><li>\u2022 preventing glucose reabsorption</li><li>\u2022 in the renal tubules,</li><li>\u2022 Option B. Exenatide is incorrect because it is a GLP-1 analogu e that mimics the action of GLP-1 to stimulate insulin release but does not inhibit DPP-4.</li><li>\u2022 Option B.</li><li>\u2022 Exenatide</li><li>\u2022 incorrect</li><li>\u2022 GLP-1 analogu</li><li>\u2022 action of GLP-1 to stimulate insulin release</li><li>\u2022 Option C. Pramlintide is incorrect because it is an amylin analogue , which has a different mechanism of action involving the modulation of gastric emptying and promotion of satiety; it does not inhibit DPP-4.</li><li>\u2022 Option C.</li><li>\u2022 Pramlintide</li><li>\u2022 incorrect</li><li>\u2022 amylin analogue</li><li>\u2022 modulation of gastric emptying and promotion of satiety;</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Vildagliptin is a DPP-4 inhibitor that enhances the action of incretins by preventing the breakdown of active GLP-1, leading to increased insulin release and decreased glucagon release , which helps to control blood glucose levels in diabetes mellitus.</li><li>\u27a4 Vildagliptin</li><li>\u27a4 DPP-4 inhibitor</li><li>\u27a4 incretins by preventing the breakdown of active GLP-1,</li><li>\u27a4 increased insulin release and decreased glucagon release</li><li>\u27a4 control blood glucose levels</li><li>\u27a4 diabetes mellitus.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "64d3dd11",
      "audio": ""
    },
    {
      "text": "All the following statements about tamoxifen are true except.",
      "options": [
        {
          "label": "A",
          "text": "It is used as an adjuvant in the treatment of estrogen receptor positive breast cancer.",
          "correct": false
        },
        {
          "label": "B",
          "text": "It reduces the risk of osteoporosis.",
          "correct": false
        },
        {
          "label": "C",
          "text": "It has a beneficial effect on lipid profile by increasing HDL/LDL cholesterol ratio.",
          "correct": false
        },
        {
          "label": "D",
          "text": "It reduces the risk of endometrial carcinoma.",
          "correct": true
        }
      ],
      "correct_answer": "D. It reduces the risk of endometrial carcinoma.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D. It reduces the risk of endometrial carcinoma.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Adjuvant in Estrogen Receptor-Positive Breast Cancer : True, tamoxifen is commonly used as an adjuvant therapy for estrogen receptor-positive breast cancer due to its antagonistic effects on the estrogen receptor in breast tissue.</li><li>\u2022 Option A.</li><li>\u2022 Adjuvant in Estrogen Receptor-Positive Breast Cancer</li><li>\u2022 True,</li><li>\u2022 tamoxifen</li><li>\u2022 adjuvant therapy for</li><li>\u2022 estrogen receptor-positive breast cancer</li><li>\u2022 antagonistic effects</li><li>\u2022 estrogen receptor in breast tissue.</li><li>\u2022 Option B. Risk of Osteoporosis : True, tamoxifen has an estrogen agonistic action on bone, leading to an antiresorptive effect that can reduce the risk of osteoporosis.</li><li>\u2022 Option B.</li><li>\u2022 Risk of Osteoporosis</li><li>\u2022 True,</li><li>\u2022 tamoxifen</li><li>\u2022 estrogen agonistic action</li><li>\u2022 antiresorptive effect</li><li>\u2022 reduce the risk of osteoporosis.</li><li>\u2022 Option C. Effect on Lipid Profile : True, tamoxifen is associated with improvements in lipid profiles , as it decreases total and LDL cholesterol without significantly affecting HDL and triglyceride levels.</li><li>\u2022 Option C.</li><li>\u2022 Effect on Lipid Profile</li><li>\u2022 True, tamoxifen</li><li>\u2022 improvements in lipid profiles</li><li>\u2022 decreases total and LDL</li><li>\u2022 cholesterol</li><li>\u2022 without</li><li>\u2022 HDL and triglyceride levels.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Tamoxifen</li><li>\u27a4 Tamoxifen</li><li>\u27a4 Tamoxifen is a SERM that has estrogen agonistic action on bone, blood (lipid profile) and liver whereas it acts as estrogen receptor antagonist in breast and endometrium. It is indicated as an adjuvant in the treatment of estrogen receptor positive breast cancer. It is associated with reduced risk of cancer in the contralateral breast. Tamoxifen also decreases total and LDL cholesterol without any change in HDL and triglyceride level. It thus has favorable effect on lipid profile by increasing the HDL/LDL cholesterol ratio . It also improves the bone mass due to antiresorptive effect, Tamoxifen is effective orally. It has biphasic plasma t\u00bd (10 hrs. and 7 days) and long duration of action. Hot flushes and nausea and vomiting occur in 25% of patients, and many other minor adverse effects are observed. Tamoxifen increases the risk of endometrial carcinoma and thromboembolic events. It causes retinal deposits , decreased visual acuity and cataracts in occasional patients\u201d</li><li>\u27a4 Tamoxifen is a SERM that has estrogen agonistic action on bone, blood (lipid profile) and liver whereas it acts as estrogen receptor antagonist in breast and endometrium.</li><li>\u27a4 SERM</li><li>\u27a4 estrogen agonistic action on bone, blood (lipid profile) and liver</li><li>\u27a4 acts as</li><li>\u27a4 estrogen receptor antagonist in breast and endometrium.</li><li>\u27a4 It is indicated as an adjuvant in the treatment of estrogen receptor positive breast cancer.</li><li>\u27a4 adjuvant in the treatment of estrogen receptor positive breast cancer.</li><li>\u27a4 It is associated with reduced risk of cancer in the contralateral breast.</li><li>\u27a4 reduced risk of cancer in the contralateral breast.</li><li>\u27a4 Tamoxifen also decreases total and LDL cholesterol without any change in HDL and triglyceride level. It thus has favorable effect on lipid profile by increasing the HDL/LDL cholesterol ratio .</li><li>\u27a4 Tamoxifen</li><li>\u27a4 decreases total and LDL cholesterol</li><li>\u27a4 increasing the HDL/LDL cholesterol ratio</li><li>\u27a4 It also improves the bone mass due to antiresorptive effect,</li><li>\u27a4 improves the bone mass due to antiresorptive effect,</li><li>\u27a4 Tamoxifen is effective orally.</li><li>\u27a4 effective orally.</li><li>\u27a4 It has biphasic plasma t\u00bd (10 hrs. and 7 days) and long duration of action.</li><li>\u27a4 biphasic plasma t\u00bd (10 hrs. and 7 days)</li><li>\u27a4 long duration of action.</li><li>\u27a4 Hot flushes and nausea and vomiting occur in 25% of patients, and many other minor adverse effects are observed.</li><li>\u27a4 Hot flushes</li><li>\u27a4 nausea and vomiting</li><li>\u27a4 25% of patients,</li><li>\u27a4 minor adverse effects</li><li>\u27a4 Tamoxifen increases the risk of endometrial carcinoma and thromboembolic events.</li><li>\u27a4 Tamoxifen</li><li>\u27a4 risk of endometrial carcinoma and thromboembolic events.</li><li>\u27a4 It causes retinal deposits , decreased visual acuity and cataracts in occasional patients\u201d</li><li>\u27a4 causes retinal deposits</li><li>\u27a4 decreased visual acuity and cataracts</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "31b5451a",
      "audio": ""
    },
    {
      "text": "All are true regarding insulin 'AFREZZA' except?",
      "options": [
        {
          "label": "A",
          "text": "It is an inhalational insulin preparation.",
          "correct": false
        },
        {
          "label": "B",
          "text": "By using afreeza, meal-time injectable bolus insulin requirement is not there.",
          "correct": false
        },
        {
          "label": "C",
          "text": "It is given in multiple doses.",
          "correct": false
        },
        {
          "label": "D",
          "text": "It is used in combination with short acting insulin.",
          "correct": true
        }
      ],
      "correct_answer": "D. It is used in combination with short acting insulin.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D. It is used in combination with short acting insulin.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. It is an inhalational insulin preparation: True. Afrezza is administered via inhalation, offering an alternative to injectable insulin forms for rapid-acting control of blood glucose levels.</li><li>\u2022 Option A. It is an inhalational insulin preparation:</li><li>\u2022 True.</li><li>\u2022 alternative to injectable</li><li>\u2022 insulin</li><li>\u2022 rapid-acting control of blood glucose levels.</li><li>\u2022 Option B. By using Afrezza, meal-time injectable bolus insulin requirement is not there: Generally true . Afrezza replaces the need for meal-time injectable insulin in many cases. However, some patients might still require an injectable form depending on their specific glucose control needs and diabetes management plan.</li><li>\u2022 Option B. By using Afrezza, meal-time injectable bolus insulin requirement is not there:</li><li>\u2022 true</li><li>\u2022 replaces the need</li><li>\u2022 meal-time injectable insulin</li><li>\u2022 injectable form</li><li>\u2022 specific glucose control</li><li>\u2022 diabetes management plan.</li><li>\u2022 Option C. It is given in multiple doses: True. Afrezza is taken at the start of each meal , thus it is administered multiple times throughout the day depending on the number of meals consumed.</li><li>\u2022 Option C. It is given in multiple doses:</li><li>\u2022 True.</li><li>\u2022 start of each meal</li><li>\u2022 multiple times</li><li>\u2022 throughout the day</li><li>\u2022 number of meals consumed.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Afrezza is an innovative inhalational insulin that provides rapid-acting blood glucose control and can potentially reduce or eliminate the need for meal-time injectable insulin. It is not typically combined with other short-acting insulins , making option D the false statement in the context of this query.</li><li>\u27a4 Afrezza</li><li>\u27a4 innovative inhalational insulin</li><li>\u27a4 rapid-acting blood glucose control</li><li>\u27a4 reduce or eliminate</li><li>\u27a4 meal-time injectable insulin.</li><li>\u27a4 not</li><li>\u27a4 combined with other short-acting insulins</li><li>\u27a4 option D</li><li>\u27a4 the false statement</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "347d8698",
      "audio": ""
    },
    {
      "text": "Which of the following is an adverse effect of dapagliflozin?",
      "options": [
        {
          "label": "A",
          "text": "Weight loss",
          "correct": false
        },
        {
          "label": "B",
          "text": "Polyuria",
          "correct": false
        },
        {
          "label": "C",
          "text": "Increased incidence of urinary tract infections",
          "correct": false
        },
        {
          "label": "D",
          "text": "All the above",
          "correct": true
        }
      ],
      "correct_answer": "D. All the above",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D. All the above</strong></p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "2d5c63f0",
      "audio": ""
    },
    {
      "text": "Anti-inflammatory action of cortisol is due to?",
      "options": [
        {
          "label": "A",
          "text": "Reduction in number of lymphocytes at the site of inflammation \u200b\u200b\u200b\u200b",
          "correct": false
        },
        {
          "label": "B",
          "text": "Decrease in production of cytokines.",
          "correct": false
        },
        {
          "label": "C",
          "text": "Inhibition of phospholipase enzyme",
          "correct": false
        },
        {
          "label": "D",
          "text": "All the above",
          "correct": true
        }
      ],
      "correct_answer": "D. All the above",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D. All the above</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The anti-inflammatory action of cortisol and other glucocorticoids is multifactorial, involving reduction in immune cell migration to inflammation sites, decreased production of cytokines, inhibition of phospholipase A2 activity , and downregulation of COX-2 expression.</li><li>\u27a4 anti-inflammatory action of cortisol</li><li>\u27a4 other glucocorticoids</li><li>\u27a4 multifactorial,</li><li>\u27a4 reduction in immune cell migration</li><li>\u27a4 inflammation sites,</li><li>\u27a4 decreased production of cytokines,</li><li>\u27a4 phospholipase A2 activity</li><li>\u27a4 downregulation of COX-2</li><li>\u27a4 expression.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ddd98e27",
      "audio": ""
    },
    {
      "text": "A 26-year-old pregnant lady was taking Antithyroid drug for Graves\u2019 disease throughout the pregnancy. Following delivery infant was diagnosed to have \u201cAplasia Cutis congenita.\u201d Most probable drug the female was taking during pregnancy was.",
      "options": [
        {
          "label": "A",
          "text": "Liothyronine",
          "correct": false
        },
        {
          "label": "B",
          "text": "Levothyroxine",
          "correct": false
        },
        {
          "label": "C",
          "text": "Carbimazole",
          "correct": true
        },
        {
          "label": "D",
          "text": "Sodium iodide",
          "correct": false
        }
      ],
      "correct_answer": "C. Carbimazole",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C. Carbimazole</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Liothyronine: A synthetic form of triiodothyronine (T3) , not linked to congenital defects like aplasia cutis.</li><li>\u2022 Option A.</li><li>\u2022 Liothyronine:</li><li>\u2022 synthetic form</li><li>\u2022 triiodothyronine (T3)</li><li>\u2022 not</li><li>\u2022 aplasia cutis.</li><li>\u2022 Option B. Levothyroxine: A synthetic form of thyroxine (T4), also not linked to congenital defects in infants.</li><li>\u2022 Option B.</li><li>\u2022 Levothyroxine:</li><li>\u2022 synthetic form</li><li>\u2022 thyroxine (T4),</li><li>\u2022 not</li><li>\u2022 congenital defects in infants.</li><li>\u2022 Option D. Sodium Iodide: Used to correct iodine deficiency, not associated with causing aplasia cutis congenita.</li><li>\u2022 Option D.</li><li>\u2022 Sodium Iodide:</li><li>\u2022 correct iodine deficiency,</li><li>\u2022 not</li><li>\u2022 aplasia cutis congenita.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Thioamides:</li><li>\u27a4 Thioamides:</li><li>\u27a4 Drugs in this include propylthiouracil, carbimazole and methimazole. These act by inhibiting the enzyme thyroid peroxidase . Later helps in formation of thyroid hormones. Most serious adverse effect of thioamides is agranulocytosis . Most common adverse effect of these drugs is purpuric rash. Cholestatic jaundice is common with methimazole. Propylthiouracil causes hepatic dysfunction, especially in children & pregnant women. Methimazole and carbimazole are rarely associated with aplasia cutis and choanal atresia if given in the first trimester of pregnancy.</li><li>\u27a4 Drugs in this include propylthiouracil, carbimazole and methimazole.</li><li>\u27a4 propylthiouracil, carbimazole and methimazole.</li><li>\u27a4 These act by inhibiting the enzyme thyroid peroxidase . Later helps in formation of thyroid hormones.</li><li>\u27a4 inhibiting the enzyme thyroid peroxidase</li><li>\u27a4 formation</li><li>\u27a4 thyroid hormones.</li><li>\u27a4 Most serious adverse effect of thioamides is agranulocytosis .</li><li>\u27a4 thioamides is agranulocytosis</li><li>\u27a4 .</li><li>\u27a4 Most common adverse effect of these drugs is purpuric rash.</li><li>\u27a4 purpuric rash.</li><li>\u27a4 Cholestatic jaundice is common with methimazole.</li><li>\u27a4 Cholestatic jaundice</li><li>\u27a4 methimazole.</li><li>\u27a4 Propylthiouracil causes hepatic dysfunction, especially in children & pregnant women.</li><li>\u27a4 Propylthiouracil</li><li>\u27a4 hepatic dysfunction,</li><li>\u27a4 children & pregnant women.</li><li>\u27a4 Methimazole and carbimazole are rarely associated with aplasia cutis and choanal atresia if given in the first trimester of pregnancy.</li><li>\u27a4 Methimazole and carbimazole</li><li>\u27a4 aplasia cutis and choanal atresia</li><li>\u27a4 first trimester</li><li>\u27a4 of pregnancy.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b3c33845",
      "audio": ""
    },
    {
      "text": "Thyroid storm is medical emergency in which there is excessive secretion of thyroid hormones. Beta blockers like propranolol are commonly used in a patient of thyroid storm. What is the most important role of beta blockers in these patients? \u200b\u200b\u200b\u200b\u200b\u200b",
      "options": [
        {
          "label": "A",
          "text": "Quick relief of symptoms",
          "correct": true
        },
        {
          "label": "B",
          "text": "To increase the metabolism of thyroxine",
          "correct": false
        },
        {
          "label": "C",
          "text": "To blockade the thyroxine receptors",
          "correct": false
        },
        {
          "label": "D",
          "text": "To decrease the synthesis of thyroxine",
          "correct": false
        }
      ],
      "correct_answer": "A. Quick relief of symptoms",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A. Quick relief of symptoms</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. To increase the metabolism of thyroxine: Incorrect because beta blockers do not increase the metabolism of thyroxine but reduce the conversion of T4 to T3.</li><li>\u2022 Option B. To increase the metabolism of thyroxine:</li><li>\u2022 Incorrect</li><li>\u2022 beta blockers do not increase the metabolism of thyroxine but reduce the conversion of T4 to T3.</li><li>\u2022 Option C. To blockade the thyroxine receptors: Incorrect because beta blockers do not affect thyroxine receptors; they block \u03b2-adrenergic receptors.</li><li>\u2022 Option C. To blockade the thyroxine receptors:</li><li>\u2022 Incorrect</li><li>\u2022 beta blockers do not</li><li>\u2022 thyroxine receptors;</li><li>\u2022 block \u03b2-adrenergic receptors.</li><li>\u2022 Option D. To decrease the synthesis of thyroxine: Incorrect as beta blockers do not directly decrease the synthesis of thyroid hormones ; this effect is mediated by drugs like propylthiouracil.</li><li>\u2022 Option D. To decrease the synthesis of thyroxine:</li><li>\u2022 Incorrect</li><li>\u2022 do not</li><li>\u2022 decrease the synthesis of thyroid</li><li>\u2022 hormones</li><li>\u2022 mediated by drugs</li><li>\u2022 propylthiouracil.</li><li>\u2022 Additional Treatment Insights:</li><li>\u2022 Additional Treatment Insights:</li><li>\u2022 Calcium channel blockers like diltiazem may be used if tachycardia persists despite beta-blocker therapy . Propylthiouracil is the preferred antithyroid drug as it reduces hormone synthesis and peripheral conversion of T4 to T3. Corticosteroids like hydrocortisone are administered to inhibit both the release of thyroid hormone from the gland and the peripheral conversion of T4 to T3.</li><li>\u2022 Calcium channel blockers like diltiazem may be used if tachycardia persists despite beta-blocker therapy .</li><li>\u2022 Calcium channel blockers</li><li>\u2022 diltiazem</li><li>\u2022 tachycardia persists despite beta-blocker therapy</li><li>\u2022 Propylthiouracil is the preferred antithyroid drug as it reduces hormone synthesis and peripheral conversion of T4 to T3.</li><li>\u2022 Propylthiouracil</li><li>\u2022 antithyroid drug</li><li>\u2022 reduces hormone synthesis</li><li>\u2022 peripheral conversion of T4 to</li><li>\u2022 T3.</li><li>\u2022 Corticosteroids like hydrocortisone are administered to inhibit both the release of thyroid hormone from the gland and the peripheral conversion of T4 to T3.</li><li>\u2022 Corticosteroids</li><li>\u2022 hydrocortisone</li><li>\u2022 inhibit both the release of thyroid hormone from the gland and</li><li>\u2022 the peripheral conversion of T4 to T3.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In a thyroid storm, beta blockers such as propranolol are essential for quickly alleviating symptoms through \u03b2-receptor blockade and reducing the peripheral conversion of T4 to T3 , thereby mitigating the effects of excess thyroid hormones.</li><li>\u27a4 thyroid storm, beta blockers</li><li>\u27a4 propranolol</li><li>\u27a4 alleviating symptoms</li><li>\u27a4 \u03b2-receptor blockade</li><li>\u27a4 reducing the peripheral conversion of T4 to T3</li><li>\u27a4 mitigating</li><li>\u27a4 excess thyroid hormones.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "cb09e9a9",
      "audio": ""
    },
    {
      "text": "Which of the following drugs can be given in renal failure safely?",
      "options": [
        {
          "label": "A",
          "text": "Saxagliptin",
          "correct": false
        },
        {
          "label": "B",
          "text": "Linagliptin",
          "correct": true
        },
        {
          "label": "C",
          "text": "Vildagliptin",
          "correct": false
        },
        {
          "label": "D",
          "text": "Sitagliptin",
          "correct": false
        }
      ],
      "correct_answer": "B. Linagliptin",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B. Linagliptin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Saxagliptin: Generally requires dose adjustments or is avoided in patients with renal failure due to its renal excretion and potential for accumulation.</li><li>\u2022 Option A. Saxagliptin:</li><li>\u2022 requires dose adjustments</li><li>\u2022 avoided in patients with renal failure</li><li>\u2022 renal excretion</li><li>\u2022 Option C. Vildagliptin: Similar to saxagliptin , it typically requires dose modifications i n patients with renal impairment to prevent adverse effects.</li><li>\u2022 Option C. Vildagliptin:</li><li>\u2022 Similar to saxagliptin</li><li>\u2022 requires dose modifications i</li><li>\u2022 renal impairment</li><li>\u2022 Option D. Sitagliptin: Also primarily eliminated renally, and thus needs dose adjustment in patients with renal dysfunction to avoid potential toxicity.</li><li>\u2022 Option D. Sitagliptin:</li><li>\u2022 primarily eliminated renally,</li><li>\u2022 needs dose adjustment</li><li>\u2022 renal dysfunction to avoid</li><li>\u2022 potential toxicity.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Linagliptin is a preferred choice among dipeptidyl peptidase-4 inhibitors for patients with renal failure due to its pharmacokinetic profile that allows safe use without the need for dosage adjustments in this population.</li><li>\u27a4 Linagliptin</li><li>\u27a4 dipeptidyl peptidase-4 inhibitors</li><li>\u27a4 renal failure</li><li>\u27a4 pharmacokinetic</li><li>\u27a4 safe use without the need for dosage adjustments</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "efbe2f5b",
      "audio": ""
    },
    {
      "text": "A patient is receiving insulin and acarbose for diabetes mellitus and developed hypoglycemia. Which of the following should be used for treatment of hypoglycemia in this patient?",
      "options": [
        {
          "label": "A",
          "text": "Sucrose",
          "correct": false
        },
        {
          "label": "B",
          "text": "Galactose",
          "correct": false
        },
        {
          "label": "C",
          "text": "Glucose",
          "correct": true
        },
        {
          "label": "D",
          "text": "Starch",
          "correct": false
        }
      ],
      "correct_answer": "C. Glucose",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C. Glucose</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Sucrose: Not suitable for quick correction of hypoglycemia in this context because acarbose inhibits the enzyme needed to break down sucrose into glucose and fructose, thereby delaying its action in raising blood glucose levels.</li><li>\u2022 Option A. Sucrose:</li><li>\u2022 Not suitable</li><li>\u2022 hypoglycemia</li><li>\u2022 acarbose inhibits the enzyme</li><li>\u2022 break down sucrose</li><li>\u2022 glucose and fructose,</li><li>\u2022 action in raising blood glucose levels.</li><li>\u2022 Option B. Galactose: While galactose is a simple sugar , it is not the preferred treatment for hypoglycemia as it is not as efficiently utilized by the body as glucose.</li><li>\u2022 Option B. Galactose:</li><li>\u2022 galactose is a simple sugar</li><li>\u2022 not</li><li>\u2022 treatment for hypoglycemia</li><li>\u2022 not</li><li>\u2022 body as glucose.</li><li>\u2022 Option D. Starch: Starch is a complex carbohydrate that would be broken down into glucose much more slowly , especially in the presence of acarbose, making it ineffective for the immediate treatment of hypoglycemia.</li><li>\u2022 Option D. Starch:</li><li>\u2022 Starch</li><li>\u2022 complex carbohydrate</li><li>\u2022 broken down into glucose</li><li>\u2022 more slowly</li><li>\u2022 acarbose,</li><li>\u2022 ineffective</li><li>\u2022 immediate treatment of hypoglycemia.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In cases of hypoglycemia, especially in patients using alpha-glucosidase inhibitors like acarbose , direct administration of glucose is recommended as it provides the fastest and most effective means of restoring blood sugar levels without the need for enzymatic digestion.</li><li>\u27a4 hypoglycemia,</li><li>\u27a4 alpha-glucosidase inhibitors like acarbose</li><li>\u27a4 direct administration of glucose</li><li>\u27a4 recommended</li><li>\u27a4 fastest and most effective</li><li>\u27a4 restoring blood sugar levels</li><li>\u27a4 without</li><li>\u27a4 enzymatic</li><li>\u27a4 digestion.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e67b943b",
      "audio": ""
    },
    {
      "text": "Mechanism of action of Voglibose is?",
      "options": [
        {
          "label": "A",
          "text": "Beta galactosidase inhibitor",
          "correct": false
        },
        {
          "label": "B",
          "text": "Beta lactase inhibitor",
          "correct": false
        },
        {
          "label": "C",
          "text": "Alpha glucosidase inhibitor",
          "correct": true
        },
        {
          "label": "D",
          "text": "Beta glucosidase inhibitor",
          "correct": false
        }
      ],
      "correct_answer": "C. Alpha glucosidase inhibitor",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C. Alpha glucosidase inhibitor</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Beta galactosidase inhibitor : There is no therapeutic class specifically targeting beta galactosidase for diabetes management. Beta galactosidase is involved in the metabolism of lactose into glucose and galactose.</li><li>\u2022 Option A. Beta galactosidase inhibitor</li><li>\u2022 no therapeutic class</li><li>\u2022 beta galactosidase for diabetes</li><li>\u2022 metabolism of lactose into glucose and galactose.</li><li>\u2022 Option B. Beta lactase inhibitor : The term \"beta lactase\" is incorrect as lactase (not \"beta lactase\") i s the enzyme that b reaks down lactose into glucose and galactose, and there are no diabetes medications targeting this enzyme.</li><li>\u2022 Option B. Beta lactase inhibitor</li><li>\u2022 incorrect as lactase (not \"beta lactase\") i</li><li>\u2022 reaks down</li><li>\u2022 lactose into glucose and galactose,</li><li>\u2022 no diabetes medications targeting this enzyme.</li><li>\u2022 Option D. Beta glucosidase inhibitor : Beta glucosidase plays a role in carbohydrate digestion , but inhibiting this enzyme is not a mechanism utilized by voglibose or other antidiabetic drugs.</li><li>\u2022 Option D. Beta glucosidase inhibitor</li><li>\u2022 carbohydrate digestion</li><li>\u2022 inhibiting this enzyme</li><li>\u2022 not a</li><li>\u2022 voglibose or other antidiabetic drugs.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Voglibose is an alpha-glucosidase inhibitor used to manage postprandial blood glucose levels in patients with type 2 diabetes . Its primary action is to slow carbohydrate digestion and absorption, which helps in controlling spikes in blood sugar levels after meals.</li><li>\u27a4 Voglibose</li><li>\u27a4 alpha-glucosidase inhibitor</li><li>\u27a4 postprandial blood glucose levels in patients with type 2 diabetes</li><li>\u27a4 slow carbohydrate digestion and absorption,</li><li>\u27a4 controlling spikes in blood sugar levels after meals.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "8604485c",
      "audio": ""
    }
  ]
}